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Abstract
The outcome of joining the WTO and implementing TRIPS agreement has caused a 
never-ending dispute in terms of both positive and negative perspectives. Patient’s 
access to essential medicines and sustainability of the domestic pharmaceutical 
industry are two important relevant topics in the developing countries. Two major 
consequences are trade liberalisation and enforcing an international intellectual property 
rights. The immediate impact will be free flow of medicines from the developed 
countries in the case of innovative drugs and more recently from India and China for 
cheap commodity medicines that are supported by the internationally enforceable 
intellectual property protections. The aim of the study was therefore to evaluate 
sustainability of the pharmaceutical industry in Iran post WTO agreement using the 
readiness index.
In the absence of previously developed instruments, two study tools were developed 
and validated in the course of this study namely WTO pharmaceutical Industry (PI) 
Impact Rating Scale and Pharmaceutical Industry Transition Instrument (PITI). Using 
the Delphi technique, an expert panel consisting of academics, industry senior
managers and regulators identified 29 parameters that the study should focus on 
generating consensus for the industry in preparation of joining the WTO. The top 6 
parameters included importation tariff, management knowledge, training, R&D,
customer satisfaction and patent review.
The study was then carried out throughout the industry to evaluate the current situation
and future importance of the identified parameters that were restructured in 66
statements of the PITI. The outcomes of the studies reported in this thesis suggest that 
with the current situation in the pharmaceutical industry in Iran, it is unlikely that the 
industry will be able to cope with the post-WTO challenges to deliver the growth needed 
to underpin its long term sustainability. The compliance of the industry with the 
requirements of the WTO at the current situation was concluded to be “unsatisfactory” 
for the majority of the PITI statements using binomial test (p<0.05). The future
importance of ail of the 15 PITI categories e.g. patient review, licence technology, 
transfer agreement, sales and marketing, GMP & QA, R&D, product packaging, 
manufacturing technology, pricing policy, training, customer satisfaction and qualified 
personnel were considered to be significant (p<0.05). The results based on the gap 
analysis and measuring the Pharmaceutical Industry Readiness (PIR) index yielded an 
overall value of 57% with a range of 37 to 67% for the PITI categories and 30 to 70% for 
the 22 companies. The priorities attached to individual activities by participating 
companies were identified by calculating the gap rank of 1 for ‘studying the financial 
impact of enforcing patent protection’ which showed the poorest readiness index of 
24%. This was followed by ‘having dedicated personnel for reviewing intellectual 
property rights to prevent patient infringements’, ‘comparability of marketing expenditure 
to that of international rivals’ and ‘to have GMP approval of international inspectors’ with 
PIR indices of 27%, 31% and 39% respectively.
The findings indicate that the pharmaceutical industry in Iran is not suitably equipped to 
meet the challenges of post WTO agreement, posing a threat to its sustainability. It is 
therefore hoped that the recommendations arising from this work are considered 
carefully by the individual pharmaceutical companies and the results synthesised in 
relation to their respective infrastructure in order to help them with their preparation for 
embracing the challenges of post WTO.
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Glossary of Terms
Biotechnology: is a field of applied biology that involves the use of living organisms 
and bioprocesses in engineering, technology, medicine and other fields requiring bio­
products. Modern use includes genetic engineering as well as cell and tissue culture 
technologies.
Copyright: is a set of exclusive rights granted by the law of a jurisdiction to the author 
or creator of an original work, including the right to copy, distribute and adapt the work. 
Exceptions and limitations to these rights strive to balance the public interest in the wide 
distribution of the material produced and to encourage creativity.
Creativity: refers to the phenomenon whereby a person creates something new (a 
product, a solution, a work of art etc.) that has some kind of value. What counts as 
"new’' may be in reference to the individual creator, or to the society or domain within 
which the novelty occurs. What counts as "valuable" is similarly defined in a variety of 
ways.
Foreign Direct Investment: refers to long term participation by country A in country B. 
It usually involves participation in management, joint-venture, transfer of technology and 
expertise.
Generic drug: is a drug which is produced and distributed without patent protection. 
The generic drug may still have a patent on the formulation but not on the active 
ingredient. A generic must contain the same active ingredients as the original 
formulation. According to the U.S. Food and Drug Administration (FDA), generic drugs 
are identical or within an acceptable bioequivalent range to the brand name counterpart 
with respect to pharmacokinetic and pharmacodynamic properties. By extension, 
therefore, generics are considered (by the FDA) to be identical in dose, strength, route 
of administration, safety, efficacy, and intended use.
Good Manufacturing Practice (GMP): is part of a quality system covering the 
manufacture and testing of active pharmaceutical ingredients, diagnostics, foods, 
pharmaceutical products, and medical devices. GMPs are guidelines that outline the 
aspects of production and testing that can impact the quality of a product. Many 
countries have legislated that pharmaceutical and medical device companies must
follow GMP procedures, and have created their own GMP guidelines that correspond 
with their legislation.
Health Technology Assessment: is the term used for the assessments made by 
government and insurance reimbursement agencies, hospital formulary committees and 
other bodies representing the payers for healthcare and medicines.
Hi-tech product: is technology that is at the cutting edge, the most advanced 
technology currently available. The adjective form is hyphenated: high-tech or high- 
technology (There is also an architectural style known as high tech.). There is no 
specific class of technology that is high tech — the definition shifts over time — so 
products hyped as high tech in the 1960s would now be considered, if not exactly low 
tech, then at least somewhat obsolete. This fuzzy definition has led to marketing 
departments describing nearly all new products as high tech.
Holding Company: is a company or firm that owns other companies' outstanding stock. 
It usually refers to a company which does not produce goods or services itself and its 
only purpose is that it owns shares of other companies. Holding companies allow the 
reduction of risk for the owners and can allow the ownership and control of a number of 
different companies. The degree of control the holding companies have over their 
companies depends on their parenting strategies.
Importation Tariff: a tariff on goods coming into a country from abroad, often used by 
governments as a way of reducing imports and protecting local industries.
Innovation: the process that renews something that exists, the introduction of 
something new.
Intellectual Property: is a term referring to a number of distinct types of creations of 
the mind for which property rights are recognised. Under intellectual property law, 
owners are granted certain exclusive rights to a variety of intangible assets, such as 
musical, literary, and artistic works; discoveries and inventions; and words, phrases, 
symbols, and designs. Common types of intellectual property include copyrights, 
trademarks, patents, industrial design rights and trade secrets in some jurisdictions.
Joint Venture (JV): the JV parties agree to develop, for a finite time, a new entity and 
new assets by contributing equity. They both exercise control over the enterprise and 
consequently share revenues, expenses and assets.
Licence Agreement: granting the permission by the licensor to the other party 
(licensee) to use the brand name, technology or design of a product.
Mergers and Acquisitions: refers to the aspect of corporate strategy, corporate 
finance and management dealing with the buying, selling and combining of different 
companies that can aid, finance, or help a growing company in a given industry grow 
rapidly without having to create another business entity.
Nanotechnology: is the study of manipulating matter on an atomic and molecular 
scale. Generally, nanotechnology deals with structures between 1 and 100 nanometres 
and involves developing materials or devices within that size.
OTC products: pharmaceutical products that do not require a prescription.
Patent Protection: is a set of legislations to enforce the exclusive rights granted by a 
state (national government) to an inventor or their assignee for a limited period of time 
in exchange for a public disclosure of an invention.
Patent Review: to review that the international filing date of a registered patent is 
expired or valid and examine the details of registered process or product in order to 
prevent patent infringement.
Pharmaceutical Industry transition Instrument (PITI): a study instrument specifically 
developed for evaluating the pharmaceutical industry during the transition state towards 
the implementation of the WTO/TRIPS regulations. The instrument consists of 66 
statements categorised in fifteen groups, namely “Research and Development”, “GMP 
and QA”, Sales and Marketing”, etc.
PIR Index: an index to measure the readiness of the pharmaceutical industry to face 
the challenges of the post-WTO/TRIPS situation. The scores given by the respondents 
to the performance of the industry in the current situation will be divided by the future 
importance of that parameter to measure PIR Index.
Privatisation: is the process of divesting the government stake both in terms of money 
and control from public companies.
Productivity: is a measure of output from a production process, per unit of input.
Quality Assurance: planned and systematic activities implemented in a quality system 
that provide confidence that quality requirements are fulfilled.
xiv
Quality audit: involves the assessment of any designated process or plant to obtain 
objective evidence that the existing requirements have been met (for example, effective 
and efficient implementation of processes and resources). Quality audits can be internal 
or external.
Quality Control: is operational techniques and activities that are used to fulfil 
requirements for quality. It involves techniques that monitor a process and eliminate 
causes of unsatisfactory performance at all stages of the quality cycle.
Quality system: the organisational structure, responsibilities, procedures, processes 
and resources for implementing quality management
R&D Expenditure: the total expenditure on all research and development activities 
relating to ethical pharmaceuticals. This includes salaries and all other personnel- 
related costs, costs related to consumable materials and supplies, and an appropriate 
share of overheads to cover administration, depreciation, space charges, rent, etc. The 
cost of R&D conducted by means of grants or contracts to other companies or 
institutions, and proportional costs for joint ventures should be included.
Regulatory Authority: a regulatory authority (also regulatory agency, regulatory body 
or regulator) is a public authority or government agency responsible for exercising 
autonomous authority over some area of human activity in a regulatory or supervisory 
capacity.
Research and Development: creative work undertaken on a systematic basis in order 
to increase the stock of knowledge, including knowledge of man, culture and society, 
and the use of this stock of knowledge to devise new applications.
Sales: The income from sales of products. This includes finished products, bulk sales 
and royalties from licensed-out pharmaceuticals.
Strategic Alliance: is a formal relationship between two or more parties to pursue a set 
of agreed upon goals or to meet a critical business need while remaining independent 
organisations. Partners may provide the strategic alliance with resources such as 
products, distribution channels, manufacturing capability, project funding, capital 
equipment, knowledge, expertise, or intellectual property.
Sustainability: is the capacity to endure. It is meeting the requirements for present 
activities without compromising future obligations.
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Technology Transfer: is the process of sharing skills, knowledge, technologies, 
methods of manufacturing, samples of manufacturing and facilities to ensure that 
scientific and technological developments are accessible to a wider range of users who 
can then further develop and exploit the technology into new products, processes, 
applications, materials or services.
Total Quality Management (TQM): this is a philosophy and style of management that 
gives all staff in an organisation responsibility for delivering quality to the customer. 
Total quality management views each task in the organisation as a process. The 
objective at each stage is to define and meet the customer's requirements in order to 
maximize the satisfaction of the final consumer at the lowest possible cost.
Trade Liberalisation: is a system of trade policy that allows traders to act and or 
transact without interference from government. According to the law of comparative 
advantage the policy permits trading partners mutual gains from trade of goods and 
services. Under a free trade policy, prices are a reflection of true supply and demand, 
and are the sole determinant of resource allocation
Validation System: the documented act of demonstrating that a procedure, process, 
and activity will consistently lead to the expected results. It often includes the 
qualification of systems and equipment. It is a requirement for Good Manufacturing 
Practices and other regulatory requirements. Since a wide variety of procedures, 
processes, and activities need to be validated, the field of validation is divided into a 
number of subsections including: Cleaning Validation, Process Validation, Analytical 
Method Validation, and Computer System Validation. Similarly, the activity of qualifying 
systems and equipment is divided into a number of subsections including: Design 
qualification (DQ), Component qualification (CQ), Installation qualification (IQ), 
Operational qualification (OQ) and Performance qualification (PQ).
WTO, PI, Impact Rating Scale: the instrument developed to identify the influencing 
parameters in the post-WTO situation. The instrument includes 29 statements under 
three headings of “Structure”, “Content”, and “Context” sections.
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Chapter 1
General Introduction
Background
The global pharmaceutical market value was more than US$800bn in 2009 and has had 
a growth rate of 6.7% for the past five years. The market value is distributed with 40% 
in US, 30% in Europe, 12% in Asia, Africa and Australia, 11% in Japan and 5% in Latin 
America (IMS, 2010). From a company perspective, Pfizer with US$57bn was at the top 
of the list followed by Merck & Co. with US$38bn, Novartis; US$38bn, Sanofi-Aventis; 
US$ 36bn and GlaxoSmithKline; US$35bn. The top five global products were Lipitor 
(Atorvastatin from Pfizer), Plavix (Clopidogrel from Sanofi and BristolMyersSquibb), 
Nexium (Astrazeneca’s Esomeprazole), Seretide (Fluticazone plus Salmetrol from 
GlaxoSmithKline) and Seroquel (Quetiamine from AstraZeneca) (IMS, 2009). The data 
indicate the best sellers are original brands as a result of intensive R&D investment by 
multinational companies.
The Pharmaceutical Industry in Iran 
History
Iran (formerly Persia) is located in southwest Asia with a territory of 1,648,195 square 
kilometres and a population of more than 70 million people. This country, also, played 
an important role in the history of medicine and pharmacy in the world. A history of 
pharmacy in Iran goes back several centuries. R Campbell Thomson examined 
hundreds of clay tablets obtained from the library of King Assurbanipal and found 
valuable materia medica. He identified 250 vegetable drugs, 120 mineral drugs, 
alcoholic beverages, and parts of animals being used as drugs (Kremers and 
Sonnedecker, 1976). From the oldest documents of medicine and pharmacy of ancient 
Persia, the holy book of Avesta should be mentioned. The term ”drug” is probably 
derived from the Avestan ancient term “dara\f meaning the stem of a plant as the origin 
of medicinal herbs, (Dar in Current Farsi language stands for tree). This word later 
changed into “darug” in the median Farsi language, and then changed to “droga” in 
Latin, “drogue” in French” drug” in English and Udaru” in Farsi language (Farsam, 2009). 
The Jundishapur academic centre was established during Sassanid Dynasty in 530 AD 
(Figure 1.1).
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Figure!.1 The Persian Empire about 500 B.C. (thejournal.org, 2010)
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This scientific centre, due to its cosmopolitan characteristics, can be considered as one 
of the earliest universities (IPM, 2003; Soylemez, 2005; University of Tehran, 2010). 
One of the famous pharmacists in this school was Shapur Sahl who composed his 
Aqrabadin Kabir (great formulary) in 869 CE, which became the first formulary that was 
used in hospitals and pharmacies (Farsam, 2009). According to Edward Brown; the 
most convincing evidence for ancient Iranian interest in pharmacy is the Iranian origin of 
many drug names in medieval medicine (Brown, 1921).
A group of medico-pharmaceutical scientists came into practice with considerable 
medical and pharmaceutical knowledge to commence a brilliant period of scientific 
knowledge, which later distributed into Europe. Ali ibn Sahl Rabban Tabari (839 A.D), 
Mohammad ibn Zakariya Razi (Rhazes in Latin) (864-930 CE) also, well known as The 
Galen of East’, Abu Mansur Muwaffaq Heravi and Abu Ali Al-Husain ibn Abdullah ibn 
Sina (Avicenna in Latin) (980-1037 CE) was also called "The prince of physicians" by 
the Europeans are some of the most reputable ones (Al-Ghazal et al, 2007; Farsam, 
200; Iran Chamber Society, 2010 and Ghomi, 2010).
The Modern Pharmaceutical Industry
The approval of the 1920 Medicine Law and foundation of the school of pharmacy in 
Tehran University in 1934 as well as the establishment of the first pharmaceutical
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factory in 1955 are the first steps towards a modern pharmaceutical industry in Iran 
(Lotfi, 2000). In 1979, a number of domestic and foreign companies were operating in a 
market with a $300 million annual cash flow. There were nearly 4,000 kinds of 
pharmaceutical products available in Iran; 70% of which was provided by imports 
(Siamak Nejad, 1989). The foundation of Generic Scheme in 1981 can be considered 
as a new era which is characterised by using the generic name of the medicines (Vaziri, 
1991 and Foroughi, 1994).
Centralised policymaking was deployed to face the challenges resulted from the Iran- 
Iraq war (1980 -  1988) mainly by categorising pharmaceuticals as basic and strategic 
commodities and accordingly, supporting the local production of inexpensive medicines 
available to the entire nation (Azarnoosh, 1991). The Ministry of Health was put in 
charge of the nomenclature framework, pricing policies and also profit margins on 
producers, importers, distributors, and pharmacies. As a result of these tough controls, 
the average drug price index increased by only 118.2% at the fixed prices of 1982, while 
the other goods reached a 706% growth in their price index during the same period 
(Basmanji, 1995).
Later on, in 1992 the government’s inexpensive foreign exchange allocations to the 
sector was removed and in 1994, the entire sector had to import all the finished 
pharmaceuticals as well as ingredients and equipment necessary for local production at 
the floating foreign exchange (Dinarvand, 1996 ). To prevent the negative 
consequences resulting from this decision on people’s purchasing power, the 
government allocated a direct subsidy to producers and importers (Montaseri, 1997). 
Due to the large investments by public sector during the 1980s, many new companies 
were operating in the sector in 1999 (Vasefi, 1997).
During the Second Plan, per capita expenditure on pharmaceutical products increased 
from US$12 to US$25 showing an annual growth of 14%. Local companies produced 
85% of the country's pharmaceutical needs in terms of value and 97% in terms of 
quantity. However, 43% of the total foreign exchange spent on the pharmaceutical 
products was used for importation of the finished drugs (Ministry of Health and Medical 
Education, 1998).
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Due to the fact that the government is the owner of a major part of healthcare facilities 
and therefore is the main purchaser of medicines, the government is a direct beneficiary 
of keeping pharmaceutical prices low (Zomorrodian, 1989). Due to the low price policy, 
local companies procure materials and equipment from the cheapest sources. They 
were also unable to invest in upgrading their production facilities or developing 
innovative products. This was also the main reason for medicine smuggling from Iran 
into the neighbouring countries and over-consumption of medicines in the country itself. 
The Third Plan defined two different categories for medicines: Essential Drugs (very 
vital and necessary drugs) and Nonessential Drugs. For the second category, the 
producers could provide higher quality goods, since they can price their products free 
from the governmental pricing policies and also under their own trade labels ( Planning 
and Budget Organisation, 2000 and Basmenji, 2004). There are several important 
socio-economic advantages in Iran’s pharmaceutical industry: good industrial 
infrastructure, an inexpensive and highly educated workforce, a large and growing 
domestic market and access to other regional markets.
Iran Pharmaceutical Market
Countries are classified by WHO into five levels according to the evaluation of their 
pharmaceutical production: 1, sophisticated pharmaceutical industry and research base; 
2, innovative capabilities; 3, reproductive capabilities—active ingredients and finished 
products; 4, reproductive capabilities—finished products from imported ingredients only; 
5, no pharmaceutical industry (Semin and Guldal, 2008). Iran is categorised as a level 4 
country indicating the capacities for production of the finished products with the 
imported material (Figure 1.2) (WHO, 2004). However in the recent years many plants 
are producing Pharmaceutical raw materials for local and international market.
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Figure 1.2 The situation of the countries from the view of their pharmaceutical industry
Local pharm aceutical production capacity varies greatly  am ong countries
The value of the Iranian pharmaceutical market in 2009-2010 (the Iranian year begins in 
March 22nd) was US$3.1 bn showing 24% growth comparing with the previous year 
(Drug and Narcotics Monitoring Directorete, 2009). The market growth rate has been 
more than 20% in the past 10 years (Figure 1.3).
Figure 1.3 The Pharmaceutical Market value in Iran
■  USSM illion
Year
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In terms of other comparable markets, although Iran scores well for its opportunities 
such as large and growing population and plans developed to improve healthcare 
services. It is believed that low intellectual property (IP) protection and other regulatory 
criteria are major weaknesses especially in the pharmaceutical environment. Iran has a 
highly educated workforce in the field of industry and science and its pharmaceutical 
manufacturing capabilities are in place to meet the bulk of local demand. The local 
pharmaceutical industry is expected to boost domestic pharmaceutical spending 
through increased diversification and new products, including biological drugs. The plan 
to export products to international markets is limited to less-regulated regional markets 
(business Monitor International, 2010). The needs of the improving healthcare system 
cannot be met by relying merely on the local production and a considerable part is 
imported. The data published by the Drugs and Narcotics Monitoring Directorate (2009) 
shows that the ratio of the imported medicines has been increased from 15% in 2000 to 
38% in 2009 (Figure 1.4). The imported products are mainly expensive new medicines 
for treating multiple sclerosis, cancers and severe infections but there are also a few 
less sensitive products such as supplements and multivitamins.
Figure 1.4 Imported and locally manufactured pharmaceuticals in Iran
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The list of the top imported drugs according to the data published by the Drugs and 
Narcotics Monitoring Directorate (2009) is presented in the Table 1.1.
Table 1.1 The characteristics of the top imported drugs in 2009
Generic Name Brand Name(s)
Number of 
Units
Sales value 
Million (USD)
1. ALBUMIN (HUMAN) 20% 50ML VIAL Different brands 833,581 43.50
2. INTERFERON B 1B 8MIU VIAL
Betaferon,
Extavia
596,917 32.83
3. CLOPIDOGREL 75MG TAB Plavix 11,606,088 28.21
4. DOCETAXEL 80MG VIAL
Taxotere,
Docetax
30,468 26.25
5. IMIPENEM+CILASTATIN(500+500)MG VIAL Tienem, 791,893 21.70
6. RITUXIMAB 500MG/50ML VIAL Mabthera 9,322 19.80
7. SALMETEROL+FLUTICASON 
25/250MIC EVOHALER
Seretide 368,726 18.02
8. IMMUNE GLOBULIN 5G INJECTION POWDER 
(IV) VIAL
Different brands 41,094 17.57
9. GLUCOSAMINE+CHONDROITIN+MSM T ripleflex 30,931,550 17.29
10. TRIPTORELIN 3.75MG VIAL
Decapeptyl,
Dipherline
167,285 17.09
11. TRASTUZUMAB 440MG VIAL 5,501 16.93
12. INTERFERON B 1A 44MCG/0.5ML AMP Avonex, Rebif 285,286 15.69
13. PANTOPRAZOLE 40MG FOR INFUSION Pantozol 972,120 15.01
14. MENOTROPINS 75 IU FSH+75IU LH AMP
Menopur, 
Menogon, IVF
1,057,298 14.98
15. VACCINE-INFLUENZA VIRUS KILLED 
SYRINGE
Influvac, Inflexal 
V, Vaxigrip,
465,010 13.98
16. ISOTRETINOIN 20MG CAP
Roacutan,
Decutan,
Oratane
13,738,022 13.28
17. GEMCITABINE HCI 1 G VIAL Gemzar 56,606 11.74
18. OXALIPLATINE 100MG VIAL Eloxatin 25,322 11.51
19. SOMATROPIN 4U AMP Nordilet 689,154 10.99
20. MULTIVITAMINE CAP
Geriatric
Pharmaton
27,282,520 10.44
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These data reveal that the ratio of the imported medicines is steadily increasing in the 
recent years. It can be also concluded that the majority of the imported products are 
high value innovative brands that have not been produced by the local companies.
The number of companies involved in the pharmaceutical market is another criterion to 
illustrate the pharmaceutical environment in Iran. The number of the companies is 
increasing for both importers and manufacturers; manufacturing companies increased 
from 52 to 86 companies between 2000 and 2009 while importer companies increased 
ever faster from 11 to 150 over the same period (Figure 1.5).
Figure1.5 The number of the companies involving in the pharmaceutical market in Iran
(2000-2009)
■  M anufacturers
■  Im porters
2000-2001 2006-2007 2008-2009
An increasing number of importer companies show that there is a significant unmet 
need in the Iran pharmaceutical market and this gap is increasingly filled by importation. 
The local industry also has the opportunity to invest on developing new products or 
produce the original brands under the licence of the patent holders. In 2009, the first,
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second and third local manufacturing companies had a total sales of 130, 100 and 96 
million US dollars which was comparable with the largest importer companies (Drug and 
Narcotics Monitoring Directorete, 2009).
The World Trade Organisation, WTO
The era of globalisation is characterised by the process by which regional economies, 
societies, and cultures have become integrated through a global network of 
communication, transportation and trade. This phenomenon is closely associated with 
economic globalisation which explains the integration of national economies into the 
international economy through trade, foreign direct investment, capital flow, migration, 
the spread of technology and military presence (Bhagwati, 2004). However, 
globalisation is recognised by a combination of economic, technological, socio-cultural, 
political and biological factors (Croucher, 2004). Trade liberalisation is the main purpose 
of the WTO that facilitates trade flow as freely as possible (WTO, 2010a). This plays a 
major role in economic integrity and the socio-economic and cultural convergence 
leading towards a global village.
The WTO; International Trade Organisation (ITO) and General Agreement on 
Trade and Tariff (GATT)
The ITO is a United Nations specialised agency that addressed trade barriers and other 
issues indirectly related to trade, including employment, investment, business practices, 
and commodity agreements. The ITO treaty was not approved by the U.S. and a few 
other signatories and thus never went into effect. The WTO's predecessor, the General 
Agreement on Tariffs and Trade (GATT), was established after World War II in 1948 
and dedicated to international economic cooperation. Until the WTO was established on 
1 January 1995, seven rounds of negotiations occurred under the GATT. The first 
rounds concentrated on reducing tariffs. Then, the Kennedy Round in the mid-sixties, 
created GATT anti-dumping Agreement. The Tokyo Round during the seventies was to 
deal with non-tariff trade barriers. Several of the GATT agreements were amended in 
the Uruguay Round, and accepted by all WTO members.
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The Uruguay Round. The eighth GATT round, known as the Uruguay Round, launched 
in September 1986, in Uruguay extended the trading system into several new areas, 
particularly trade in services and intellectual property (WTO, 2010c).
The Doha Round. The current round of negotiations, Doha Round, was launched at the 
fourth ministerial conference in Doha, Qatar in November 2001. The Doha round was 
an effort to involve more countries and help poor nations, particularly by removing 
barriers and subsidies in farming. The initial agenda included both trade liberalisation 
and new regulations, highlighting the need and commitment to help developing 
countries (Fergusson, 2008). On the 10th December 2002, the General Council agreed 
a new range of measures enabling the world’s poorest countries, the least-developed 
countries (LDCs), to join more quickly and easily. Member governments agreed to apply 
“special and differential treatment” to those countries as soon as they become 
members, and to grant transitional periods in specific WTO agreements. Levels of the 
countries’ development, financial, trade and technical needs were taken into 
consideration (the accession procedure for Nepal and Cambodia completed in the light 
of these measures) (WTO, 2010b).
Functions
WTO is an organisation for liberalising trade, a forum for governments to negotiate trade 
agreements and a place to settle trade disputes (WTO, 2010a). The WTO purpose is to 
help trade flow as freely as possible, so long as there are no undesirable side effects 
(WTO, 2010a). The main functions of the WTO (WTO, 2010) are to:
• Oversee implementation, administration and operation of the relevant 
agreements.
• Provide a forum for negotiations and for settling disputes.
• Review and publish the national trade policies, and to ensure their consistency 
and transparency.
• Assist developing, least-developed and low-income countries in transition to 
adjust to WTO rules and disciplines through technical cooperation and training.
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• Conduct economic research and analysis with regular assessments of the global 
trade situation in its annual publications.
• Cooperate with the International Monetary Fund (IMF) and the World Bank.
Principles of the Trading System
The five important principals are (WTO, 201 Oi):
1. Non-Discrimination. There are two major components related to this topic: the 
Most Favoured Nation (MFN) rule, and the national treatment policy. The MFN 
requires that a WTO member must apply the same conditions on all trade with 
other WTO members. In other words, if a country grants a special favour to a 
country, it has to do the same for all other WTO members. National treatment 
means that imported goods should be treated equally in comparison to the local 
products and was introduced to tackle non-tariff barriers to trade (e.g. technical 
standards, security standards as discriminations against imported goods).
2. Reciprocity. This reflects that trade relationships under WTO should secure 
mutual benefits of the involved countries.
3. Binding and enforceable commitments. The tariff commitments made by WTO 
members in a multilateral trade negotiation and on accession are listed to 
establish "ceiling bindings": A country can change its bindings, but only after 
negotiating with its trading partners, which could mean compensating them for 
loss of trade. If satisfaction is not obtained, the complaining country may appeal 
to the WTO dispute settlement procedure.
4. Transparency. The WTO members are required to publish their trade 
regulations, review the administrative decisions affecting trade, respond to 
requests for information by other members, and report changes in trade policies 
to the WTO.
5. Managing Special Cases. Governments can restrict trade in three specific 
circumstances: to attain noneconomic objectives; to ensure "fair competition"; 
and intervention in trade for economic reason. Exceptions to the MFN principle
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also allow for preferential treatment of developing countries, regional free trade 
areas and customs unions.
Organisational structure
The General Council meets either as the Trade Policy Review Body or Dispute 
Settlement Body. It has multiple groups which monitor committees in different areas; 
Council for Trade in Goods, Council for Trade-Related Aspects of Intellectual Property 
Rights, Council for Trade in Services and Trade Negotiations Committee (WTO, 201 Od).
Voting System
The WTO operates on a one country, one vote system. In fact, votes have never been 
taken and decision-making is based on consensus generating to find the most widely 
acceptable decision. It should be taken into consideration that relative market size is the 
primary source of bargaining power. In reality, WTO negotiations proceed by a process 
of informal negotiations between small groups of countries that is criticised by many of 
the developing countries which are often excluded from these negotiations. Some 
analysts argue that the WTO's consensus governance model favours Europe and the 
U.S (Steinberg, 2002)_(WTO, 201 Oj).
Accession and Membership
The process of becoming a WTO member depends on the situation in each country, its 
economic development and current trade regime. The process takes about five years, 
on average, but it can last longer due to political and economical issues. The accession 
procedure will be completed once consensus is reached among the interested parties 
(The Centre for International Development at Harvard University, 2010).
Members and Observers
The WTO has 153 members with 30 countries nominated as observers including Iran 
that are currently negotiating their membership. Russia is the biggest economy outside 
WTO but after the completion of Russia's accession; Iran would be the biggest economy
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outside the WTO. Having become observers, accession negotiations must start within 
five years. There are 14 states and 2 territories currently with no official interaction with 
the WTO (WTO, 2010b).
WTO Agreements
The WTO covers about 60 different agreements as international legal texts. Member 
countries must sign and ratify all WTO agreements on accession. Some of the most 
important agreements are; The Agreement on Trade-Related Aspects of Intellectual 
Property Rights, The Agreement on Technical Barriers to Trade (ensures that technical 
negotiations and standards, as well as testing and certification procedures, do not 
create unnecessary obstacles to trade) and The Agreement on Customs Valuation, 
formally known as the Agreement on Implementation of Article VII of GATT (WTO, 
2010c).
Iran Trade Regulations
Iran is gradually modifying its trade regulations in accordance with the WTO 
requirements. Here are the most important aspects:
Customs Tariff Structure
The average of import duties in Iran's National Tariff System (NTS) is currently 25.5%. 
There are 2278 tariff lines (that is 33.8% of the total tariff lines) that have the minimum 
tariff rate of 4 percent (which has the highest frequency among tariff groups) and about 
44% of the tariff lines have tariff rates less than or equal to 10 percent. Goods having 
tariffs more than 100% constitute less than 0.5% of the tariff lines in the NTS. The 
highest tariff rate is 200%. The statistics for the Iranian year 1385 (2006-2007) indicates 
that an average import duty of 11.6 percent was actually collected for the total imported 
goods in that year (Ministry of Commerce, 2009). The importation tariff for finished 
pharmaceutical products that have local production is around 60% which plays a major 
role in protecting the local pharmaceutical industry.
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Application of Most Favoured Nation, Tariff Rates and Tariff Preferences
Iran applies tariff rates on a non-discriminatory basis for all countries. However, a 
limited number of goods have been subject to the exchange of concessions in the 
framework of the Preferential Trade Agreement between Iran and Pakistan (Ministry of 
Commerce, 2009).
Tariff Quotas, Tariff Exemptions
No tariff quota is applied to Iran’s trade regime. In addition, since March 2003, all tariff 
exemptions enjoyed by some government agencies have been removed by virtue of the 
"Act on Consolidation of Duties" (Ministry of Commerce, 2009).
Other Duties and Charges
There are no taxes, fees or charges, other than "import duties". The last version of 
import duties is annually published as an attachment to "the Act on Export-lmport 
Regulations Book" by the Ministry of Commerce. (Ministry of Commerce, 2009). 
Quantitative Import Restrictions
There are no quantitative restrictions on imports in Iran’s trade regime. Import 
prohibitions are only applied on items whose sales, purchases and consumption is 
prohibited by the Islamic principles or according to laws as dictated by the specific 
agencies of the country (Ministry of Commerce, 2009).
TRIPS Agreement
The Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) is an 
international agreement administered by the World Trade Organisation (WTO). It 
defines minimum standards for intellectual property (IP) regulation and is applicable to 
all WTO members. TRIPS agreement was negotiated at the end of the Uruguay Round 
of the General Agreement on Tariffs and Trade (GATT) in 1994. This agreement 
contains requirements for copyright; industrial design; patents; trademarks; and 
undisclosed or confidential information. TRIPS agreement also determines enforcement 
procedures, compensations, and dispute settlement procedures. The philosophy behind 
the protection and enforcement of intellectual property rights is to contribute to the 
promotion of technological innovation and to the transfer and distribution of technology, 
in a manner to secure the rights of its producers.
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The concerns of the developing countries about the strict interpretation of TRIPS by 
developed countries initiated a round of talks in 2001 that resulted in the Doha 
Declaration. The Doha declaration is a WTO statement that clarifies the scope of 
TRIPS, stating for example that TRIPS can and should be interpreted in the light of the 
goal to promote access to medicines for all. The ministerial conference held in Doha 
issued a declaration on the TRIPS agreement and public health to recognise the 
importance of the public health problems affecting many developing and least 
developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria 
and other epidemics (WTO, 2001). TRIPS has been criticised by the social movements 
due to its consequences with regard to the AIDS pandemic in Africa.
Background and History
Modern patent legislation has its roots back in three or four centuries ago. At that time, 
a pharmaceutical product was called “nostrum” and were mainly made in some 
monasteries in Italy, France, and Germany. In some cases the rulers paid their 
investors for the valuable nostrums and published them to the public. A famous story for 
such a deal is selling the formula of decoction of cinchona bark by an Englishman to 
Luis XIV of France in 1680 for an undisclosed high price. Similarly in 1775, the inventor 
of a nostrum for the treatment of tapeworm received immunity and a noble title from 
Fredrick, the great of Prussia. England was the first country to establish governmental 
regulations in this regard (Agrawal and Takkar, 1997).
The recent development to strengthening intellectual property rights has happened 
since the formation of the WTO as a result of a intense lobbying by the United States, 
supported by the European Union, Japan and other developed countries (Braithwaite 
and Drahos, 2000).
Ratification of TRIPS is a compulsory requirement of WTO membership, in order to 
obtain easy access to the numerous international markets. Furthermore, unlike other 
agreements on intellectual property, TRIPS has a powerful enforcement through the
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WTO's dispute settlement mechanism (Braithwaite and Drahos, 2000 and WTO, 
201 Oe).
The Requirements of TRIPS
The central part of the TRIPS agreement is article 27, which states that all signatories 
are obliged to grant protection to any invention including products and processes in all 
technology sectors. The TRIPS agreement requires member countries to grant strong 
protection for intellectual property rights, for example, under TRIPS (John and 
Masterson, (2002); WTO, 2010k and WTO, 2010m):
• Copyright must be granted automatically, and not based on any "formality", such 
as registrations or systems of renewal.
• National exceptions to copyright (such as "fair use" in the United States) are 
constrained by the Berne Convention.
• Patents must be granted in all "fields of technology," although exceptions for 
certain public interests are allowed (Art. 27.2 and 27.3) and must be enforceable 
for at least 20 years (Art 33).
• Exceptions to the exclusive rights must be limited, provided that a normal 
exploitation of the work (Art. 13) and normal exploitation of the patent (Art 30) is 
not in conflict.
• Legitimate interests of third parties have to be taken into account by patent rights 
(Art 30).
• In each country, intellectual property laws may not offer any benefits to local 
citizens which are not available to citizens of other TRIPs signatories.
Compulsory Licensing; Compulsory licensing is when a government allows someone 
else to produce the patented product or process without the consent of the patent owner 
(WTO, 201 Og). Compulsory licensing as explained by the WTO ( 2003) is an important 
flexibility resulted from the Doha Declaration in 2002. This is also known as ‘use without 
authorisation of the rights holder’. There are some preconditions for compulsory 
licensing such as: being unsuccessful in voluntary licensing from the patent holder and
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the presence of a national emergency for public non-commercial use (Dhar and 
Gopakumar, 2006).
Parallel Importation; ‘Parallel imports’ or ‘grey imports’ are considered where a country 
can legally import a patented drug from another country (with lower prices) without the 
permission of the patent owner (WTO , 2003).
Burden of Proof; This means that the party claiming a violation of a provision of the 
WTO Agreement, the complainant, must prove its claim. In turn, the party appealing in 
defence of a provision that is an exception to an obligation (i.e. the respondent) bears 
the burden of proof that the conditions set out in the exception are met (WTO, 201 Oh). 
Burden of proof is an important legal issue especially while a country or a company 
intends to take advantage of the exceptions to the WTO/TRIPS provisions.
Mailbox System; Article 70.8 considers the establishment of a “mailbox system” for 
receiving and filing patent applications upon entry into force of TRIPS. The files in a 
mailbox are to be retrieved after a specific period of time and reviewed by the 
authorities for patentability (Chulalongkorn University, Feb 2001). If the products 
obtained marketing approval in any WTO Member country, then exclusive marketing 
rights for five years had to be granted before the patent on the product was either 
granted or rejected (Dhar and Gopakumar, 2006).
The TRIPS agreement has forced many countries to adapt their national legislation in a 
way to comply with its provisions mainly 20 years of patent protection from the date of 
filing (Ganguli, 2003). Some of the legislative modifications in different countries are 
summarised in Table 1.2.
Access to Essential Medicines
An interpretive statement in the Doha Declaration was issued in November 2001 which 
indicated that TRIPS should not prevent states from dealing with public health crises 
(WTO, 2001). Despite the role that patents have played in maintaining higher costs of 
drugs that were necessary for public health programmes across Africa, no revision of 
TRIPS has occurred. After Doha, Pharmaceutical Research and Manufacturers of
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America (PhRMA) and other developed nations began working to minimise the effect of 
the declaration. The agreement that allowed developing countries to export to other 
countries where there is a national health problem without a commercial or industrial 
interest is no longer enforceable (WTO, 2003).
Table 1.2 Modifications of the legislations to comply with TRIPS agreement in different
countries
Country Year Modified Regulation
USA 1995 The Term of Patent was extended from 17 to 20 years.
EU
July 8, 1998
Legal protection was granted to biotechnology products and 
processes.
Japan December 14, 1994 Patent law was extended and classification was changed.
India March 10, 1999 Transitory mailbox provision was approved.
Spain
January 1998
Obtaining interim injunctions against patent infringers was 
facilitated.
Argentina
1995
20 years protection from the date of filing instead of 15 years 
from the date of granting was approved.
Australia August 10, 1988 Patents effective term increased to 20 years.
New Zealand Rules on parallel importation were relaxed.
Estonia June 16, 1998 Protection granted to process patent.
Mexico 1994 Patentability to practically all types of inventions was allowed.
Brazil
April 1966
Included a shortened year transition period before WTO 
intellectual property rules come into force.
Kuwait Patents are granted to all industrial products, methods or new 
applications.
South Africa December 12, 1997 Parallel importation and patent protection were approved.
In 2003, the Bush administration announced a new policy concluding that generic 
treatments might be a component of an effective strategy to combat HIV. Bush created 
“the President's Emergency Plan for AIDS Relief (PEPFAR) programme, which 
received $15 billion from 2003-2007, and was re-authorised in 2007 for $30 billion for 
the next five years. Despite wavering on the issue of compulsory licensing, PEPFAR 
began to distribute generic drugs in 2004-5 (Office of the Global AIDS Coordinator, 
2008).
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Implementation in Developing Countries
The obligations under TRIPS, apply equally to all member states, however developing 
countries were given more time to implement the changes to their national laws, in two 
protocols of transition according to their development level. The transition period for 
developing countries expired in 2005. The transition period for least developed 
countries to implement TRIPS was extended to 2013, and until 1 January 2016 for 
pharmaceutical patents, with the possibility of further extension (WTO, 201 Of).
Developed countries are major exporters of copyright, patent and trademark-related 
royalties. It has therefore been argued that the TRIPS standard will be harmful to poorer 
countries' development (WIPO, 2005). A report in 2005 by the WHO stated that many 
developing countries have not incorporated TRIPS flexibilities (compulsory licensing, 
parallel importation, limits on data protection, use of broad research and other 
exceptions to patentability, etc.) into their legal system that were permitted under the 
Doha declaration (Braithwaite and Drahos, 2000; Musungu and Oh, 2005). This is 
probably caused by the lack of legal and technical expertise needed to draft legislation 
that implements flexibilities. This often resulted in directly copying developed countries’ 
IP legislation (Finger, 2000), or relying on technical assistance from the World 
Intellectual Property Organisation (WIPO), which encourages them to implement 
stronger intellectual property monopolies.
Post-TRIPS Expansionism
The requirements of TRIPS are extremely strict. Despite this, some of the developed 
countries tried to strengthen existing forms of intellectual property rights such as; 
restricting the possibility of compulsory licences, aggressive enforcement demands in 
bilateral agreements and extension of the patent system by using the wording of TRIPS 
27 on non-discrimination (Braithwaite and Drahos, 2000). It is recommended that 
developing countries should be cautious about enacting legislation that is stricter than 
the TRIPS requirements (“TRIPS-plus”) (Chulalongkorn University, Feb 2001).
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Controversies, the supporters and opponents of Intellectual Property Rights
Since TRIPS came into force, it has received a growing level of criticism from 
developing countries, academics, and non-governmental organisations. Some of this 
criticism is against the WTO as a whole, but many supporters of trade liberalisation also 
consider negative consequences for TRIPS. They believe TRIPS facilitates moving 
money from people in developing countries to copyright and patent owners in developed 
countries (Drahos and Braithwaite, 2003).
It is obvious that TRIPS has a legal base for protecting innovation and rewarding 
investors in high risk areas of research and development. This will result in the 
development of novelty products that are necessary for a healthier society in the future. 
On the other hand, we have patients which need the best available medicines right now. 
The only way to ensure their efficient accessibility to medicines and make a balance to 
reach intergeneration equity is to carefully define the strength and the period of patent 
protection. The supporters of TRIPS underline the necessity of strong protection for 
patent holders and innovators to ensure sustainable innovation. They consider it as a 
challenging trade-off between inexpensive drugs today and novel drugs for the future 
(Agrawal and Takkar, 1997).
Multinational companies generally prefer higher standards of intellectual property 
protection due to their investment in R&D. The need for more income is also influenced 
by shorter product cycles due to technological changes and market forces. This also 
causes an opportunity for developing countries to host some R&D and production 
facilities for the multinational companies. (Vogel, 2006). Some researchers believe 
these solutions create a midway approach emphasising the intellectual property rights 
of the patent holders and at the same time, sharing their benefits with developing 
societies (Ganguli, 2003). Some opponents investigate more deeply the financial 
structure of reported R&D expenditures and conclude some parts of it, phase IV clinical 
trial expenses for instance are arguably a marketing cost (Moerman and Laan, 2006)
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The Impact of the WTO/TRIPS Agreement on developing countries
Jordan is a successful example of joining the WTO. According to some local 
pharmaceutical executives, enacting the new patent law could “run their business into 
the ground”. The current patent law offered pharmaceuticals protection for "process" but 
not for the end product. At that time, Jordan had 17 pharmaceutical companies with 
3500 employees and 2% under licence products. The Pharmaceutical industry was the 
second largest exporting industry after mining in Jordan. The US industry claimed their 
losses for unauthorised copies in Jordan to be $20-25 million/year. The American 
Pharmaceutical Industry Association reported only 10% of the market value would be 
affected but, would bring foreign investment to the country and create jobs. At the same 
time, the head of the Arab Union for Drug Security indicated that the $400 million 
pharmaceutical industry’s turnover in Jordan would suffer (Maayeh, 1999). By 2006 this 
country’s pharmaceutical industry exported $250 million to 60 countries and the industry 
was a major contributor to the national economy (Sboul, 2006). This experience was 
also repeated in some other Arabian countries in the Persian Gulf such as Saudi Arabia 
(Taher, 1999).
In India, industry analysts believed that most of the new medicines would be priced out 
of reach of the great majority of people by joining the country to WTO in 2005. Until that 
time, India had allowed only manufacturing process patents for pharmaceuticals but not 
for the end products. In India, 60,000 generic brands in 60 therapeutic areas were 
available which accounted for 1% of the value and 8% of the volume of the 
pharmaceuticals sold in the world. A governmental report stated only in antibiotics; new 
patent law would cost Indians $700 million each year against a gain of $57million in 
profits of multinationals. Others believed that only 10% of people could pay for costly 
medicines and the new law would cost the lives of millions for the greater profit of rich 
multinationals (James, 2004). Some researchers tried to quantify the impact of this 
monopoly under patent. They concluded that in the case of a linear demand function the 
price of pharmaceuticals would increase by 26% but if the demand function was 
considered with constant elasticity, the price rise would be as high as 242%. They
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suggested that compulsory licensing could be a solution to prevent welfare loses 
(Watal, 2000).
The final impact on the pharmaceutical industry in India was not so negative. 
Companies like Ranbaxy were more optimistic to adapt to a research based strategy or 
offer low cost production for high income multinationals (James, 2004). The main 
reason for this optimism was the strong bases of the generic pharmaceutical companies 
in India that emerged as a result of the implementation of the Patents Act in 1970. Two 
key provisions facilitated this process. The first was the introduction of a process patent 
regime for chemicals and the second, a shortening the validity period of the patents 
granted for pharmaceuticals. The proper use of TRIPS flexibilities played a major role in 
the future prospect of the industry. Analysis of the generic pharmaceutical industry 
shows that they developed strategies to meet the challenges posed by the post-TRIPS 
patent regime. These strategies include the consolidation of the Indian firms and the 
increase in the R&D spending of some of the leading firms. This resulted in them 
receiving market approvals in both the US and the UK and playing the role of a hub for 
contract research and manufacturing. A number of major pharmaceutical companies 
are establishing joint ventures with the Indian generic producers. Indian firms have also 
increased their focus on the more profitable regulated markets and received the FDA 
approvals for 60 manufacturing plants that are more than any other country. There is 
also an increased focus on product innovation; one-third of all FDA applications came 
from India in 2003. Multinational companies are attracted by the lower cost structure 
estimated to be one eighth (in R&D) to one-fifth (in manufacturing) compared to 
Western countries and identified the prospects of the Indian pharmaceutical industry as 
extremely positive (Dhar and Gopakumar, 2006). Positive impacts are also reported in 
Singapore due to absorbing FDI, establishing R&D and manufacturing facilities by 
multinational companies and higher training and qualifications for employees (Lim and 
Wei, 2010).
China is primarily known as the lowest cost source of pharmaceutical ingredients and 
generics. However, some of the major local generic companies have focused on 
innovative R&D. China has the language barriers and insecure institutional environment
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for intellectual property protection, long registration approval processes, and regulatory 
favouritism towards local firms. The availability and pricing of approximately 90% of 
medicines in India and China, including most the WHO Model List of Essential 
Medicines should not be affected by the introduction of product patents (Grace, 2004). 
The impacts of TRIPS is also discussed as a source of concern in several other 
countries such as; Thailand (Supakankunti, 2001), Morocco (World Trade Organization, 
2006) and Turkey (Semin and Guldal, 2008).
Recommendations for Concerned Countries
A study by Ryan and Graduno (2004) concludes comprehensive recommendations 
regarding intellectual property rights to develop a national strategy for supporting 
innovation. The summary of their recommendations along with the findings in other 
countries (Agrawal and Takkar, 1997; Dhar and Gopakumar, 2006; Erixon et al, 2008; 
Semin and Guldal, 2008; Chaudhry, 2009; Lim and Wei, 2010) can be summarised as 
follows:
■ Enact a local patent protection law that gradually meets the international level.
■ Expand the scope of patentable subjects to include different innovations.
■ Establish a national framework for technology transfer by providing patent property 
rights to universities and national research centres.
■ Build the capacity to engage in technology transfer offices.
■ Provide broad education and training programmes on intellectual property use and 
management.
■ Encourage the development of a world class intellectual property rights.
■ Leverage the national innovation awards.
■ Establish human and organisational capacities regarding international intellectual 
property diplomacy.
■ Enhance intellectual property Enforcement.
■ Provide additional training to judges focused on patent and trade secret arbitration.
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Intellectual Property Rights (IPRs) in Iran
Based on the data published by the World Intellectual Property Organisation (2010), 
Iran is a member of the WIPO since 2002 and has joined several intellectual property 
treaties and joined the Convention for the Protection of Industrial Property (Paris 
Convention) in 1959. In December 2003, Iran became a member to the Madrid 
Agreement and the Madrid Protocol for the International Registration of Marks. In 2005 
Iran joined the Lisbon Agreement for the Protection of Appellations of Origin and their 
International Registration, which ensures the protection of geographical names 
associated with products. Iranian laws and regulations provide specific legal rules 
respecting a number, but not all of the industrial properties. However, no patent 
application is acceptable for pharmaceutical products and processes. Trademarks are 
the most protected industrial property in Iran; therefore, a practical way for the owners 
of trade names and industrial designs is registering them as trademarks. The 
milestones of establishing the current IPRs in five-year development plans are 
presented in the Table 1.3 (Akhlaghi and Habiba, 2006).
Table 1.3 IP considerations in Iran's Development Plans (1990-2009)
Five Years Plan
The degree of considering 
IPRs in the documents of 
the plan
Clarity of special policies and 
strategies for improving IPRs 
system in the documents of the 
plan
First Five-Year Plan 
(1990-94)
None Lack of a specific policy or strategy
Second Five-Year 
Plan (1995-99)
None Lack of a specific policy or strategy
Third Five-Year Plan 
(2000-2004)
Reference to the defects in 
Iran's IPRs regime and the 
necessity of solving problems
Lack of a specific policy or strategy
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Fourth Five-Year Plan Clear reference to the Obliging the government to plan
(2005-2009) existence of many defects in and implement a comprehensive
Iran's IPRs regime and the IPRs system
necessity of removing them
during the execution years
This Table shows that the Iranian policy-makers have recently paid increasing attention 
to strengthening national IPRs system. It should also be noted that Iran has not joined 
any international copyright agreements such as the Berne convention. Since Iran is 
planning to join WTO, it is necessary to join the relevant agreements as well. According 
to the 20 year development programme, the country has developed a strategy to be one 
of the major players in the region with the pharmaceutical industry as a priority.
The Act of Acceding to the Patent Cooperation Treaty was enacted by the Iranian 
parliament (Majlis) in 2007. Based on this law, the enforcement will become liable only 
after the process of acceding has been completed and also provided that enough 
facilities are made available. In March 2008, the “Law of Registration of Inventions, 
Industrial Designs and Trade Marks” was enacted (the 2008 Law), to be implemented 
for a five-year tentative period (Rasekh, 2009 ). The country has also a legal system to 
protect the proprietary and intellectual rights of works produced inside Iran as the Law 
for the Protection of Authors dated January 12, 1970, (Parstimes, 2010) supplemented 
in the Iranian year 1352 (1973) and the Iranian year 1379 (2000) (Ministry of 
Commerce, 2009). These laws however do not cover works from outside Iran as it is not 
a signatory to the Berne Convention for the Protection of Literary and Artistic Works, the 
WIPO Copyright Treaty, or a member of the WTO (Press TV, 2010).
According to the Iranian Law of Registration of Marks and Patents of 1931, a trademark 
is any type of logo, design, picture, number, letter, word, seal or wrapper etc. with 
essential requirement that the mark presented for registration should be distinctive. 
Article 30 of the law provides that any inventor or discoverer who holds an unexpired 
patent certificate outside Iran may apply for a patent in Iran. But if a person or company
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has used the invention or discovery in Iran prior to the foreigner’s application or has 
made preparations to exploit the same, the foreign patentee will not have the right to 
stop the operation of that person or company (Akhlaghi and Habiba, 2006).
The Registration of Patents, Industrial Designs and Trademarks Law, 2008
The Law of Registration of Patents, Industrial Designs and Trademarks were first 
passed by the Iranian parliament on 23 January 2008 for a trial period of five years, 
effective from May 5, 2008. In October 2007 Iran’s parliament approved becoming a 
signatory to the Patent Cooperation Treaty (PCT) which enables inventors to register 
their patents in PCT member countries simply by filing a single application with the 
related national registration authority (Press TV, 2008).
The Majlis (Parliament) also approved a bill in May 2001 to recognise and enforce 
international arbitration awards, to grant companies greater protection over their 
property. By acceding to the Convention on the Recognition and Enforcement of 
Foreign Arbitral Awards, commonly known as the New York Convention, Iran has 
agreed to enforce arbitration awards made in other countries. Awards issued in Iran will 
also be enforceable in other member countries. According to the State Registration 
Organisation of Deeds and Properties, a total of 9,570 national inventions were 
registered in Iran during 2008. Compared with the previous year, there was a 38- 
percent increase in the number of inventions registered by the organisation (Ministry of 
Commerce, 2009).
Patents are registered in Iran for 5, 10, 15 or 20 years, at the option of the applicant. 
Pharmaceutical formula and compounds are not patentable, but a patent application 
can be filed for processes related to the manufacture of pharmaceuticals. A trademark 
may be registered for ten years and can be renewed indefinitely for additional ten-year 
periods. The legal effect of Registration is to give exclusive right to an owner to use a 
trademark on the goods for which the trademark is registered (Alavi and Associates, 
2010).
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The Impact of WTO/TRIPS on Pharmaceutical Industry
Regardless of positive or negative approaches toward the WTO/TRIPS, it seems all 
countries around the world are gradually joining this global harmonisation, intending to 
be proactive and provoke innovation in local industry, absorbing foreign investment and 
promoting exports.
Apart from building up capacities in the knowledge system, Iran has also substantial 
technological capacity in the productive sector. It has a well developed manufacturing 
capacity in the automotive industry, telecommunications and pharmaceuticals. In 
general, enterprises only are involved in production but do not perform innovative 
activities. While such a strategy fits an import-substitution economy, it does not result in 
a dynamic capability for sustainable development. (Molanezhad, 2010). Iranian
pharmaceutical manufacturers are disadvantaged by the poor intellectual property 
protection regime. Developing a molecule for combination therapies may qualify for 
patent protection in other countries. However, while weak patent protection continues in 
Iran, it is expected this will create significant challenges for Iranian companies pursuing 
trade on the global market (Business Monitor International, 2009).
The reviews in this chapter suggest that:
■ WTO/TRIPS has caused many debates in developing countries with eventually 
success stories in most of them,
■ Iran has a long history and strong infrastructure in the pharmaceutical industry,
■ The improvement of the industry in recent years has not been sufficient for a well- 
established local and international presence,
■ It is expected that the legal environment support innovativeness of the local industry,
■ A stepwise patent protection is needed to support local companies’ innovativeness 
and simultaneously, the international companies’ presence and contribution. These 
steps would include granting protection to the locally developed processes and 
products and subsequently enforcement of international intellectual property rights,
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■ The Pharmaceutical industry and all relevant stakeholders need to study the current 
situation with respect to the future challenges and develop a roadmap to secure the 
sustainability of the local industry.
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Aims and Objectives of the Study
Aim
The aim of this study is the development and application of instruments to study the
impact of WTO/TRIPS on the sustainability of the pharmaceutical industry in Iran.
Objectives
■ Develop and apply a validated rating scale for generating experts’ consensus to 
identify the factors that influence the pharmaceutical industry in the post-WTO 
situation
■ Rate the relative importance of the factors influencing the pharmaceutical 
environment in the post-WTO agreement
■ Develop and apply a validated instrument to study the situation of the 
Pharmaceutical Industry in Iran
■ Identify the future importance of the various parameters that reflect the industry’s 
aspirations to meet the challenges
■ Rank and prioritise the actions that need to be taken by the industry
■ Propose scenarios for developing appropriate strategies to ensure the sustainability 
of the pharmaceutical industry
■ A Gap analysis and introduce an index for measuring the Iranian industry’s 
readiness for the post-WTO situation
■ Develop a strategy map for the Iranian pharmaceutical industry in order to secure its 
post-WTO sustainability and translate the identified parameters into a series of 
balanced scorecards
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Chapter 2
Study Rationale and Methodological Framework
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STUDY RATIONALE
The origin of intellectual property (IP) rights and the evolution of the concept through 
history have been explained in chapter 1. The underlying principles for granting 
protection to innovators include the following:
• Legal aspects, through which the IP of any individual can be protected from
unauthorised usage by others
• Economical/financial aspects, which involve using financial rewards as an
effective way to promote the innovative attitude among talented people
• Social/people-related aspects, which involve not only facilitating the access of 
individuals to innovative knowledge by ensuring that innovators are protected by 
the law but also creating an idea-generating atmosphere in society
Chapter 1 also outlined how this protection has been combined with free trade 
agreements by the World Trade Organisation (WTO). In fact, enforcing worldwide IP 
protection has become a prerequisite for any country that wishes to join the WTO and 
become an active and responsible member of the international trade community.
In view of the pharmaceutical industry’s high level of dependency on new patents and 
innovations, enforcing worldwide IP protection has created some complications, 
especially in developing countries. Accession to the WTO requires that all trade 
barriers, including importation tariffs and quotas, should be removed on the basis of a 
timetable decided through bilateral or multilateral negotiations. This, in turn, means that 
the free flow of finished medicines from developed countries can easily capture the 
home market of local industries. At the same time, enforcing worldwide IP protection 
based on the agreement on trade-related aspects of intellectual property rights (TRIPS) 
will require the local industry to either stop production of patented products or pay 
licence fees to innovators. Without sufficient preparation, the consequences of these 
legal adaptations may severely affect the viability of the local industry that have a key 
role in the access of patients to medicines. There appears to be very few comparable 
published studies of these effects. Therefore, this study proposes to gather the
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necessary information from the pharmaceutical industry and other related sectors in 
order to;
• Identify those parts of the industry that could potentially be more vulnerable to 
the negative impacts of WTO/TRIPS;
• Provide further insight into the current situation with respect to the critical factors;
• Evaluate whether the current efforts are sufficient to sustain a profitable industry;
• Assess the impact of the companies’ policies on their readiness to deal with the 
forthcoming situations.
Thus, this research aims to evaluate the impact of WTO/TRIPS on the sustainability of 
the pharmaceutical industry in Iran.
METHODOLOGICAL FRAMEWORK 
Study Design
While designing a research study, it is necessary to first decide whether the study seeks 
to explain a new theory (hypothesis generating) or test existing ones (hypothesis 
testing).
In general, inductive strategies are used for generating a new hypothesis, whereas 
deductive strategies are used for hypothesis testing. Thus, during hypothesis 
generation, the researcher uses his or her initial observations as the starting point on 
which to formulate hypotheses. These hypotheses may be subsequently either rejected 
or modified based on the observations obtained during the study. In deductive 
procedures, however, a conceptual and theoretical structure is constructed prior to 
taking observations; this structure is then tested through experimental work (Cassel and 
Symon, 2004).
It is believed that the inductive strategy is more appropriate for social research because 
theory building and data collection are closely interlinked. Explanations of social 
phenomena based on systematic empirical research based on the data collected are
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more reasonable and accessible. On the other hand, the deductive approach involves 
imposing a set of pre-assumptions upon the behaviour of social phenomena in order to 
explain the phenomena (Cassel and Symon, 2004).
This study is based on the inductive approach and hence will begin with systematic data 
collection, which will be followed by further analysis and subsequently, the suggestion of 
solutions to the research question.
The various ways to design a research study are as follows:
Single case study
In this method, every detail in a single sample is recorded and studied.
Multiple cases study
Under this method, details of multiple samples are recorded and studied so that 
quantitative data can be collected through the study for statistical analysis.
Panel study
In this method, the researcher obtains the consensus of experts, which can be very 
useful in defining terms and making predictions; this is the main objective of a panel 
study. The Delphi method is probably the most frequently cited technique for panel 
studies (Flynn, 1990). This method lends itself to the aims and objectives of this study 
and will be the focus of chapters 3 and 4 to generate baseline data for further analysis 
and conclusions. Therefore, this technique is explained here in more detail.
The Delphi technique:
The Delphi technique can be defined as a method for structuring a group 
communication process in such a manner that the process enables a group of 
individuals, as a whole, to deal with a complex problem (Linstone, 2002).
History; This method was developed by the RAND Corporation (Santa Monica, CA) in 
the 1950s but was published only ten years later because the project was defence- 
related and much of its content needed to be suppressed in the interests of national 
security (Meyrick, 2003).
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Modifications; The Delphi method has undergone steady development since then, and 
this study discusses some major modifications that have been made to the conventional 
Delphi method. The conventional, also referred to as traditional or standard Delphi 
technique, involves reaching a consensus among experts.
• In 1970, the technique was modified into what came to be called the ‘Policy 
Delphi technique’, which aims at identifying the widest possible range of valid 
solutions to a policy problem (Linstone, 2002).
• Another modification involves convening a meeting between experts only 
after taking all the conventional steps to resolve the remaining conflicts 
between the panel members. It should be noted that due to the presence of 
certain constraints, this meeting cannot replicate the main panel members; 
moreover, the anonymity of the experts will also be breached by this process 
(Meyrick, 2003).
• A third modification involves preparing a list of issues in advance and 
presenting it to the panel members for further discussion, with the final 
objective of reaching a consensus (Meyrick, 2003). In conventional Delphi, 
this list is prepared by the panel members. Although such a process can 
save time and resources in conducting the study, it may, at the same time, 
deprive the study of a wider range of ideas.
• The George Washington University has introduced a modification in the 
Delphi method in that one Delphi round is repeated every two years. The final 
aim is to forecast the emerging technologies, with no intention of achieving 
consensus among the panel members (Halal, 1998).
Applications; Delphi initially was used for forecasting possible outcomes through 
discussions conducted by a panel of experts (Murphy, 1998). It systematically gathers 
inputs from the expert panel on a topic which may be beyond the expertise or 
experience of a lay person. The original experiment pertaining to this method in the 
1950s involved a panel of seven experts attempting to estimate the bombing 
requirements for a hypothetical Soviet attempt to disable USA’s production capacity 
and thereby its capacity to maintain a war effort (Meyrick, 2003). During the ensuing
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years, however, the applications of the Delphi method have dramatically increased in 
terms of both how it is applied and to what it is applied.
While many people label Delphi as a forecasting tool because of its significance in that 
area, it has a variety of other applications, for example, examining the significance of 
historical events, evaluating possible budget allocation, revealing causal relationships in 
complex economic and social phenomena, distinguishing real and perceived human 
motivations and the prioritising of personal and social goals (Linstone, 2002). The 
Delphi technique has also been applied in a variety of health-related situations such as 
health education and the prioritising, planning and developing of clinical practice as well 
as health service organisations (Jones , 2000).
Selecting the participants; In order to deal with complex topics that arise when 
attempting to determine the best practice for a particular procedure, it is generally 
necessary to input the opinions of an ‘expert’, not those of the general population. 
Hence, a simple random sample is often unsuitable and it is crucial to secure the 
participation of the appropriate experts with in-depth knowledge and vision in the 
concerned field, thus ensuring the inclusion of a variety of viewpoints (Meyrickde, 2003). 
The experts should also be interested in and committed to participating in the study as 
efficiently as possible. Appropriate measures should be taken to minimise sampling and 
coverage errors (Brenson, 2009). Furthermore, the experts should be fully informed 
about the tasks they are required to perform.
In order to identify the experts, Delbecq et al. (as qouted by Okilo, 2004) have 
suggested the following multi-step iterative approach:
i. The first step involves preparing a knowledge resource nomination worksheet 
(KRNW) by categorising the experts before identifying them. This is mainly 
intended to avoid overlooking any important class of experts. The categories 
may be based on their organisations, disciplines or skills (the experts may be 
academics, practitioners, government officials or from non-governmental 
organisations (NGOs). It also includes reviewing relevant literature.
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ii. The second step involves populating the KRNW with the names of the
potential experts. There may be an overlap between the categories of
experts. It is usually needed to utilise personal networks because of the need 
for cooperation between experts throughout the study.
iii. The third step includes the first round of contact-nominations for additional 
experts; the study objectives are explained to the existing experts, who in turn 
are asked to nominate new experts for inclusion in the list.
iv. The fourth step involves ranking the experts according to their qualifications.
v. In the final step, the experts are invited to join the study based on their
rankings in order to form a panel with the optimum number of members.
These steps are illustrated in Figure 2.1.
Practical steps; The administration procedure of the Delphi technique can be 
outlined based on the concepts of brainstorming (for collecting a wide range of 
expert opinions), narrowing down the original list to the most relevant ones and 
ranking the list of identified items (Okilo, 2004). These concepts will be used in this 
study in the following phases:
• First phase: Exploration of the subject by collecting information pertaining to 
each participant. This step commonly involves asking the participants open- 
ended questions. An open-ended question is one where the range of possible 
answers is not suggested to the participants; hence, the participants are 
expected to answer it in their own words (Brace, 2004).
• Second phase: Understanding the views of the group, mainly by exploring the 
level of their agreement or disagreement with the statements concluded from 
the first round and formulated as the first questionnaire.
• Third phase: Exploring the differences in the level of agreement and 
disagreement among the group members and analysing the underlying 
reasons. In this step, all the members are provided the opportunity to revise 
their answers through a second Delphi questionnaire. This questionnaire will 
include the median, maximum and minimum scores of the responses.
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Figure 2.1 Key steps in the Delphi technique to identify and select
experts
Identifying relevant disciplines or skills academics 
practitioners, government officials and industry 
Identifying relevant organisations 
Identifying relevant academic and practitioner literature
Listing the individuals in relevant disciplines or skills
Listing the individuals in relevant organisations
Listing the individulas from academic and practitioner literature
Contacting the experts listed in KRNW  
Asking them to introduce other experts
Step 4: 
Rank Experts
Step 1: 
Prepare KRNW
Step 2:
Populate KRNW  
with names
Step 3:
Nominate 
Additional Experts
Creating sub-lists, one for each discipline
Categonsing experts according to appropriate list
Ranking experts within each list based on their qualifications
• Inviting experts for each panel, with corresponding to each 
discipline
> Inviting experts in the order of their ranking within their 
discipline sub-lists
’Soliciting experts will be when each panel size is 
reached, target size is 10-18.
‘ Knowledge Resource Nomination Worksheet Source: Adapted from Okilo, 2004
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Ultimately, the final responses are evaluated and results are analysed. These phases 
are presented in Figure 2.2.
Figure 2.2 Practical steps for the implementation of the Delphi technique
M l
•Collectingparticipants'views to preparea pool of \  
ideas.
• This step commonly involves asking the participants 
open-ended questions wherein the range of possible 
answers is not suggested and the respondents are 
expected to provide an answer for these questions 
in their own words.
y............................................ . . .........  ............. — ■ ■ ........................
• Understanding the views of the group, mainly by 
exploringthe level of their agreementor 
disagreement with the statements concluded from 
the first round and formulated as the first 
questionnaire.
J
T _ ■
• Exploringthe differences in the level of agreement 
anddisagreementamongthe group members and 
analysingthe underlying reasons.
• In this step, all the members are provided the 
opportunity to revise their answers through a 
second Delphi questionnaire.
. - ..... ...............J
Evaluation of the Final 
Responses 
Analvsis of the Data
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Measuring the consensus; In many Delphi projects, achieving a real consensus is 
almost impossible especially with a broad and complex topic. In such cases, the 
multimodal consensus’ or bimodal distribution’ technique may be applied (Meyrick, 
2003 and Linstone, 2002). The aim of these methods is to measure the degree of 
convergence or consensus among the experts by using statistical techniques. The most 
widely used methods include noting down the median ratings or rankings, standard 
deviations and Chi-square analysis (for categorical data) and the analysis of variance 
(ANOVA) (for continuous data). Taking note of the mean is suitable for data with normal 
distribution, while median ratings are useful when the distribution is skewed and there 
are extreme values (outliers) in the data set (Marczyk, 2005). By using the inter-quartile 
range, the researcher can assume that the consensus has been reached if a certain 
percentage of votes fall within a prescribed range (two units in a ten-unit scale). In most 
cases, three iterations of the Delphi technique are found to be sufficient for achieving 
consensus among experts (Linstone, 2002). In addition, the intra-class correlation 
coefficient is also applied to measure consensus among experts (Futrell,1995). The 
present study uses this method, which will be explained further on in this chapter.
In the conventional Delphi, the responses of all the panel members are fed back to the 
participants, thus giving them a chance to modify their responses according to their 
reaction to the collective opinions of the group. The validity of the results of the entire 
panel is typically measured in terms of the explicit ‘degree of consensus’ among the 
panel members (Linstone, 2002). The level of consensus in the Delphi technique is 
illustrated in terms of how the participants rate their agreement or disagreement with 
each statement and is usually measured on a numerical scale. The dispersion of the 
responses can later be calculated using statistical techniques (Brace, 2004).
Advantages; (i) It is not necessary for the experts to meet face-to-face, which is a 
significant advantage because it overcomes the usual time- and distance-related 
constraints (Meyrick, 2003). This advantage, along with the possibility of using e-mail 
technology, makes it possible to collect the opinions of geographically dispersed people 
and individuals with different work patterns and timings, (ii) The opinions of each 
participant remain anonymous to the rest of the panel. The participants are also able to
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change their position in response to further input from the panel members (Meyrick,
2003). This anonymity provides a creative environment that is ideal for continuous 
innovative idea generation in the absence of all socio-psychological barriers. This is 
also important when the experts are required to comment on sensitive economic or 
political issues. Therefore, this technique enables the researcher to source ideas that 
cannot be generated using other research methods.
Pitfalls; Linstone (2002) lists eight basic pitfalls that can undermine the success of the 
Delphi method; these are as follows: (1) Discounting the future: The short planning 
horizon may happen when panel overlooks more sustainable solutions or additional 
options to deal with the currently unsolved problem. (2) Prediction urge: There is a 
tendency to forecast the future; however, there is a high degree of uncertainty in any 
forecast of the future and suppressing this uncertainty can mask the real significance of 
the Delphi. (3) Simplification urge: People normally prefer simplicity to complexity, and 
in scientific research, this temptation may lead researchers to overlook certain important 
aspects of the problem. (4) Illusory expertise: Bringing together a group of people with 
expertise in a particular subsystem does not necessarily result in a comprehensive 
conclusion regarding the total system. (5) Sloppy execution: In this regard, the 
sloppiness can be on the part of both the researcher and the participant. In the former 
case, it can include the poor selection of participants, poor interaction with panel 
members, poor formulation of the statements and superficial analysis of the participants’ 
inputs. In the latter case, the participants may be tempted to ‘get on with the job’ or 
come to an ‘artificial consensus’, which is a potential limitation of this method. This may 
occur when some members who are not really convinced with the inputs provided by 
others, attempt to bring the process to a speedier end. This pretended conformity 
makes it important for researchers to select only committed experts as panel members. 
(6) Optimism—pessimism bias: Participants in the Delphi technique commonly tend to be 
over-pessimistic in their long-term forecasts and over-optimistic in their short-term 
forecasts. (7) Overselling: Repeated Delphi studies on the same subject will result in 
diminishing results. (8) Deception: It is absolutely possible for the Delphi technique to be 
used for data cooking and false inputs. The participants’ anonymity may facilitate the 
deception process.
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Despite the above pitfalls, the researcher’s degree of familiarity with the topic of the 
study can ensure the success of the Delphi technique. It should be mentioned that 
although the Delphi technique appears to be a very simple concept that can be easily 
employed, ignoring its basic principles— such as a free environment for idea expression, 
efficient communication skills, an appropriate technique of summarising and presenting 
the responses, ensuring common interpretation of the statements and scales, and 
preventing the dissenters and non-motivated participants from being discouraged— can 
easily lead to the failure of a Delphi practice (Linstone, 2002).
Due to a lack of consensus among the experts and decision-makers regarding the 
research question of this study, it is concluded that the “panel study” is the most 
appropriate technique for identifying the influencing parameters. Chapters 3 and 4 will 
provide a detailed explanation of the use of the Delphi technique in a panel study, 
starting with an open-ended question that will be followed by two consequential 
iterations for creating a convergence of the ideas.
Focus group
This technique is similar to the panel study; however, in this approach, the group is 
physically assembled and its members’ opinions are expressed orally rather than in the 
written form. The role of the facilitator who conducts the session is very important. The 
facilitator asks the questions, and every participant has the chance to express his or her 
opinion. Group members may discuss the question until they reach a consensus 
(Linstone, 2002). An important limitation of this method is the possibility of problems 
associated with face-to-face interaction, which may limit the range of generated 
opinions; the problems mainly result from the normative pressure for conformity, 
existence of dominant personalities, difficulties faced by members in contradicting their 
colleagues in higher positions and certain socio-psychological factors (Mead and 
Moseley, 2001).
Survey
This is a powerful tool for studying populations in an objective manner (Anon, 2000). 
The survey method relies on the self-reporting of factual data as well as opinions (Flynn,
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1990). There are several different types of survey, based on their approaches and 
objectives, including snap-shot, baseline, longitudinal and comparative surveys. Snap­
shot surveys offer a representative picture of the current situation. They can also be 
included in baseline surveys to provide a ‘before’ picture that can be used for 
comparison with an ‘after’ picture. This concept is most helpful for studying the impact 
or change taking place during a specific period of time. The longitudinal survey method 
involves using the same population to provide the ‘after’ picture, and it can be repeated 
over a period of time. In a comparative survey, two similar subgroups are compared 
(Anon, 2000). Surveys are also classified based on the method of data collection, for 
example, through mail, by telephone, through personal interviews and through web-mail 
and e-mail surveys (Falconer, 2001).
Sample selection; Generally, the more randomised the sample selection, the less 
biased are the results. Even if the samples are selected from a specific group, the 
actual sample should be drawn randomly. For example, if the study is at the plant level, 
the size of the company, number of employees and sales volume can be incorporated 
into the sample selection process (Flynn, 1990). A sample is the portion of a population 
that has been selected for analysis as the representative of the larger group. The results 
obtained from the sample are, therefore, generalised to the entire population. The 
sampling method is generally used because time- and resource-related constraints, in 
many circumstances, make it absolutely impossible to study the entire population under 
consideration. The sampling process begins with the definition of the sampling frame, 
which lists the items that constitute the population. There are two kinds of samples: 
probability samples and non-probability samples.
Probability sample: These samples are taken based on known probabilities. The four 
types of probability samples are as follows: (i) simple random samples are those in 
which every item within the frame has an equal chance of being selected (the table of 
random numbers is commonly used in this type of sampling); (ii) systematic samples 
are taken from the partitions within the sampling frame; (iii) stratified samples are 
selected from subdivisions in the frame, on the basis of common characteristics such as 
gender; (iv) cluster samples are taken from different clusters, such as territories.
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Non-probability sample: Under this method, the samples are not selected according to 
their probability. Common types of non-probability sampling include convenient 
sampling, which is based on the availability of samples, and cost and judgement 
sampling, which involves obtaining the opinion of the pre-selected experts in the subject 
matter (Brenson, 2009).
Strengths; The strengths of the survey method can be summarised as follows (Anon, 
2000 and Falconer, 2001):
• Ease of application and comparatively low administration cost
• Opportunity for including multiple participants
• Simple data analysis
• Possibility of preserving the anonymity and/or confidentiality of the 
participants
• Flexibility to generate different forms of quantitative and qualitative data 
and information
• Requiring relatively short period of time for data collection
The ultimate purpose of the survey studies is to be able to generalise the results to the 
entire population, and this is possible only if the errors in the study have been 
minimised. There are six types of survey errors:
• Coverage error: This occurs if a group of people is excluded from the sampling 
frame and results in a ‘selection bias’.
• Non-response error: This arises from a failure to collect data from all cases in
the sample and results in a ‘non-response bias’.
• Sampling error: This results from a chance variation between samples, due to
the probability of particular items being selected in particular samples, and is
reported as a ‘margin of error’.
• Non-sampling error: Non-sampling errors arise from mistakes made in areas 
such as the coding and data-entry processes of the survey; these errors include
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not only the mistakes committed by interviewers but also those made during the 
development of the questionnaire (Brace, 2004).
• Measurement error: This error occurs when a study tool does not accurately 
measure the component it is designed to measure. This may be due to 
ambiguous wording in a questionnaire, the Hawthorne effect (the respondent’s 
wish to please the interviewer) or respondent error (e.g. insufficient effort) 
(Brenson, 2009).
• Social desirability bias (SDB): SDB arises because participants like to appear 
to be different from their real selves. This can occur consciously, when 
participants want to manage the impression that they are projecting of 
themselves in terms of social responsibility, or subconsciously, when they believe 
themselves to be other than what they are, which is possibly a form of denial. 
Some of the common desirables include being a good citizen, being a well- 
informed and cultured person, fulfilling the expected moral and social 
responsibilities. A common technique to avoid SDB is to ensure confidentiality. 
Other techniques involve the removal of the interviewer, using the random 
response and question enhancement techniques, and asking face-saving 
questions and indirect questions (Brace, 2004).
Non-respondents analysis; In social sciences, the response rates generally exceed 
40-60%, while in operations management these rates can be as low as 10-20%, which 
is really unreliable even if non-respondents are mined. In order to achieve results that 
are both reliable and can be generalised, it is necessary to obtain a response rate of 
50%, along with non-respondent checking. There are several ways to increase the 
response rate, such as sending a reminder letter to the participants, ensuring 
confidentiality of the collected data, contacting potential participants and obtaining their 
commitment to the study, provision of feedback and other incentives, and appointing a 
coordinator in geographically dispersed studies (Flynn, 1990).
In cases where systematic differences are observed between the respondent and non­
respondent groups, it generally becomes very difficult to generalise the results to the 
entire population. For example, firms with quality problems may not respond to a
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questionnaire investigating quality, which means that those who do respond may not 
represent the entire population. Hence, it is necessary to analyse the important 
characteristics of the non-respondents in order to determine whether they are 
systematically different, which will be difficult if the questionnaires are distributed 
anonymously. However, if the non-respondents are identified, they may agree to answer 
some brief questions on the telephone. In fact, strict non-respondent analysis is 
especially recommended if the non-response rate is more than 50% (Flynn, 1990).
Limitations and challenges; The way in which questions are formulated can bias the 
responses, for example, if the questions have not been properly formulated in an 
unambiguous manner and convey different meanings to different participants. 
Questions can also reveal the bias of non-respondents; for instance, if the non­
respondents are found to have some different characteristics from the participants, the 
results of the sample cannot be generalised to the entire population (Falconer, 2001).
The application of more than one method or mixed methods reportedly improves the 
value of a survey; for example, conducting a focus group first can help in the 
development of questions for a survey questionnaire. Conducting a survey first can 
assist in the development of questions for a focus group that will allow both confirmation 
and clarification or elaboration of the responses collected in the survey (Falconer, 
2001). Engaging both quantitative and qualitative methods in one single study is 
regarded as an emerging approach in the field of research (Lunenburg , 2008). Some 
authors have explained the specific steps involved in mixed research design (Johnson, 
2004).
The approach that will be undertaken in this study will be a mixed design including the 
current situation of the pharmaceutical industry and will use a specific rating scale in an 
attempt to collect the opinions of the study participants for further examination.
Data Collection Methods
An appropriate data collection method should be selected based on the study design 
and the nature of the data that are likely to be generated.
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Data types
The collected data can be categorised in four main types of: nominal, ordinal, interval 
and ratio data.
Nominal data have no numerical meaning and include items such as dichotomies 
(responses that have only two options, such as yes/no, male/female) and categorical 
data (age-group or ethnicity). Nominal data are mainly descriptive and can be used in 
content analysis (Marczyk, 2005 and Milller, 2008). In the context of the present study, 
the nominal data are in the form of the participants’ responses to demographical 
questions.
Ordinal data have a ranked order and are represented numerically; however, the 
differences between their values may not be equal. Therefore, ordinal data do not have 
a true numerical meaning. For example, responses to a question on how often the 
respondent uses online banking could be represented as ranging from the number zero 
(never uses online banking) to the number four (uses online banking at least once a 
week) (Somekh, 2005). Such responses may provide a higher level of measurement 
compared to that of the nominal data (Marczyk, 2005).
Interval data have true numerical values but no true zero, for example, a thermometer 
measuring temperature in degrees Celsius or Fahrenheit. While addition and 
subtraction are possible with this level of measurement, the lack of an absolute zero 
point makes division and multiplication impossible (Marczyk, 2005).
Ratio data, in contrast, do have a true zero, for example, the distances travelled to work 
(Somekh, 2005). Time, height, weight and money are other examples of this kind of 
data. Ratio data provide the highest level of measurement and allow for the use of more 
powerful statistical techniques (Marczyk, 2005). Variables containing nominal or ordinal 
data are sometimes referred to as discrete variables, whereas those containing interval 
or ratio data are sometimes referred to as continuous data (Somekh, 2005). In this 
study, the data will be obtained mainly from ordinal levels of measurement. The 
participants will be selecting figures from a range of response options on an ordinal 
scale to rate their agreement with the statements in the questionnaire.
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Data collection
The commonly used data collection methods for studies of such nature are as follow:
■ Historical archive analysis: The archival sources are used in many research 
projects. The researcher may intend to make the data public at the appropriate time 
or keep them as internal records. While access to the first group is always 
convenient, the second group is also accessible in some instances. Archival data 
are unbiased because the provider is unaware of how they will be used in 
subsequent studies. However, the user's lack of control on the data collection 
environment may be a limitation for using this kind of data. This method may be 
used in conjunction with a survey or panel study (Flynn, 1990).
■ Participant observation: This method is frequently used in case studies for
observing the participants of the study and recording their behaviour or their manner 
of doing things (Flynn, 1990; Cassel and Symon, 2004).
■ Outside observation: This involves collecting data in a systematic manner, for
example, by employing an unbiased observer. This method is suitable for both case 
studies and panel studies.
■ Content analysis: Sometimes referred to as document analysis, this method deals 
with the systematic study of records or documents as sources of data (Singh, 2006). 
It is based on transforming the often qualitative, open-ended survey responses into 
quantitative data. This may involve developing coding procedures, establishing the 
reliability of the coding procedures, and developing careful data screening and 
cleaning procedures (Marczyk, 2005).
■ Interviews: This method is based on collecting data through conversations with the 
participants while focusing on study-related topics. The following list includes some 
modifications to the simple interview method:
i) Structured interview: The interviewer asks questions from a written form as well 
as new questions based on the direction taken by the conversation.
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ii) Ethnographic interview: In this case, a hierarchy of questions is asked, and the
next question is selected according to the previous responses. An interview 
using transcriptions adds value to the work. However, even though the 
transcripts can be used for further analyses, many interviewees do not like to 
be taped.
iii) Face-to-face CAPI: Computer-assisted personal interviewing (CAPI) involves the
use of a portable computer; the questions and pre-codes are provided on the 
computer screen. The computer can be either a tablet computer with a touch 
screen, on which participants can record their responses by using a stylus, or 
laptop personal computers, wherein answers can be recorded by clicking the 
cursor on the appropriate box. Laptops may have multimedia capabilities. In 
central locations, desktop personal computers may be used. Personal digital 
assistants (PDAs) can be used in circumstances where the number of 
questions is relatively small (PDAs have also been used successfully as a 
self-completion medium). In computer-assisted telephone interviewing 
(CATI), the telephone is used instead of face-to-face interviews (Brace,
2004). The advantages and disadvantages of different interviewing media are 
summarised in Table 2.1:
Table 2.1 A comparison of face-to-face and telephone interviews (Brace, 2004)
Face-to-face interviews Telephone Interwies
Advantages Disadvantages Advantages Disadvantages
-Response cards can 
be shown
-Stimulus materials 
can be shown
-Self-presentation bias
-Selection bias 
-Tird party bias
-Relative anonimity 
can reduce bias
- to use prompts
- It is difficult to show 
stimulus material
More complex 
questions can be 
asked
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■ Questionnaires: Questionnaires or rating scales are established methodologies 
used in research studies. Since it was decided to use the questionnaire method in 
this study, this type of data collection method will be explained in further detail in this 
chapter.
Questionnaires and interviews are the most commonly used data collection 
methods. The key difference between them is that in the former, the respondent 
records the responses directly, while in the latter, the interviewer completes the 
questionnaire on the basis of the verbal answers of the respondent. With regard to 
the time, cost and logistic issues, questionnaire techniques are more appropriate for 
collecting a high volume of data or data from geographically dispersed participants. 
This method is also recommended when the sample population is oriented to this 
methodology (Trochim, 2002).
A number of approaches for data collection methods are available while using rating 
scales. These are briefly described below:
• Paper or electronic-mail-delivered questionnaire - For this method, a 
printed questionnaire is mailed to the participants, and they are asked to 
complete it at a convenient time.
Advantages: The benefits of this method are that it requires only a modest 
amount of resources, the wishes of the study participants with respect to 
confidentiality and anonymity can be respected and the cost is low, especially 
if electronic methods are applied.
Limitations: Administering questionnaires in this manner is time-consuming, 
and it is necessary to perform a follow-up in order to improve response rate 
and reduce bias; these are the main limitations of delivering questionnaires by 
mail. In addition, there is limited scope for routing the respondent to the 
appropriate next question (on the basis of their response to the previous 
question).
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•  Group administered questionnaire - Under this method, a group of 
participants are gathered together and asked to complete the questionnaire 
individually.
•  Telephone administered questionnaire - This involves organising 
telephone interviews for data collection. The participants are telephoned 
according to an agreed time schedule. It is also possible to use an automated 
system for administering the questionnaire, where the users are connected to 
a computer-based interview system.
•  Web~based questionnaire - This method has become more prevalent in 
recent years due to the developments in Web-based communications. Its 
strengths include faster data collection, cost benefits and the fact that the 
participants can reply at a flexible and convenient time; however, the 
participants must have access to computers and the Internet—this is the main 
limitation of this method. There are several different ways of carrying out 
surveys using the Internet. The questionnaire can either be delivered by e- 
mail or accessed via a Web page, either in the form of an Open Web— a Web 
site open to anyone who visits it or a Closed Web—wherein participants are 
invited to visit a specific Web site to complete a questionnaire. Other kinds of 
Web-based methods include the e-mail URL embedded questionnaire, where 
a respondent is invited to the data collection media survey site through an e- 
mail that contains a URL or Web address on which the respondent clicks, the 
simple e-mail, or an e-mail with questions contained in it, and an e-mail 
attachment, in which the questionnaire is sent in the form of an attachment to 
an e-mail. The participants also receive directions on how to download the 
questionnaire, complete it and then return it. However, questionnaires 
embedded within e-mails can have distorted layouts, depending on the e-mail 
software used to open them. Most practitioners now use questionnaires 
hosted on a Web site to which participants are invited or routed in some ways 
(Brace, 2004). The summary of the characteristics of interviews and self­
completion methods is presented in Table 2.2:
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Some studies may require the application of more than one method, for example, 
a study may use a combination of questionnaires, structured interviews and 
archival financial data (Flynn, 1990).
For this study a mixture of data collection methods will be used including the 
structured interview, as a part of the Delphi technique, and the development of 
rating scales in the format of e-mail attachments or closed web-based 
instruments.
Table 2.2 A comparison of interviewer-administered and self-completion questionnaires
Interviewer-administered Self-administered
Paper Electronic Paper Electronic
-Flexible Allows complex -Flexible Allows complex
routing; can route routing, can route
-Inexpensive to set questions and -Wide reaching questions and
(A
O
O)
up responses, builds responses, builds
(0 links between links betweenc
(0> questions, uses questions, uses
T3< advanced stimuli advances stimuli, no
(face-to-face), no data entry and fast
data entry and fast analysis.
analysis.
-Requires data entry Can be slow to set Require high quality Requires high
(0
0)o> up, Software skills design, respondents respondents
(0 -Limited routing are needed for CAPI can read through, commitments,cre> and CAT I spontaneous response rate is low
T3re questionnaires. measures and limited and questionnaire
.52o circulation. layout may beU
distorted.
Source: (Brace, 2004)
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Data collection procedure
A confidential procedure will be used for data collection in this study. An identifier will be 
used to mark the participants in the Delphi technique in order to secure the traceability 
of the responses during different steps of the technique, as will be described in next 
chapters. The same policy will be followed in chapters 5, 6 and 7, when collecting data 
from the industry managers, considering the sensitivity of the collected data pertaining 
to the current situation in the companies. However, the confidentiality procedure will not 
be applied for collecting the data during the content validation steps in chapters 3 and 5 
due to the purely linguistic nature of the data.
Information sources
The data required for carrying out this study will be sought from the following sources 
for each chapter:
• Chapter 3: Eleven experts will act as panel members in the first round of the 
Delphi technique
• Chapter 3: Eight experts will form the content validation panel for validating the 
Delphi technique questionnaire
• Chapter 4: Eighteen experts will be consulted in the second round of the Delphi 
technique in order to identify the influencing parameters of the study
• Chapter 5: Eighteen experts will perform content validation of the study 
instrument
• Chapter 6: A total of 109 managers from 25 pharmaceutical companies will be 
invited to evaluate the current situation and future aspirations of the 
pharmaceutical industry. The data will be used for further analysis in chapters 
seven and eight.
Development of the Study Instrument
In the absence of a suitable instrument, a questionnaire to identify the parameters 
influencing the sustainability of the industry in the post-WTO situation will be developed
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to accommodate the use of the Delphi technique. In addition, an instrument will be 
developed to evaluate the current environment and future aspirations of the industry.
The major limitation pertaining to questionnaires is the complexity of generating a set of 
unambiguous items. Researchers often need to perform a pilot study or apply other 
techniques to ensure the validity of the questionnaire. Therefore, formulating a 
questionnaire is an important step towards reliable data collection. Good questionnaire 
design is a no- or low-cost option in any study, which reaps major benefits by delivering 
the best, or most accurate, responses (Brace, 2004). However, the real importance of 
creating a good questionnaire is often underestimated. After all, anybody can write a set 
of questions, ‘but if those questions are the wrong questions, poorly phrased, or in the 
wrong order, the answers obtained may be worse than meaningless or at best 
misleading’ (Brace, 2004).
In order to develop a robust study instrument, it is crucial to observe the following 
guidelines (Falconer, 2001):
• Declare the aim of the study and introduce who is administering the study
• State the confidentiality and/or anonymity of the participants
• Provide instructions for completing and returning the questionnaire
• Ask the appropriate number of questions
• Ask one item per question
• Ensure the linguistic clarity and completeness of the questions (use of 
appropriate wording)
• Offer incentives for efficient participation.
The present study used a multi-source and multi-stage process to develop the study 
instruments.
Step 1 -  Conceptualisation
The instrument should be developed based on the age, population and characteristics 
of the study participants. Questions such as; do they require a simple and
54
straightforward tool or; do they have the necessary motivation and expertise to 
participate in a more technical and complicated data collection procedure were 
considered. In other words, a self-administered tool may be completed in five minutes, 
while an interview requires more active participation. In the population selection step, 
data can be obtained from individuals at the individual level. The target population that 
the instrument is intended for should be the determinants of the underlying concepts of 
the measuring instrument.
Step 2 - Item generation
This step involves probing the target audience in order to generate an initial pool of 
items reflecting the views of individual members of target population (Clark and Watson, 
1995). Item generation may be continued until a saturation point is reached. It is also 
possible to borrow some items from existing instruments. The sample size may be fixed 
at this stage. The first round of the Delphi technique, which is characterised by open- 
ended questions, may be considered as the item generation phase in this study.
Step 3 - Item reduction
This step involves deciding if an item can be removed from the initial pool, based on the 
importance or priority of the generated items. This study will use the Friedman ranking 
method to prioritise the items.
Step 4 - Development of taxonomy
This includes generating a list of areas under which headings the items can be grouped 
and thereby categorised. In this study, the items were grouped based on their structure, 
content and context or according to industry departments such as R&D, marketing, and 
Good Manufacturing Practices (GMP).
Step 5 - Scale development
Selecting appropriate scale plays an essential role in determining the quality of the 
collected data and the sophistication of the data analysis. Since this study was based 
on the degree to which the participants agree with the statements provided by the study 
instruments, the Likert scale will be considered to be suitable for the study. This scale,
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which is known as an ‘agree-disagree’ scale, is frequently used and is suitable for 
measuring intervals. Moreover, the data collected by using this scale can be easily 
analysed. The response options can be simply and flexibly arranged and their 
summated values can be obtained to measure a general construct. It should be 
mentioned that the study participants may tend to quietly mark the same response for 
each item; to deal with this, the direction of the questions may be changed thorough the 
questions (Flynn, 1990). The Likert scale was first published by the psychologist Rensis 
Likert in 1932. The scale presents respondents with a series of attitude dimensions, and 
they are asked whether, and how strongly, they agree or disagree with each of those 
dimensions, using one of a number of positions on a five-point scale (Brace, 2004). The 
nine-point Likert scale is also widely used, in which 1 shows strong disagreement and 9 
shows strong agreement. While most researchers use Likert scales varying from three 
to seven points, the shorter scales give little scope to the study participants if they want 
to modify their responses during the study (Mead and Moseley, 2001; Linstone, 2002).
Whether to use an odd or even number of response options is an important issue in 
scale development. Some researchers prefer to use a scale with an even number of 
points to eliminate the neutral mid-point in an attempt to force those who would 
otherwise choose it to give an inclination one way or the other. In studies where it is 
expected that most people would have a view on a particular topic, for example, studies 
about an important social issue or a criminal action, it can be argued that most people 
hold an opinion even if they are unaware of doing so. It is therefore reasonable for a 
researcher to force a response in one direction or the other. Studies have shown, 
though, that including a neutral scale position significantly increases the number of 
neutral responses compared to accepting them spontaneously. This indicates that 
eliminating the middle neutral point does increase the commitment of respondents to be 
either positive or negative (Brace, 2004).
Psychometric evaluation of the study instruments
Psychometric evaluation involves assessing a number of measurement properties of an 
instrument. The psychometric properties assessed in this study will include applicability 
and acceptability, practicality, validity, reliability and sensitivity or responsiveness.
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Applicability and acceptability for use
The applicability of the study instrument describes the suitability of an instrument for its 
intended use in terms of wording, linguistic clarity and simplicity (Higginson and Carr, 
2001). It also assesses whether the content and emphasis of the measure fits the 
intended purpose of developing the instrument (Deyo, 1984). Another important criterion 
is how acceptable the study instrument is to the participants and whether they are 
comfortable answering the questions. It is also necessary to consider the instrument 
completion time and whether the questions are concise, clear and easy to understand 
(McLeod, 2008).
Practicality
The practicality of the study instrument includes the respondent burden, cost of 
administration, mode of administration of the instrument (e.g. interviews or self­
administered questionnaires), ease of scoring and whether the instrument is 
understandable (Deyo, 1984). The indicators of respondent burden include high refusal 
rates, missing responses and high administration time (Ware, 1981).
Validity
Validity measures two things: First, does the instrument measure what it has been 
designed to measure? Second, does it measure anything else? For an instrument that 
is suitable for use in a research study, the response to both these questions must be 
positive (Flynn, 1990 and Lunenburg, 2008). There are three main types of validity:
Content validity: This is the degree to which an instrument measures an intended 
content area ensuring that the focus and emphasis of the instrument as a whole and its 
individual components are fit for the purpose for the intended area and respective 
population. This type of validity is very important in testing instruments. Content validity 
of an instrument is normally established based on the judgment of a panel of experts. 
This method will be used in the chapters 3 and 5 of this study.
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Criterion validity: There are two types of criterion validity—concurrent validity shows the 
correlation between the results of two tests when both tests are administered at roughly 
the same time, while predictive validity is the ability of the test to predict how the 
individuals will perform in the future. This is especially important in cases where people 
are seeking admission to colleges or have applied for jobs. Criterion validity is often not 
carried out because of the resource limitations.
Construct validity: This is a very important form of validity because it evaluates what the 
instrument is really measuring. It justifies the use of the instrument in the research study 
and should ideally be evaluated by a series of studies due to the complexity of 
measuring the construct (Lunenburg, 2008). Factor analysis can also be used in 
establishing construct validity (Flynn, 1990).
A detailed content validation of the study instrument will be carried out and reported in 
the respective chapters.
Reliability
Reliability is measured by the extent to which a questionnaire or item which is 
repeatedly administered to a particular group will yield the same results (Flynn, 1990; 
Marczyk, 2005 and Lunenburg, 2008).
Test-retest reliability: This shows the extent to which the results of an instrument are 
consistent over time. Test-retest reliability can be determined from the correlation 
coefficient of the results of administering the instrument to a group of people twice, with 
an interval of one week (seven days) between the administrations.
Equivalent-form reliability: Equivalent forms are two instruments that are identical in all 
respects except for the actual items included in them. The correlation coefficient of the 
results of administering two equivalent forms of an instrument to a group of people 
indicates the degree of equivalent form reliability.
Inter-rater reliability: This is a type of inter-judge reliability which is often carried out for 
interviewer administered instruments and can be calculated by using correlation 
techniques. It also can be expressed as a percentage of agreement between the raters 
when they are observing or evaluating the performance of others (Marczyk, 2005).
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Internal consistency reliability: This is a commonly used form of reliability, and there are 
different approaches to measure it:
i) Cronbach’s alpha reliability: This method estimates the instrument’s internal 
consistency reliability by determining how all the items in an instrument relate to 
one another and to the total instrument (UCLA.edu, 2009).
ii) Intra-class correlation coefficient (ICC): This test is a reliability index to assess 
the extent to which the ratings or classifications of an instrument are made on a 
consistent basis. ICC results of 0.61-0.8 illustrate substantial consistency, and 
any result exceeding 0.81 indicates near-perfect reliability (Futrell, 1995). ICC 
can be measured by using statistical software such as SPSS, and the equation to 
calculate the coefficient correlation is the same as that used to calculate 
Cronbach’s alpha. The ICC interpretation guide is presented in Table 2.3:
Table 2.3 Interpretation of ICC values
Kappa or ICC Interpretation
< 0 No agreement
0.0 — 0.20 Slight agreement
0.21 — 0.40 Fair agreement
0.41 —  0.60 Moderate agreement
0.61 —  0.80 Substantial agreement
0.81 — 1.00 Almost perfect agreement
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iii) Split-half reliability: In order to measure split-half reliability, a single instrument 
is first split into two halves, such as items with odd and even numbers, and then 
the complete form as well as the halves are administered to a group. The 
correlation coefficient between the results indicates the split-half reliability 
(Lunenburg, 2008).
ICC will be used in this study to measure the consensus among the experts, while 
Cronbach’s alpha will be used to test the reliability of the data.
Sensitivity
Sensitivity assesses the ability of the instrument to measure change over time 
(Higginson and Carr, 2001, McLeod, 2008). Study instruments that are designed to 
measure the differences between different groups of people are called discriminative 
instruments, while those designed to examine change over time are known as 
evaluative instruments (Guyatt, 1987).
Pilot study
A pilot test is an essential part of questionnaire development as it provides a practical 
understanding of how easy it is for the participants to complete the questionnaire and 
helps to identify the parts of the questionnaire that are vague, unclear or beyond the 
speciality or expertise of the participants. A pilot study is expected to provide answers to 
the following questions: Do the questions sound right? Do the interviewers understand 
the questions? Do the participants understand the questions? Have we included any 
ambiguous questions? Can the participants answer the questions? How long does the 
interview take or what is the completion time? (Brace, 2004). The procedure includes 
administering the developed version of the questionnaire to a small, typical group of 
participants, based on their availability and readiness. It may be concluded after the 
pilot study when the questionnaire needs some revision in order to make it more user- 
friendly. If the pilot study indicates that the questionnaire contains confusing items, it 
may be necessary to arrange an explanatory session prior to administrating the 
questionnaire to the intended study participants (Flynn, 1990).
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Data Processing and Analysis
Data processing
It is important to carefully examine all the data obtained through data collection 
instruments in order to prevent data analysis errors. Incomplete or blank items, 
handwritten comments and inappropriate responses should be dealt with using 
standardised techniques.
Data processing and analysis in this study will be carried out using Microsoft Excel and 
SPSS version 17. Descriptive statistics such as mean, median, ranges and frequency 
charts will be used for quantitative data, with content analysis being performed to 
identify the major themes. The respective chapters will use descriptive tables and bar 
charts in order to illustrate the key characteristics of data distribution. One of the most 
difficult tasks in analysing data consists of selecting the most appropriate statistical 
technique that both addresses the research question and fits the data that have been 
collected.
Generating and testing the hypothesis
Hypothesis testing implies testing a theory that is accepted to be true or regarded as a 
basis for discussion. A hypothesis is the re-articulation of a research question 
(grounded in theory and/or literature) to form a precise statement, which may include 
the prediction of an outcome, in such a manner that it can be tested statistically 
(Somekh, 2005). In either case, two competing hypotheses are examined: the null 
hypothesis, denoted as Ho, and the alternative hypothesis, denoted as H-i.
The null hypothesis is regarded as the focal point and relates to the statement being 
tested, whereas the alternative hypothesis relates to the statement that will be accepted 
if or when the null hypothesis is rejected. The testing procedure begins with the 
assumption that the null hypothesis is true, and the aim of the process is to determine 
whether there is enough evidence to infer that the alternative hypothesis is true (keller, 
2007).
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If the value of the sample significantly differs from the expectation based on the null 
hypothesis, the null hypothesis will be rejected and the alternative hypothesis will be 
accepted. To evaluate the significance of the difference, it is possible to apply decision­
making techniques such as t-distribution, p-value and critical value (Brenson, 2009). 
Two possible errors can occur while testing the hypothesis: A type I error occurs if a 
true null hypothesis is rejected, while a type II error involves failing to reject a false null 
hypothesis. The probabilities of type I and type II errors are denoted by a (which is also 
called the significance level) and (3, respectively (keller, 2007)
Statistical analysis
Inferential statistics is defined as using the results of a small group (study sample) to 
make a conclusion about a larger population (Brenson, 2009). Statistical methods are 
divided into two main types: parametric and non-parametric.
Parametric statistics are based on the principles of the normal distribution curve. 
Therefore, in order to be able to use parametric statistics, the data must be normally 
distributed as one of its main required assumptions. The required sample sizes can vary 
according to the kind of research enquiry and respective statistical test; a general rule- 
of-thumb is to take a minimum sample of about 30. However, with the samples of less 
than 30, it is often better to use non-parametric statistics (Marczyk, 2005). Non- 
parametric tests are applied to non-normally distributed data (Motulsky, 1995). In 
identifying differences between groups (i.e. to understand if the differences between 
several groups are real or have occurred by chance), researchers use statistical tests 
that target differences and then use methods of calculating the statistical significance of 
those differences. Parametric techniques for identifying differences include the t-test 
(when there are only two groups) and the ANOVA (when there are more than two 
groups) (Marczyk, 2005).
Non-parametric techniques for identifying differences include the Mann-Whitney U test 
(the nonparametric equivalent of the independent sample t-test) and the Wilcoxon 
signed-rank test (the nonparametric equivalent of the paired sample t-test).
6 2
Non-parametric tests are more robust but less sensitive. They are sometimes referred 
to as assumption-free tests, and their techniques are based on ranking rather than 
exact differences. Non-parametric tests are appropriate for ordinal and nominal data. 
They can also be used when the necessary assumptions for parametric tests are not in 
place (e.g. absence of a normally distributed data set) (Somekh, 2005).
Statistical tests
This study will use the Friedman test and the binomial test, which are appropriate for 
ordinal data. This selection is based on the measurement levels and types of data as 
explained earlier in this chapter.
a) Friedman test
The Friedman test is a nonparametric test that compares three or more groups. 
This test is an alternative for the repeated measures ANOVA when normal 
distribution cannot be demonstrated. In this study, Friedman test will be used to 
rank the identified parameters in chapters four and six.
b) Binomial test
The binomial test is used with dichotomous data when each item in the sample is 
classified in one of two categories; it is used to find out whether the distribution of 
the items in each category is produced by chance or is the result of some pre­
specified probabilities (Brenson, 2009). This test will be used in chapter six to 
evaluate the level of “satisfaction” or “importance” of the study parameters.
Gap analysis, a simple approach for prioritising improvement areas
The study of the gap plays an essential role in analysing the situation of the 
pharmaceutical industry in this research. The gap will be simply measured by 
subtracting the scores pertaining to the current situation from the future importance of 
the respective parameter. The questionnaire for this purpose will be designed with a 
rating scale investigating both the current situation and the future importance of each 
parameter. By the participants being questioned about both the present and the future, 
it will be possible to rank the potential areas for improvement in relation to the
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importance of that parameter. It is expected that this gap will be filled by actions and 
corrections in order to reach the desirable condition.
Gap analysis is the study of the existing distance between the current and the desirable 
situation and has been widely recognised as an appropriate method to analyse the 
situation when there is an intention to move from a starting point towards a desirable 
state. In fact, gap analysis is a very useful tool for helping industry managers and policy 
makers decide about the strategies they should follow. In later stages, the aim is to look 
at ways to bridge the gap by backward-chaining logical sequences of actions from the
target state to the current state. This implies that the following questions should be
answered in a gap analysis process (Figure 2.3):
What (b) must be in place, or must have happened, in order that this desired state (a)
can exist?
Then, what (c) must be in place, or must have happened, in order that this state (b) can 
exist?
For analysing the gap, it becomes necessary to answer two questions: Where are we 
now? Where do we want to be? The gap is in essence, the difference between these 
two situations. The main question is how to overcome the gap and reach the target 
state. As shown in Figure 2.3 the lower line represents where a person will be if he or 
she does nothing. The upper line is where the person wants to be.
Figure 2.3 The concept of gap analysis
The GapWhere do we want to be?
Where we are now?
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The next step is to close the gap. In general, strategies and tactics are targeted at 
closing the gap.
Another way to describe the gap is to measure the distance between two situations. In 
this method, each item can be evaluated in terms of its current and desirable situations 
by using a nominal scale. For example, the R&D budget at present and in the future 
may show a big or small gap throughout the industry. The extent of this gap may be 
different between companies, and companies may follow a special pattern in their 
different aspects. This leads to the recognition of a relative or comparative gap which 
reveals the differences in achievements in similar items and, needless to say, reflects 
the sustainability of single company as well as the entire industry in the future and 
identifies the high payback areas of improvement.
In addition, gap analysis provides a basis for comparing all items based on the extent of 
the gap. For instance, if the gap in GMP is bigger than the R&D budget, it may indicate 
the need for greater focus on the former item. The same argument is applicable to all 
the other areas of the pharmaceutical industry.
By asking the participants about both the current situation and its future importance, it is 
possible to rank the potential areas for improvements in accordance with the 
participants’ perceptions of importance. This idea has been explained in detail by 
Dahlgaard-Park and Dahlgaard (2010) in ‘Organisational Learnability and Innovability: a 
system for assessing, diagnosing and improving innovations’. The most important areas 
are related to the statements wherein the difference or gap between the current 
situation and its future importance is the highest. According to the authors, the theory 
behind this type of questionnaire is that the optimal situation is characterised by equality 
between the importance and agreement. An assumption behind this simple rule is that 
the marginal costs that will be incurred to reduce the gaps by one unit are the same for 
all the statement areas. Without doubt, this assumption is a simplification, because 
some areas (i.e. the ‘low-hanging fruits’) may be easier to improve than other areas. 
Hence, this assumption should be questioned when prioritising the areas that should be 
improved first. If the simplified assumption can be accepted, the simplified rule can be 
used. This means that if the importance of a particular parameter is significantly higher
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than its current situation, the area should be improved. However, in some cases, the 
agreement measurements may be higher than the importance attributed to the 
parameters because the respondent believes that the company is investing in an area 
that is likely to have less importance in the future. It may be also a sign that the 
respondent has not really understood the importance of the statement or has over­
estimated the current situation.
By using this simple approach, the gaps between various parameters will be analysed 
and the biggest gaps regarded as the participants’ indications of where to begin the 
improvement process. Therefore, the first step in the simple approach is to rank the 
statements according to the size of the gaps (Dahlgaard-Park and Dahlgaard, 2010).
Measuring the opportunity score to recognise under-served areas
Measuring the opportunity score turns the study of the gap into a future-driven approach 
which enables the companies to reinvent themselves by exploring areas of opportunity. 
This refers to identifying the under-served areas which will be important in the future. 
These areas represent improvement opportunities, and if the right strategies are 
pursued, the opportunity is realised. To find growth opportunities, the industry must be 
able to determine how the importance of the parameters is likely to change with time 
and with respect to their abilities and potentials. This is only possible if they are actually 
able to determine the future importance of the current gap and identify which 
dimensions of the industry represent the greatest opportunity for improvement.
Ulwick (2009) explains that an opportunity exists when there is an important need that is 
not well-satisfied. The more important the need is, and the less satisfied the customers 
are, the greater is the opportunity for value creation.
In a future-driven approach, the areas of opportunity are defined as under-served areas 
that will be important in the future but are not in a good condition at present. These 
under-served areas represent those measures of industry performance that need to be 
improved in the future. On the contrary, the areas that are likely to be unimportant
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and/or are already satisfied represent little opportunity for improvement and 
consequently should not receive any resource allocation.
If it turns out that ‘GMP and QA’ is an important and unsatisfied area, then the future 
requires and would value a company that will improve this area more effectively. This 
opportunity area often goes unexplored and yet offers tremendous growth potential.
Using the future-driven approach rather than normal gap analysis or ranking parameters 
on the basis of their current situation or future importance in order to define where 
opportunities lie, provides companies with more reliable measures with which they can 
prepare for the future.
The opportunity algorithm is based on adding the future importance to the normal gap, 
as is illustrated in the equation given below (Figure 2.4).
Figure 2.4 The equation to calculate the opportunity score
The Gap
1/
Opportunity Score =  Future Importance +  [Future Importance — Current Situation]
If a statement is rated 8 in terms of importance and 4 in terms of satisfaction (out of a 
possible 10, where 10 represents the highest score), its opportunity score would be [8 + 
(8 -  4)] or 12. A statement with an importance of 7 and a satisfaction of 5, however, 
would have an opportunity score of [7 + (7 — 5)] or 9—a much less attractive target for 
improvement. Using this formula, the needs that are most important and least satisfied 
receive the highest priority. This algorithm has been used to explore unmet customer 
needs in order to identify value-creation areas for companies (Ulwick, 2002; Strategyn
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Inc., 2004). This algorithm has also been used to explain outcome-driven innovation 
(Ulwick, 2007).
Introducing the (PIR) index as an indicator of pharmaceutical industry readiness
This part of the study will introduce a method for measuring the performance of the 
pharmaceutical industry in order to attain sufficient readiness for the post-WTO 
situation. This measure is called the Pharmaceutical Industry Readiness index or the 
‘PIR index’. The PIR index has values between zero and one, and the nearer the 
measure is to one, the better is the industry’s performance in that area. In contrast, a 
low measure indicates that the performance of the industry in that area is poor and 
needs improvement.
To calculate the PIR index, the ratio of average scores of the current situation and its 
future importance is measured. For a statement with the current situation average of 7 
and future importance of 8, the PIR index will be 7/8 or 0.875. To cite another example, 
a statement with the current situation average of 5 and future importance of 9 will have 
a PIR index of 5/9 or 0.555, which is obviously lower than the previous example and 
indicates that the area covered by this statement needs more development.
The examples presented below reveal the simple logic behind this measure: in optimal 
conditions, the averages of the current situation and its future importance are equal, and 
the index value will be 1.0. Conversely, in the worst-case scenario, the current situation 
may receive an average of zero against an importance average of 10, which will result 
in a PIR index value of 0 (zero). A PIR index of 1.0 indicates that the industry has 
excellent performance in that area, and zero indicates that the industry has done 
nothing to improve a very important area.
If the average current situation score is higher than that of the future importance, the 
PIR index may be misleading; hence, it is suggested that these results be removed from 
the calculations. This problem also occurs in gap analysis and, as explained before in 
this chapter, is mainly due to over-estimating the situation or under-estimating the 
parameter’s importance.
The PIR index can be calculated for all areas that will be included in the Pharmaceutical 
Industry Transitional Instrument (PITI). It is possible to calculate the PIR index for all the
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areas of pharmaceutical development, after which their average will provide the index 
for the related area. The average index for all the areas will result in the total index. It is 
also possible to use the average of the scores of each area or the total average of all 
the areas for measuring the index of the related areas or total index. The assumption 
behind this calculation is that all the areas have the same importance and for this 
reason, they should carry equal weight when calculating the scores for the area or total 
index. If the assumption of equal weights for areas or the activities is not valid, then it 
should be decided what weight be given to them.
In this study, the weights of all pharmaceutical areas, activities will be assumed to be 
equal. Thus it would be possible to calculate the index for the areas or activities. The 
basis for this argument is that the origin of the PITI statements can be traced back a 
long way from the Delphi technique for pooling the opinions of experts for the pilot 
testing of the instrument for exploring the importance and relevance of the articulated 
statements in such a manner that we can finally claim that all important criterions are 
included and conversely, that the irrelevant issues are excluded from the instrument.
It should be noted that the managers of companies can calculate this index in order to 
determine their readiness for the post-WTO situation. In the event that the indices of 
different companies need to be compared, it would be necessary to use a harmonised 
scoring procedure. However, the PIR index is a strong tool for internal benchmarking, 
prioritising company goals and deciding improvement plans.
SUMMARY
• This study aims to identify the impacts of WTO/TRIPS on the pharmaceutical 
industry; for this, a group of experts will be selected according to the Delphi 
technique and their opinions will be pooled together through structured 
interviews. The collected ideas will thereafter be used to design a questionnaire 
for the second round of the Delphi technique. The identified parameters will be 
used to develop the Pharmaceutical Industry Transition Instrument (PITI) in order 
to collect data from the pharmaceutical industry
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• Two instruments will be developed, tested and applied for data collection in this 
study. The steps of item generation, item reduction, development of taxonomy 
and scale development will be followed while developing the study instruments
• Psychometric evaluation of the developed instruments will be also carried out. 
The validity and reliability of the instruments will be tested using a content 
validation procedure, and the reliability of the collected data will be examined by 
calculating either ICC or Cronbach’s alpha
• The PITI will be also evaluated for applicability, acceptability and practicality, 
which will be determined on the basis of a pilot study
• Data processing and analysis will be carried out using Microsoft Access, 
Microsoft Excel and SPSS. While the mean, median and standard deviation will 
be used for the quantitative data, statistical analysis will be performed by 
applying the binomial test and Friedman test
• Thereafter, gap analysis and evaluation of development opportunities will be 
performed, which will be continued by introducing an index for assessing the 
readiness of the pharmaceutical industry (the PIR index) for the post- 
WTO/TRIPS situation
• The study will conclude with the development of a strategy map based on the results
and conclusions of the previous steps of the study.
The methodological aspects considered in this study are presented in Figure 2.5.
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Figure 2.5 Methodological structure of the study
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Chapter 3
Development of a Rating Scale for Assessing the Impact of 
the WTO/TRIPS on the Pharmaceutical Environment
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INTRODUCTION
Over the last few decades, joining the WTO and implementing TRIPS regulations have 
had a dramatic impact on the pharmaceutical industry. These changes have been 
particularly significant for the pharmaceutical industry because of its dependence on 
innovative products and technologies at the cutting edge of human knowledge. In many 
situations, the local industries receive a significant amount of protection owing to high 
importation tariffs. In other words, joining the WTO will have a major negative impact on 
an unprepared local pharmaceutical industry, which in turn is likely to have tremendous 
socioeconomic consequences. To address such a complicated issue, it is important to 
take into consideration the opinions of experienced and informed people in different 
fields associated with the pharmaceutical industry.
A systematic literature review has demonstrated the lack of this kind of study. Before 
commencing such a project, it was necessary to design an instrument to measure the 
parameters that would be considered by such a study. This chapter focuses on 
collecting the ideas of experts for designing and validating a rating scale that can be 
used for measuring the study parameters, which will be described in the next chapter.
OBJECTIVES
The objectives of this chapter were to:
■ Identify the factors that influence the pharmaceutical industry in the post-WTO 
situation
■ Develop a rating scale for generating experts’ consensus for the identified factors
■ Establish content validity for the developed rating scale.
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METHODS
This study applied the consensus-based Delphi technique in order to generate expert 
opinions regarding the impact of trade liberalisation and international intellectual 
property rights protection on the Iranian pharmaceutical industry. The process was 
initiated by a semi-structured interview, followed by two rounds of self-reported 
questionnaire administration using the Delphi technique. The following practical steps 
were carried out in this process:
• Selection of expert participants
• Conducting a semi-structured interview with the experts (first round of the Delphi 
technique)
• Analysis of the interview contents and preparation of the preliminary list of study 
factors
• Preparation of the rating scale
• Content validation of the rating scale.
Study Participants 
Phasel. Delphi technique
Regarding the methodology of the Delphi technique, it is very important to ensure that 
the study participants consist of experts with an in-depth knowledge and vision of the 
field and that they are able to offer a substantial variety of viewpoints (Meyrick, 2003). 
Based on this fundamental guideline, the present study included 30 experts divided into 
three groups namely academicians, industry representatives and regulatory officials (8, 
13 and 9 respectively). Finally a group of 11 experts was selected based on their 
qualifications, familiarity with the topic, availability and willingness to cooperate (with 3, 
4 and 4 experts from each of the groups mentioned above, respectively). The inclusion 
factors for all experts were minimum 10 years of experience in their field of activity with
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good knowledge of pharmaceutical practice and drug development. The interviews were 
continued until a consensus was reached.
Phase 2. Content validation
A group of content validation experts was selected, including eight linguistic experts 
from CMR International and the British Council in Tehran to validate the content of the 
rating scale. The first inclusion factor was fluency in the English language and the 
second one was familiarity with the research area.
Data Collection
Phase 1. Interviewing the study participants for developing the rating scale
According to the work flow of the Delphi technique presented in chapter 2, all panel 
members participated in separate interviews as a part of the item-generation phase. 
The participants were asked the following questions:
As you know, the environment of the pharmaceutical industry practice in 
Iran is characterised by relatively high importation tariffs with limited or 
no patent protection law, which are contrary to the WTO and TRIPS 
regulations. In view of the accession procedure towards full 
membership by 2016, what will be the impact on the sustainability of the 
Iranian pharmaceutical industry? Which parts of the industry are more 
susceptible to negative impacts?
How can these negative effects be prevented?
The panel members were asked to consider all industry aspects when responding to 
these questions, including the following aspects:
• Hardware, equipment and facilities
• Software, management and human resources
• Regulatory environment and key players in society
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These three groups of parameters were later labelled as structure, content and context, 
respectively. All the interviews with experts were recorded and their contents were 
analysed in order to prepare the list of study parameters.
Phase 2. Data for content validation of the instrument
A special rating form was designed for this group of experts, which enabled them to rate 
their agreement on the validity of each statement with regard to the following criteria:
Linguistic Clarity: The item should be clear, unambiguous, jargon-free and elicit a 
spontaneous rather than a delayed response after some reflection.
Completeness: The sentences pertaining to each item should be complete and should 
clearly articulate the underlying concept, with emphasis in the right places.
Relevance: The item should be relevant to the area of study and focus on what needs to 
be measured.
Scoring: The response options on the rating scale (ranging from 1 strongly disagree to 9 
for strongly agree) and its anchors should fit the item’s sentence structure and phrasing.
The content validation experts were asked to indicate their opinions regarding each 
statement based on the four criteria of linguistic clarity, completeness, relevance and 
scoring as follows: 1 for ‘completely satisfactory’, 2 for ‘acceptable with changes’, 3 for 
‘needs changing’ and 4 for ‘needs replacing’. These options are presented in Figure 3.1.
Figure 3.1 Response options for the content validation experts
A c c e p t a b l e
5»ng ' y
1 2
N e e d s  N e e d s  w i t h  C o m p l e t e l y
R e p la c in g  C h a n g i n C h a n g e s  S a t i s f a c t o r y
3
The content validation experts were also asked for their suggestions at the end of each 
statement. The content validation procedure was performed in two steps. In the first 
step, the opinions of the content validation experts were collected; after modifying the
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questionnaire accordingly, it was sent back for their review. The questionnaire was in an 
electronic format and it was sent to the content validation experts via email. The cover 
page of the questionnaire contained directions for answering the questionnaire, and the 
experts had to rate their opinions simply by clicking on the circle in front of each item. 
The questionnaire also had enough space for the experts to jot down their suggestions. 
All 8 experts returned their responses by email in both steps of the content validation 
process. Figure 3.2 illustrates how the statements appeared in the content validation 
questionnaire. The cover page of the questionnaire provided to the experts for the two 
steps of content validation is presented in appendix 1.
Figure 3.2 A sample statement of the rating form for content validation
1. WTO/TRIPS agreement will impact the allocation of R&D expenditure.
1 2  3 
Strongly Disagree
4 5 6 7 8 9 
Strongly Agree
C om plete ly A cceptab le N eeds N eeds
Satisfactory with C hanges C h an g es R ep lacem en t
L an gu age  C larity □ □ □ □
C om p leteness □ □ □ □
R e levan ce □ □ □ □
Scoring □ □ □ □
Suggestions.
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Data Analysis
Phase 1: Interviewing the study participants for developing the rating scale
• Step 1. A list of the factors was prepared from the experts’ interviews.
• Step 2. From these factors a number statements were developed
• Step 3. A scale ranged from 1 (strongly disagree) to 9 (strongly agree) were 
assigned to each statement.
Phase 2: Data for content validation of the instrument
• Stepl.The responses of the content validation panel for rating language clarity, 
completeness, relevance and scoring for each statement were compiled from the 
four options listed in figure 3.2.
•  Step 2. The intra-class correlation coefficient (ICC) was used to measure the 
agreement between the content validation panel responses.
The practical steps and work flow of this chapter are summarised in Figure 3.3.
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Figure 3.3 Steps for developing the study instrument in the first round of the Delphi
technique
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RESULTS
Phase 1. Interviewing the study participants for developing the rating scale -  
Item Generation
The first step in phase 1 involved generating the rating scale items based on the 
opinions of the panel members. These items were then formulated into statements 
which were then grouped into three categories namely structure, content and context 
(29 statements). Subsequently a rating scale was designed in order to achieve a 
consensus among the panel members.
The interviews with experts identified the study parameters, the results of which are 
summarised in Table 3.1. These parameters are grouped under the headings of 
structure, content and context, and are further subdivided according to the individual 
groups of academicians, regulatory executives and industry experts. This table also 
illustrates the frequency of the parameters, that is, how often that parameter was 
repeated by different participants.
These parameters were used to design a rating scale for further study. Each item was 
incorporated into one statement and placed in one of three sections, which resulted in a 
rating scale with 29 statements. The participants were asked to rate their agreement 
with each statement on a 9-point Likert scale, where 1 indicated strong disagreement 
and 9 indicated strong agreement with that statement. Higher numbers indicated that 
the parameter was associated with a greater impact of joining the WTO/TRIPS. The 
instrument was accompanied by an introductory letter on the cover page, providing a 
summary of the background, objectives and methodology of the study. The cover page 
is included in appendix 1.
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Table 3.1 Study parameters identified by the interviews
Study Parameter Description
Corresponding 
Statem
ent 
(«)*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
1) Structure Parameters
a) Hi-tech Products
The local industry needs to adopt 
new technologies such as 
biotechnology, nanotechnology, 
new drug delivery systems and 
new formulations in product 
development.
A1
A4
4 3 3
b) R&D Infrastructures
The required equipment, facilities, 
people and information should be 
provided for research and 
development.
A2
A3
A11
4 4 3
c) Production Technology
The current production lines need 
to be replaced by more advanced 
ones.
A6 2 1 3
d) GMP Standards
More compliance with the GMP 
requirements will be encouraged. 
This will be mainly due to the 
necessity of exporting the 
products or technical cooperation 
with international companies.
A5 4 4 4
e) Automation and Machinery
Manual production and packaging 
as well as manual environmental 
control (such as air handling 
systems) should be replaced in 
order to remove human errors.
A6
A5
1 1 4
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Study Parameter Description
Corresponding 
Statem
ent
(s)*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
f) New Methods and 
Systems
The local industry needs to 
improve operating procedures in 
order to increase quality 
assurance and decrease the cost 
of production.
A7
A10
3 1 3
g) Product Packaging
The packaging of the products 
should be improved for both 
better appearance and enhanced 
protection of the products.
A8 1 4 2
h) Distribution System
The distribution system should 
become more efficient and more 
reliable with respects to the 
handling and storage condition.
A9 2 2 3
2) Content Parameters
a) Management Knowledge 
and Skills
The industry directors and 
managers will require more 
knowledge and skills especially in 
the fields of human resources, 
corporate finance, marketing 
strategies and international 
business.
B1 3 2 4
82
Study Parameter Description
Corresponding 
Statem
ent 
(s )*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
..... 
_____I
b) Organisational Culture
The norms and values of the 
companies should support 
sustainability in a competitive 
situation e.g. Respect to the 
customers’ needs, hard working 
colleagues and innovative 
attitudes.
B2 1 1 2
c) Innovation and Creativity
The local industry needs to 
encourage innovation and 
creativity of the employees 
throughout the organisations.
B3 2 2 4
d) Human Resource
The employees should be hired, 
trained, rewarded and promoted 
in accordance to the future needs 
of the industry.
B4
B5
2 3 3
e) Personnel Training
Any special training needed for 
employees, especially in the 
areas of GMP, should be 
provided.
B5 3 1 3
f) Under Licence Production
Production of the new products 
under the licence of the 
innovative companies will 
facilitate the local industry’s 
improvement.
B6 3 3 3
g) Strategic Alliance and 
Mergers
Mergers, acquisitions and 
strategic alliances are possible 
ways for the local industry to gain 
more resources and decrease 
costs.
B9 2 2 4
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Study Parameter Description
Corresponding 
Statem
ent 
(s)*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
h) Technology Transfer 
Agreements
The local industry needs to 
acquire the needed technologies 
from international companies to 
speed up development 
procedures.
B6 2 2 1
i) Marketing and Advertising
One of the characteristics of the 
competitive situation is the need 
for marketing and advertising 
activities that are not so 
developed in the current situation.
B7 3 3 4
j) Customers Behaviour 
(Doctors & Patients)
The local industry should study 
the needs of its customers and 
monitor their behaviour in order to 
meet their expectations.
B8 3 2 3
k) Ownership and Holding
The efficiency of the way of 
management in the large 
organisations and holding 
companies should be re­
evaluated.
B10 1 1 3
1) Privatisation
The majority of large 
pharmaceutical companies are 
now linked to the governmental 
organisations that should be 
changed in a competitive situation 
that will result in the post-WTO 
condition.
B10 2 2 2
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Study Parameter Description
Corresponding 
Statem
ent 
(s)*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
3) Context Parameters
a) Patent protection Law
TRIPS regulation will enforce a 
patent protection law that prevent 
the local industry from copying 
the protected products.
C2 3 2 3
b) Tariffs and Custom Taxes
Post -WTO reduction of the 
importation tariff will negatively 
affect local companies and they 
will have major challenges to 
compete with the international 
rivals.
C1 2 2 3
c) Local Production Support 
and Subsidies
In the post -WTO situation the 
government will change the 
policies for paying the subsidies.
C8 2 2 3
d) Pricing Policy
The local companies should 
evaluate the prices of their 
products in comparison with their 
international rivals.
C4 4 4 4
e) Expenditure on Medicines
Removal of the illegally copied 
products from the market will 
increase the price of medicines.
C 7 1 2 n r "
f) Bargaining Power of the 
Payers and Customers
The competitive environment will 
provide more choices for the 
patients and doctors that may 
negatively impact the local 
industry.
C3
C5
4 3 2
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Study Parameter Description
Corresponding 
Statem
ent 
(s)*
Frequency of 
Results
Academ
ia
Regulatory
officials
Industry
The regulatory body will adapt
g) Regulatory Affairs and itself to the international norms
C6 1 3 3
Drug Registration and standards for the quality of
the submitted documents.
*The column includes the related number of the statements in the sections of the instrument 
(section A for structure, section B for content and section C for context parameters).
** No Response
Looking at table 3.1 reveals some of the differences in the opinions of the experts based 
on their area of activity. Some of these differences are expected because of the 
different experiences and backgrounds of the experts while some of them were 
surprising for the research team.
It was expected that industry experts place more emphasis on the need for automated 
operations and controls to reduce human errors (four industry experts mentioned this 
parameter against only one expert from each group of academia and regulatory 
officials). The subject of the ownership of the companies is also expectedly mentioned 
more by industry that reflects the importance of this topic in comparison with the two 
other groups of experts.
Conversely, it was surprising that the need for improved packaging was only highlighted 
by regulatory authorities while industry experts were supposed to be aware of the 
technical and cosmetic defects of the product packaging. This finding suggests the need 
for measuring customer satisfaction in the pharmaceutical companies. It may also 
indicate that the regulatory officials have some information including patients or 
physicians complaints about the quality of the packaging of local products. This kind of 
information must be shared with the industry as soon as convenient. Similar results
8 6
obtained for the parameters such as GMP and pricing policies illustrate a common 
understanding within the three groups of experts with regard to these topics.
It should be noted that the above parameters were identified from the experts’ 
interviews responding to the open ended question about the impact of WTO/TRIPS on 
the local pharmaceutical industry in Iran. It is anticipated that listing and sorting the 
parameters will result in a re-evaluation of the responses by the experts.
Phase 2. Validation of the Instrument
This phase aimed to validate the content of the instrument by developing a specific 
rating form for the content validation panel. After measuring the reliability of this specific 
rating form as well, the final step involved refining the instrument by incorporating the 
outcomes of the validation phase. The respective results for the four validity criteria of 
language clarity, completeness, relevance and scoring are presented in Table 3.2.
Refinement and development of the instrument statements is presented in Table 3.2. 
The suggested changes were categorised as follows:
• Editorial modifications made the statements to be more understandable 
preventing misunderstanding and biased responses. These kind of changes are 
applied to the statements A1, A8, A10, B1, B4, B9, C1, C2, C5 and B8.
• Adding or removing words or phrases specified the scope and clarified meaning 
for such statement A2, A3, A11, B6, B7, C3, C4 and C6.
• Restructuring the statements differentiated the natural consequences from the 
legal obligations of joining WTO illustrated in statements A4, A5, A6, A7, A9, B2, 
B3, B5 and C8.
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Table 3.2 content validation results for the four validity criteria in two steps
Statements Before Content 
Validation
Median of the 
Responses
Statements After First Step of 
Content Validation
Median of the 
Responses
Final StatementsLanguage
Clarity
Com
pleteness
R
elevance
Scoring
Language
Clarity
C
om
pleteness
R
elevance
Scoring
Structure Statements
A1. WTO/TRIPS agreement will create an 
environment which would encourage 
innovation in the pharmaceutical sector, 
resulting in new molecules and/or processes.
3 3 4 4
WTO/TRIPS agreement will create an 
environment which would encourage 
innovation in the pharmaceutical sector, for 
example: new molecules or new processes.
4 4 4 4
WTO/TRIPS agreement will create an 
environment which should encourage 
innovation in the pharmaceutical sector, for 
example: new molecules or new processes.
A 2. WTO/TRIPS agreement will impact the 
allocation of R&D expenditure.
3 3 3 3
WTO/TRIPS agreement will impact the R&D 
expenditure by local pharmaceutical 
companies.
4 3 4 4
WTO/TRIPS agreement will impact the R&D 
expenditure by local pharmaceutical 
companies
A 3. WTO/TRIPS agreement will influence 
requirements for specific skills in R&D staff.
3 3 3 3
WTO/TRIPS agreement will result in need 
for new and specific skills among R&D staff 
in local industry.
4 4 4 4
WTO/TRIPS agreement will result in the 
need for new and specific skills among R&D 
staff in local industry.
A 4. WTO/TRIPS agreement will influence 
deployment of modem technologies like 
biotechnology and nanotechnology in drug 
development.
3.5 3 3.5 4
WTO/TRIPS agreement will encourage the 
deployment of new technologies such as 
biotechnology and nanotechnology in drug 
development.
4 4 4 4
WTO/TRIPS agreement will encourage the 
deployment of new technologies such as 
biotechnology and nanotechnology in drug 
development.
A 5. W TO/TRIPS will influence the 
pharmaceutical industry adherence to 
manufacturing standards (GMP).
3.5 3 3 3
The changes resulting from implementing 
WTO/TRIPS agreement could have an 
impact on adherence to Good 
Manufacturing Practices (GMP) by the local 
pharmaceutical industry.
4 4 4 4
The changes resulting from implementing 
WTO/TRIPS will encourage the adherence 
to Good Manufacturing Practices (GMP) by 
the local pharmaceutical industry.
A 6. WTO/TRIPS will influence adoption of 
modern manufacturing techniques and 
machinery.
3 3 3 3
The changes resulting from the 
implementation of WTO/TRIPS will 
encourage the adoption of modern
4 4 4 4
The changes resulting from the 
implementation of WTO/TRIPS will 
encourage the adoption of modern
88
Statements Before Content 
Validation
Median of the 
Responses
Statements After First Step of 
Content Validation
Median of the 
Responses
Final StatementsLanguage
C
larity
C
om
pleteness
Relevance
Scoring
Language
C
larity
C
om
pleteness
Relevance
Scoring
manufacturing techniques and the 
installation of new machinery.
manufacturing techniques and the 
installation of new machinery.
A 7. WTO/TRIPS agreement will influence 
the required competency in operational 
management.
3 3 3 3
The changes resulting from the 
implementation of W TO/TRIPS agreement 
will necessitate improvement of operational 
management in local industry.
4 4 4 4
The changes resulting from the 
implementation of WTO/TRIPS will 
encourage the improvement of operational 
management in local industry.
A8. WTO/TRIPS agreement will change the 
competitive environment and leads to 
increased demand for improved packaging.
2.5 3 3 3
WTO/TRIPS agreement will change the 
competitive environment leading to more 
improved product packaging.
4 4 4 4
WTO/TRIPS agreement will change the 
competitive environment leading to more 
improved product packaging.
A 9. WTO/TRIPS agreement will demand 
more efficient distribution system.
3 3 3 3
Changes resulting from adoption of the 
WTO/TRIPS agreement require a more 
efficient distribution system for local 
pharmaceutical industry.
4 4 4 4
The changes resulting from adoption of the 
WTO/TRIPS agreement will require a more 
efficient distribution system for local 
pharmaceutical industry.
A 10. Competitive environment after 
WTO/TRIPS agreement will require the 
reduction of production cost.
3 3.5 3 4
The competitive environment after 
WTO/TRIPS agreement will necessitate the 
reduction of production cost.
4 4 4 4
The competitive environment after 
WTO/TRIPS agreement will necessitate the 
reduction of production costs.
A11. WTO/TRIPS agreement needs stronger 
regulatory affairs and patent review 
departments.
3 3.5 4 3.5
WTO/TRIPS agreement will result in the 
need for more efficient patent review 
departments in the local industry.
4 4 4 4
WTO/TRIPS agreement will result in the 
need for patent review departments to be 
set up in the local industry.
Content Statements
B1. WTO/TRIPS agreement influences the 
need for improved management knowledge 
and skills.
3.5 4 3 4
WTO/TRIPS agreement will promote the 
need for improved management knowledge 
and skills.
4 4 4 4
WTO/TRIPS agreement will promote the 
need for improved management knowledge 
and skills.
B 2. WTO/TRIPS will change organisational 
culture in order to support productivity.
3 4 3.5 4
WTO/TRIPS agreement will necessitate 
organisational culture which supports
4 4 4 4
WTO/TRIPS agreement will encourage 
organisational culture which supports
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Statements Before Content 
Validation
Median of the 
Responses
Statements After First Step of 
Content Validation
Median of the 
Responses
Final StatementsLanguage
C
larity
C
om
pleteness
Relevance
Scoring
Language
C
larity
C
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pleteness
R
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Scoring
productivity in local industry. productivity in local industry.
B 3. WTO/TRIPS agreement necessitates 
promoting employees based on innovation 
and creativity.
3 3.5 3 3
WTO/TRIPS agreement will necessitate the 
promotion of employees to be based on 
their innovation and creativity.
4 4 4 4
WTO/TRIPS agreement will encourage the 
promotion of employees to be based on 
their innovation and creativity.
B 4. W TO/TRIPS agreement will require 
higher qualifications for jobs in all 
organisation levels.
3.5 4 3 4
WTO/TRIPS agreement will result in higher 
qualifications for jobs in all organisational 
levels.
4 4 4 4
WTO/TRIPS agreement will result in the 
need for higher qualifications for jobs at all 
organisational levels.
B 5. Training for employees will be much 
more important after WTO/TRIPS.
4 3 3 4
WTO/TRIPS agreement will necessitate 
more training for employees in local 
pharmaceutical industry.
4 4 4 4
WTO/TRIPS agreement will necessitate 
more training for employees in local 
pharmaceutical industry.
B 6. WTO/TRIPS will encourage licence and 
technology transfer agreements.
3.5 4 3.5 4
WTO/TRIPS agreement will encourage 
licence and technology transfer agreements 
between local and international companies.
4 4 4 4
WTO/TRIPS agreement will encourage 
licence and technology transfer agreements 
between international and local companies.
B 7. WTO/TRIPS will influence marketing 
strategies and marketing expenditure to 
maintain or gain market share.
3.5 4 3.5 4
WTO/TRIPS agreement will influence 
marketing expenditure in order to maintain 
or gain market share.
4 4 4 4
WTO/TRIPS agreement will influence 
marketing expenditure in order to maintain 
or gain market share.
B 8. W TO/TRIPS agreement will increase 
the role of customer satisfaction and 
company image.
3 3 3 4
WTO/TRIPS agreement will result in 
companies giving more attention to 
customer satisfaction.
4 4 4 4
WTO/TRIPS agreement will result in 
companies giving more attention to 
customer satisfaction.
B 9. WTO/TRIPS agreement will influence 
the tendency for mergers and strategic 
alliances between companies.
3 4 3.5 4
WTO/TRIPS agreement will have an impact 
on the tendency for mergers and strategic 
alliances between companies.
4 4 4 4
WTO/TRIPS agreement will have an impact 
on the tendency for mergers and strategic 
alliances between companies.
B 10. WTO/TRIPS agreement will stimulate 
privatisation of pharmaceutical companies.
3.5 4 4 4
WTO/TRIPS agreement will stimulate the 
privatisation of pharmaceutical companies.
4 4 4 4
WTO/TRIPS agreement will stimulate the 
privatisation of pharmaceutical companies.
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Context statements
C 1. WTO/TRIPS agreement will impose 
decreasing of the importation tariffs.
3 3 3 3
WTO will require the reduction of the 
importation tariffs which has deep impact on 
local companies.
4 4 4 4
WTO will require the reduction of the 
importation tariffs which will have a major 
impact on local companies.
C 2. WTO/TRIPS agreement will enforce a 
strong patent protection law.
3.5 3 3.5 3
Enforcing a strong patent protection law by 
WTO/TRIPS will have deep impact on local 
pharmaceutical industry.
4 4 4 4
Enforcing a strong patent protection law by 
WTO/TRIPS will have a major impact on 
local pharmaceutical industry.
C 3. WTO/TRIPS agreement supports the 
bargaining power of payers.
3 3 3 4
One important impact of the WTO/TRIPs 
agreement will be to increase the bargaining 
power of the payers, e.g. insurance 
companies.
4 4 4 4
One important impact of the WTO/TRIPS 
agreement will be to increase the 
bargaining power of payers for medicines, 
e.g. insurance companies.
C 4. WTO/TRIPS will alter the pricing policy 
for medicines.
3 4 4 4
A consequence of the WTO/TRIPS 
agreement will be to alter the pricing policy 
of the local pharmaceutical industry.
4 4 4 4
A consequence of the W TO/TRIPS  
agreement will be to alter the pricing policy 
of the local pharmaceutical industry.
C 5. WTO/TRIPS agreement will increase 
the bargaining power of nongovernment 
organisations (e.g. patients’ associations).
4 4 4 4
One important impact of the WTO/TRIPs 
agreement will be to increase the bargaining 
power of nongovernmental organisations, 
e.g. patient associations.
4 4 4 4
One important impact of the WTOfTRIPS 
agreement will be to increase the 
bargaining power of nongovernmental 
organisations, e.g. patient associations.
C 6. WTO/TRIPS agreement will influence 
regulatory system and registration procedure 
in the ministry of health.
3 4 3.5 4
WTO/TRIPS agreement will influence the 
regulatory system for medicinal products 
operated by the ministry of health.
4 4 4 4
WTO/TRIPS agreement will influence the 
regulatory system for medicinal products 
operated by the ministry of health.
C 7. WTO/TRIPS agreement will change per 
capita expenditure for medicines.
3 3.5 4 3
WTO/TRIPS agreement will change the per 
capita expenditure on medicine.
4 4 4 4
WTO/TRIPS agreement will change the per 
capita expenditure on medicines.
C 8. WTO/TRIPS agreement will affect the 
policies for paying subsidies.
3 4 4 4
WTO/TRIPS agreement will result in 
changes in the governmental policies for
4 4 4 4
WTO/TRIPS agreement will result in 
changes in the governmental policies for
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paying the subsidies. paying the subsidies.
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Some of the statements remained unchanged during the steps of content validation 
(statements B10, C7). The improvement of the scores in two steps of content validation 
is illustrated in Figure 3.4.
Figure 3.4 Summary of the median scores in the two steps of the content validation
Language C larity C om pleteness Relevance Scoring
According to the designed rating form, the content validation responses ranged from 1 
to 4. In the first step of content validation, the median of the responses was 3.08, 3.18, 
3.11 and 3.25 for language clarity, completeness, scoring and relevance respectively 
which subsequently improved to 3.83, 3.88, 3.91 and 3.98 indicating that the content 
validation experts were satisfied with the structure and formulation of the statements. 
Each of the statements showed similar results. These data also demonstrate a high 
degree of satisfaction between the content validation experts regarding the 
completeness of the statements, the results of which improved from 3.45 in the first step 
to 3.97 in the second step.
Reliability of the content validation rating form
The intra-class correlation coefficient (ICC) was used to differentiate the consensus 
reached among experts from those that could be achieved by chance. The calculations 
were performed using the SPSS version 17 (Figure 3.5).
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Figure 3.5 The ICC values for the two steps of the content validation
■  First Step
■  Second Step
Language Com pleteness Relevance Scoring 
Clarity
Interpreting these results in the light of Table 2.4 (chapter 2) reveals that the level of 
agreement among content validation experts improved from ‘fair agreement’ to ‘almost 
perfect agreement’ during the two steps of content validation.
The interpretation table also indicates that there was a lack of agreement between the 
members of the panel for content validation in the first step that is reflected in a low 
value obtained for ICC (ICC values of 0.55, 0.32, 0.35 and 0.24 for language clarity, 
completeness, relevance and scoring respectively). ICC values of more than 0.7 
indicate that the agreement among the experts has not occurred by chance. In the first 
step, none of the questionnaire attributes were valid, since all ICC values were less than 
the acceptance level (0.7); however, incorporating the comments of the experts 
significantly improved the results in the second step (ICC values of 0.94, 0.90, 0.87 and 
1.00 for language clarity, completeness, relevance and scoring respectively). These 
results demonstrate the importance of using ICC for evaluating the reliability of this kind 
of data. It should be noted that while the ICC value helps evaluate the agreement 
between experts, it has no implication on the validity of the results (Futrell, 1995).
The average values of results in step one were 3.19, 3.45, 3.36 and 3.60 for language 
clarity, completeness, relevance and scoring, respectively (Table 3.3). These values 
were all higher than 3, which can be interpreted as acceptable on a 4-point form and
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may subsequently indicate that the developed instrument has been ‘validated’. 
Conversely, the ICC calculations resulted in the values of 0.55, 0.32, 0.35 and 0.24 for 
language clarity, completeness, relevance and scoring, respectively. The ICC value for 
language clarity shows ‘moderate agreement’ and those for the other criteria show ‘fair 
agreement’. According to Table 2.3 (chapter 2), all these results indicate the necessity 
for another content validation step in order to achieve ‘substantial’ or ‘almost perfect’ 
agreement. This indicates that it is not advisable to rely merely on the median of the 
responses: the ICC results clearly indicate the need for further iterations in order to 
design a better instrument. In other words, the content validation process should be 
iterated until a saturation point is reached, especially when the median of the results is 
being considered.
By comparing the results of the two content validation steps, as illustrated in Table 3.4, 
we can see a dramatic increment of ICC values, which indicates a significant 
improvement between the two steps. The highest difference between the two ICC 
values pertains to the ‘scoring’ criteria, mainly due to the different opinions of the 
content validation experts during the first step, specifically regarding the use of an odd 
or even number of points (see chapter 2). In the second step, all the experts accepted a 
9-point scale, which improved results.
Language clarity has the highest ICC value in the first step, which indicates that the 
developed questionnaire had better language clarity to begin with, as compared to the 
other criteria. Nevertheless, it should be emphasised that the results for the first content 
validation step were not acceptable and it was imperative to conduct a second 
validation step in order to formulate a clear, easy-to-understand and applicable 
questionnaire.
Final Version of the Instrument
Completing the first phase of this study, which was to interview the study participants for 
developing the rating scale on the basis of the Delphi technique and of the second 
phase, which was validating the developed instrument, has resulted in a more refined 
version of the instrument. This instrument is referred to as the final version of the world
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trade organisation, pharmaceutical industry (WTO, PI) impact rating scale (Figure 3.6). 
Being refined by means of the content validation process, the WTO, PI impact rating 
scale is characterised by a high degree of consensus among the content validation 
experts, which made it suitable for its further use in the study. The cover pages of the 
final rating scale are presented in appendix 2.
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Figure 3.6 The final version of the WTO, PI Impact Rating Scale
Please rate your agreem ent w ith  the follow ing statem ents, taking into account: 
a- The research evidence  
b- Your opinion/experience  
c- The realities of pharm aceutical industry situation
It would be helpful if you answer all questions, but if you feel th a t a question is outside  
your area of practice, leave it blank.
Section A: Structure Variables
1. WTO/TRIPS agreement will create an environment which should encourage innovation in the 
pharmaceutical sector, for example: new molecules or new processes.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
2. WTO/TRIPS agreement will impact the R&D expenditure by local pharmaceutical companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
3. WTO/TRIPS agreement will result in the need for new and specific skills among R&D staff in local 
industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
4. WTO/TRIPS agreement will encourage the deployment of new technologies such as biotechnology 
and nanotechnology in drug development.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
5. The changes resulting from implementing WTO/TRIPS will encourage the adherence to  Good 
Manufacturing Practices (GMP) by the local pharmaceutical industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
Cardiff
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6. The changes resulting from the implementation of WTO/TRIPS will encourage the adoption of modern 
manufacturing techniques and the installation of new machinery.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
7. The changes resulting from the implementation of WTO/TRIPS will encourage the improvement of 
operational management in local industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
8. WTO/TRIPS agreement will change the competitive environment leading to more improved product 
packaging.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
9. The Changes resulting from adoption of the WTO/TRIPs agreement will require a more efficient 
distribution system for local pharmaceutical industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
10. The Competitive environment after WTO/TRIPS agreement will necessitate the reduction of 
production costs.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
11. WTO/TRIPS agreement will result in the need for patent review departments to be set up in the local 
industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
Section B: Content Variables
1. WTO/TRIPS agreement will promote the need for improved management knowledge and skills.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
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2. WTOARIPS agreement will encourage organisational culture which supports productivity in local 
industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
3. WTO/TRIPS agreement will encourage the promotion of employees to be based on their innovation 
and creativity.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
4. WTO/TRIPS agreement will result in the need for higher qualifications for jobs at all organisational 
levels.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
5. WTO/TRIPS agreement will necessitate more training for employees in local pharmaceutical industry. 
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
6. WTO/TRIPS agreement will encourage licence and technology transfer agreements between 
international and local companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
7. WTO/TRIPS agreement will influence marketing expenditure in order to maintain or gain market 
share.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
8. WTO/TRIPS agreement will result in companies giving more attention to customer satisfaction. 
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
99
9. WTO/TRIPS agreement will have an impact on the tendency for mergers and strategic alliances 
between companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
10. WTO/TRIPS agreement will stimulate the privatisation of pharmaceutical companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
Section C: Context Variables
1. WTO will require the reduction of the importation tariffs which will have a major impact on local 
companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
2. Enforcing a strong patent protection law by WTO/TRIPS will have a major impact on local 
pharmaceutical industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
3. One important impact of the WTO/TRIPS agreement will be to increase the bargaining power of 
payers for medicines, e.g. insurance companies.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
4. A consequence of the WTO TRIPS agreement will be to alter the pricing policy of the local 
pharmaceutical industry.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
5. One important impact of the WTO/TRIPS agreement will be to increase the bargaining power of 
nongovernmental organisations, e.g. patient associations.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
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6. WTO/TRIPS agreement will influence the regulatory system for medicinal products operated by the 
ministry of health.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
7. WTO/TRIPS agreement will change the per capita expenditure on medicines.
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
8. WTO/TRIPS agreement will result in changes in the governmental policies for paying the subsidies. 
1 2  3 4 5  6 7 8 9
Strongly Disagree Strongly Agree
If you believe that an important topic(s) has not been included in the above statements, please feel free 
to list them below.
DISCUSSION
The ideas that were discussed during the interviews in the first step of the Delphi 
technique were the focal point of the review for all the experts throughout this part of the 
study. The experts were mainly concerned about the sustainability of the local industry, 
underlining that it has not been developed in order to be competitive in a situation that 
would result from the country’s accession to the WTO. They also stressed the need for 
initiating such a project to explore the impact and discuss the strategies that can be 
adopted by the local industry in order to minimise the negative consequences of 
implementing the WTO/TRIPS.
This part of the study sought to address three major topics, namely, item generation, 
categorisation and instrument development.
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The first major challenge was to select the most relevant parameters from a group of 
important items. This complexity was overcome by forming a balanced group of experts 
from the three areas of academia, industry and regulation. The results of this chapter 
establish that the Delphi technique is an efficient method for designing such a study. 
This fact was also emphasised by the experts in the course of the interviews, who 
especially realised the consensus-generating nature of the technique when they learnt 
that the study participants comprised a balanced group of academicians, regulatory 
executives and industry experts.
Taxonomic categorisation of the items was instrumental to the participants’ 
understanding of the structure, content and context of the measurement technique. It is 
clear that a large number of criteria are likely to play a key role in the outcome when the 
industry joins the WTO; grouping together these parameters can facilitate their 
evaluation by not only researchers and experts but also all those that participate in such 
studies. The feedback received from the experts during the study supported the 
simplification role of this grouping and highlighted the different aspects of this multi­
dimensional approach.
Encapsulating the thought process of the study participants through the item generation 
and categorisation resulted in the development of a robust, valid and reliable 
instrument. This is a major step forward in understanding the impact of WTO accession 
on the sustainability of the local pharmaceutical industry.
The methodology followed in this study, including the brain storming procedures in the 
context of Delphi technique and iterations of content validation that resulted in 
developing a comprehensive and sophisticated instrument, was not traced in similar 
studies.
The study of Supakankunti et al. (2001) about the impact of WTO/ TRIPS agreement on 
the pharmaceutical industry in Thailand was mainly based on a literature review of 
relevant research and statistical analysis of the impact assessments and surveys. The 
Delphi technique and instrument development were not reported in their study. The 
parameters that they identified and discussed were: drug registration, technology 
transfer and foreign direct investment (FDI), R&D, spending on healthcare, patent law
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and prices of the drugs. They also discussed TRIPS related topics such as compulsory 
licensing, exclusive marketing rights and burden of proof (Supakankunti, 2001).
The case study of Turkey published by Semin and Guldal (2008) regarding the growing 
dependency of developing countries and the globalisation of the pharmaceutical 
industry was also based on literature review and secondary data sources. They 
discussed the effects of globalisation on the pharmaceutical sector’s structural 
characteristics, the production, patent, trade, prices, profit, and consumption in this 
sector (Semin and Guldal, 2008).
The study of Vogel about the impact and the implications of TRIPs in a knowledge- 
based global economy (a developing country’s perspective) also focused on reviewing 
the impact with regards to the published laws and regulations and relevant discussion 
and assessments. Topics such as technology transfer policies, strength of protection of 
intellectual property rights, internationalisation of production and R&D were discussed in 
this study (Vogel, 2006).
The above review underlines the uniqueness of the WTO, PI impact rating scale 
developed and validated in this study and highlights the value of the consensus 
generating concept for identifying the influencing parameters through the laborious work 
of interviewing a balanced group of pharmaceutical sector’s experts.
SUMMARY
•  This chapter focused on the development of a questionnaire with the view to
identifying the parameters influencing the post-WTO sustainability of the 
pharmaceutical industry. This questionnaire was prepared by interviewing a 
panel of experts in line with the first round of the Delphi technique.
•  In all, a total of 29 items were identified and categorised into three groups and 
designated as structure, content and context parameters.
•  This questionnaire was also successfully validated through two content 
validation steps by a second group of experts, and it was made sure that the 
final questionnaire was complete, written in clear language, relevant, and had an 
appropriate scoring system.
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•  The consensus among the experts during the two steps of content validation 
was investigated by measuring the ICC for each of the above mentioned criteria; 
according to the interpretation tables, the final results were in almost perfect 
agreement.
•  Based on the Delphi technique, this instrument namely “WTO, PI impact rating 
scale” will be utilised for creating consensus among the experts participating in 
the study and this process will be further described in the next chapter.
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Chapter 4
Evaluation of the Parameters Influencing the Post-WTO 
Sustainability of the Pharmaceutical Industry
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INTRODUCTION
The in-full WTO-PI Impact Rating Scale was described in chapter 3 and has provided 
the necessary tool for carrying out the Delphi technique for creating consensus among a 
panel of experts on the elements required for the development of the strategies in 
preparing for the post-WTO/TRIPS agreement in Iran. This procedure was based on 
collecting the ideas and perceptions of well-known professionals and authorities 
regarding the assessment of the impact of the introduction of the WTO/TRIPS 
agreement on the pharmaceutical industry in the near future. This is an important 
undertaking because its output will later be used to determine the way forward for a 
concerned industry.
The previous chapter has described how the study commenced with interview sessions 
with a balanced group of experts (from academia, industry and regulatory authority). 
The contents of these interviews were later analysed in order to identify and list the 
necessary items with a view to developing a rating scale for further analysis. This 
process was based on the first round of the Delphi technique for creating consensus 
among experts. This chapter describes how the WTO-PI Impact Rating Scale will be 
used by the panel members to rate their agreement with the statements provided. This 
helped obtain the basic data for understanding the opinions of the participants and 
provided the researchers the opportunity to compare and prioritise the items that 
reflected the concerns and aspirations of the study participants.
The content validation expert panel assisted in the development of the instrument, 
where the final version consisted of 29 independent and categorised statements. It was, 
nevertheless, a challenging task to ensure that the statements were comprehensive, 
complete, relevant and clear. These concerns were the rationale behind the content 
validation process described in chapter 3.
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This chapter will also demonstrate the instrument’s capacity to create a consensus 
among the panel members and identify the divergence of their opinions in a reliable 
manner.
OBJECTIVES
The objectives of this chapter were to:
• Present the study instrument to the expert panel and to obtain their opinions 
regarding the study parameters
• Rate the relative importance of the factors influencing the pharmaceutical 
environment post-WTO agreement
• Measure the degree of consensus among experts representing academia, 
industry and regulatory authority using the Delphi technique
METHODS
The methodological approach for this chapter in order to rate the relative importance of 
the factors influencing the post-WTO sustainability of the pharmaceutical industry is 
presented in Figure 4.1. Data considered in this chapter were obtained by means of the 
instrument whose development was described in the previous chapter. This process 
was carried out according to the methodology of the second round of the Delphi 
technique.
Study Participants
The expert panel consists of seventeen experts, of which eleven had already been 
involved in the previous step (chapter three) and in addition, there were six new 
participants. The main reason for including more experts in this step was to strengthen 
the resulting consensus and improve the generalisation of the final results.
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Figure 4.1 The methodological flow chart for the second round of the Delphi technique
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It should be noted that there was more willingness by the potential participants to take 
part in this study. This was mainly due to the relatively easier procedure for answering 
the questionnaire in comparison with the previous step that required participating in a 
semi-structured interview. The final group of 17 experts consisted of 5, 6 and 6 experts 
from academia, industry and regulatory officials respectively. The demography of the 
study participants is presented in the Table 4.1.
Table 4.1 Demography of the participants in the Delphi method
Gender
Female: Two persons (12%) 
Male: Fifteen Persons (88%)
Work Experience
10-20 years: Eleven Persons (65%) 
More than 20 years: Six Persons (35%)
Education
PhD: Five Persons (29%)
Pharm. D: Eleven persons (65%) 
MSc: One Person (6%)
It should be mentioned that the content validation experts did not participate in this step 
of the study and there was no overlap between these two groups of experts.
Data Collection Procedure
The content for the instrument was extracted from the interviews with the experts and 
put through two steps of content validation in order to ensure the applicability and 
practicality of the instrument. This validation was crucial to obtaining consistent 
responses from respondents who were hailing from different fields of activity. Definitions 
were provided along with the questionnaire to encourage reliable answers. The cover 
page of the questionnaire also included the study background, methodology and 
instructions for answering the questions, as presented in appendix 3.1.
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The final version of the WTO-PI Impact Rating Scale was e-mailed to the participants. 
They were asked to return their responses within the proposed deadline for data 
collection. During this period, telephone contact was maintained with all the participants 
in order to make sure that they understood how to complete the questionnaire and to 
remind them of the timetable for data collection. Respondents were instructed to rate 
their opinions about each statement on a scale ranging from one to nine (1-9), where 1 
means strong disagreement and 9 means strong agreement with that statement. They 
were also encouraged to comment on the statement and propose items that had not 
been identified so far. This step is mentioned as “Experts’ first evaluation” in Figure 4.1. 
After the participants had submitted their responses, the data were used to calculate the 
median, maximum and minimum of the responses, which were incorporated into the 
questionnaire.
The experts’ second evaluation was started by resending the modified questionnaire to 
the experts, who could also look at the group’s responses; hence, they had the 
opportunity to modify their own responses. This instrument will be referred to as the 
second Delphi questionnaire. As explained in chapter 2, this step of the Delphi 
technique plays a crucial role in creating consensus among the experts. Figure 4.2 
contains a sample statement of this questionnaire:
Figure 4.2 A sample statement of the second Delphi questionnaire
The changes resulting from the adoption of the WTO/TRIPS agreement will require a more 
efficient distribution system for the local pharmaceutical industry.
1 2 3 4 5 6 7  8 9
Strongly Disagree Strongly Agree
Your Score = 6 Median of the group = 5.5 Max = 9 Min = 2
110
Data Processing and Analysis
All collected data were entered into a database and quality controlled for preventing 
data entry errors. The data were subject to further analysis, as follows:
• The median of the responses was calculated for all the statements in order to 
explore the central tendency of the experts’ opinions regarding each criterion.
• Cronbach’s alpha was used to measure the reliability of the collected data 
and to indicate the internal consistency of the results.
• The Friedman test was used to rank the study parameters in order to
determine the most important items from the viewpoint of the experts.
The calculations were carried out using SPSS software version 17.0. The work flow of 
this part of the study is presented in Figure 4.1.
RESULTS
The scores given by all the participants in their first evaluation were collected, and the 
medians of the responses were calculated and used for further analysis. Table 4.2 
groups together the data pertaining to the responses for each section of the 
questionnaire (sections A, B and C) from the relevant group of experts.
This step involved providing the experts with the opportunity to revise their answers 
after reviewing the median of the group as well as their own answers. As described in 
the methodology of the Delphi technique in chapter two, this is an essential step in 
consensus-building among experts through the convergence of ideas. The median of 
the scores given to the instrument statements by each group of experts (academicians,
regulatory officials and industry experts) is summarised in Table 4.2.
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Table 4.2 The median scores given by each group of experts from the fields of academia, 
industry and regulatory regulation in their first and second evaluations using the WTO-PI 
Impact Rating Scale
WTO-PI Rating Scale Statements
Academia RegulatoryAuthority Industry Total
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
Structure Statements
1. WTO/TRIPS agreement will create an 
environment which should encourage 
innovation in the pharmaceutical sector, for 
example: new molecules or new processes.
6.5 6 6 6 7 6.5 6.5 6
2. WTO/TRIPS agreement will impact the R&D 
expenditure by local pharmaceutical 
companies.
7 7 7 7 7 6 7 7
3. WTO/TRIPS agreement will result in the 
need for new and specific skills among R&D 
staff in local industry.
7.5 8 7 7 8 8 7.5 8
4. WTO/TRIPS agreement will encourage the 
deployment of new technologies such as 
biotechnology and nanotechnology in drug 
development
7 7 5 5 7 5 7 5
5. The changes resulting from implementing 
WTO/TRIPS will encourage the adherence to 
Good Manufacturing Practices (GMP) by the 
local pharmaceutical industry.
7.5 8 9 9 7.5 7.5 8 8
6. The changes resulting from the 
implementation of WTO/TRIPS will encourage 
the adoption of modern manufacturing 
techniques and the installation of new 
machinery.
6.5 7 7 7 6 6.5 6.5 7
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WTO-PI Rating Scale Statements
Academia RegulatoryAuthority Industry Total
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
7. The changes resulting from the 
implementation of WTO/TRIPS will encourage 
the improvement of operational management in 
local industry.
6.5 7 6 6 7 6.5 6.5 6.5
8. WTO/TRIPS agreement will change the 
competitive environment leading to more 
improved product packaging.
7.5 7 8 8 7 7.5 7.5 7.5
9. The changes resulting from adoption of the 
WTO/TRIPS agreement will require a more 
efficient distribution system for local 
pharmaceutical industry.
6 6 5 5 5 6.5 5.5 5.5
10. The Competitive environment after 
WTO/TRIPS agreement will necessitate the 
reduction of production costs.
7 7 5 5 7 8 6 6
11. WTO/TRIPS agreement will result in the 
need for patent review departments to be set 
up in the local industry.
8 8 8 8 7 7.5 7.5 8
Content statements
1. WTO/TRIPS agreement will promote the 
need for improved management knowledge 
and skills.
7.5 8 7 7 8 8.5 7.5 8
2. WTO/TRIPS agreement will encourage 
organisational culture which supports 
productivity in local industry.
7 7 7 7 7 8 7 7
3. WTO/TRIPS agreement will encourage the 
promotion of employees to be based on their 
innovation and creativity.
7.5 7 6 6 6 5.5 6.5 6
4. WTO/TRIPS agreement will result in the 
need for higher qualifications for jobs at all 
organisational levels.
7.5 8 6 6 6 7 7 7
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WTO-PI Rating Scale Statements
Academia RegulatoryAuthority Industry Total
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
5. WTO/TRIPS agreement will necessitate 
more training for employees in local 
pharmaceutical industry.
7.5 7 7 7 8 8.5 7.5 7.5
6. WTO/TRIPS agreement will encourage 
licence and technology transfer agreements 
between international and local companies.
8 8 7 7 7 7 7 7
7. WTO/TRIPS agreement will influence 
marketing expenditure in order to maintain or 
gain market share.
8.5 8 6 6 8 7.5 8 8
8. WTO/TRIPS agreement will result in 
companies giving more attention to customer 
satisfaction.
7 7 8 8 8 8 8 8
9. WTO/TRIPS agreement will have an impact 
on the tendency for mergers and strategic 
alliances between companies.
8 8 8 8 7 6.5 7 7.5
10. WTO/TRIPS agreement will stimulate the 
privatisation of pharmaceutical companies.
7.5 8 6 6 6 6.5 6.5 6.5
Context Statements
1. WTO /TRIPS will require the reduction of the 
importation tariffs which will have a major 
impact on local companies.
8.5 8 8 8 8 7 8 8
2. Enforcing a strong patent protection law by 
WTO/TRIPS will have a major impact on local 
pharmaceutical industry.
8.5 8 8 8 6 5 7 7
3. One important impact of the WTO/TRIPS 
agreement will be to increase the bargaining 
power of payers for medicines, e.g. insurance 
companies.
6 6 5 5 8 6.5 6 6
4. A consequence of the WTO TRIPS 
agreement will be to alter the pricing policy of
7.5 7 8 8 8 7.5 8 7.5
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WTO-PI Rating Scale Statements
Academia RegulatoryAuthority Industry Total
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
First
Evaluation
Second
Evaluation
the local pharmaceutical industry.
5. One important impact of the WTO/TRIPS 
agreement will be to increase the bargaining 
power of nongovernmental organisations, e.g. 
patient associations.
4 5 6 6 6 5.5 5.5 5.5
6. WTO/TRIPS agreement will influence the 
regulatory system for medicinal products 
operated by the ministry of health.
7.5 8 6 6 7 7 7 7
7. WTO/TRIPS agreement will change the per 
capita expenditure on medicines.
8 8 7 7 6 6 7 7
8. WTO/TRIPS agreement will result in 
changes in the governmental policies for 
paying the subsidies.
7.5 8 6 6 7 7.5 7 7.5
The above table shows that the median scores given by academics have increased in 
10 statements decreased in 8 statements and remained constant in the remaining 11 
statements. Surprisingly, the median scores given by regulatory authorities remained 
unchanged for all statements which shows the dominant tendency in this group of 
experts to reiterate their original scores. The responses of the industry experts were 
incremental for 11 statements while decreased for 12 statements and remained 
constant for 6 statements. In general the median of the scores given by the experts in 
the two steps of evaluations remained constant for 19 statements and slightly changed 
for the rest of the statements (increased for 6 and decreased in case of 4 statements). 
The fact that the scores in the two steps of evaluation only slightly changed, underlines 
the reproducibility of the data collected by WTO-PI impact rating scale.
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Relative importance of the structure parameters
The importance of the panel responses to the structure statements are presented in 
Figure 4.3.
Figure 4.3 The expert group’s responses to the ‘Structure’ statements
u  Industry ■ Regulatory Authority a Academia
Patent Review Department
Production Cost
Distribution System
Product Packaging
Operational Management
Manufacturing Techniques
Biotechnology and Nanotechnology
Skillsof R&D Staff
Research and development
Innovating Molecules & Processes
The regulatory authorities rated that the ‘WTO/TRIPS agreement will encourage the 
deployment of new technologies such as biotechnology and nanotechnology in drug 
development’ as the most important in this group (with the median of 9). This item 
received high ratings (medians of 8 and 7.5) from the academic and industry group, 
respectively (Figure 4.3). The items associated with the ‘patent review departments’, 
‘production cost’ and ‘R&D expenditure’ also received high scores from all the experts, 
while the items relating to the ‘distribution system’ showed the biggest gap between the 
industry and regulatory authorities, thus reflecting the different priorities for these two 
groups of experts. This inter-group difference in the rating of statements was also
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observed for the ‘skills of R&D staff, which received a score of 7 from the academics, 
while industry and regulatory experts did not rate that higher than 5. This is contrary to 
expectation because the importance of the skills of R&D staff should have been 
highlighted by the industry experts. One reason may be that these experts mainly have 
their experiences from the production departments, Industry experts also rated ‘product 
packaging’ higher than academia and regulatory experts which was expected. 
Interestingly, GMP appeared to be a common concern for all three groups of experts 
and received a relatively high score from all of them which underlined a high awareness 
about the importance of GMP among the experts with different backgrounds. The 
‘patent review department’ category was also one of the most mentioned items for all 
three groups, which indicated its high importance with regard to the consequences of 
implementing TRIPS requirements.
The different views concerned with innovating new molecules and processes showed 
that while the academicians and regulatory authorities expected the development of 
more innovative products to result from the country’s accession to the WTO, the 
industry however was not so optimistic in this regard.
The scores given to the content related items
The experts’ panel evaluation of the impact of WTO/TRIPS on content statements are 
summarised in Figure 4.4.
The experts from the industry gave the highest scores to items ‘management 
knowledge and skills’ and ‘employees’ training’ (Figure 4.4). These items were 
important for other groups of experts as well. However, ‘promotion of employees on the 
basis of their innovation and creativity’ received the lowest figure from the industry 
experts which is contrary to expectations. The expert groups gave differing scores to 
marketing expenditure, the academics and industry experts gave higher scores 
compared with the regulatory authorities and these data indicate that the academics 
and industry experts seem to be more aware of the significance of focusing on 
marketing activities in the pharmaceutical industry, while the regulatory authorities are
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regulatory authorities are critical of the international companies with respect to their 
marketing efforts. Both academicians and regulatory authorities gave higher ratings to 
mergers and strategic alliances than did the industry experts. This is surprising because 
more consideration was expected from the industry experts.
Figure 4.4 The expert group’s responses to the ‘Content’ statements
Si Industry ■ Regulatory Authority ■ Academia
Privatisation 
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Productivity 
Management Knowledge & Skills
0 1 2 3 4 5 6 7 8 9
Customer satisfaction received an equally high score (with the median of 8) from both 
industry and regulatory authorities, while this item appeared less important for 
academics in the post-WTO situation. This may be due to the lack of appreciation with 
respect to the importance of this item in the academic environment.
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The importance of the contextual items
WTO/TRIPS will provoke a series of changes in the pharmaceutical environment with 
direct and indirect effects on the industry. The expert panel responses to the context 
statements reflect these environmental challenges (Figure 4.5).
All experts considered reduction of the importation tariff in the post-WTO situation to be 
the most important item. It is interesting to note this item’s importance was rated higher 
by academics and regulatory authorities than by the industry (industry experts gave 
higher scores to pricing policies and policies for paying the subsidies).
Figure 4.5 The expert group’s responses to the ‘Context’ statements
y  Industry H Regulatory A u thority  ■  Academ ia
Policies for Paying the  Subsidies 
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Regulatory System  
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Im p orta tion  Tariffs
1 2 3 4 5 6 7 8 9
The industry experts, moreover, gave their lowest scores to the consequences of a 
strong patent protection law (with the median of 5); this item received relatively high 
scores from the other two groups of experts (with the median of 8 from both of them) 
which was absolutely contrary to expectations. It will be discussed later in this chapter 
that strong patent protection will be a major challenge for local generic companies that
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illegally copy patented products. The item related to the bargaining power of NGOs 
such as patients’ associations was rated as the least affected area by academics as 
well as industry experts, while the regulatory authorities gave the lowest scores to the 
bargaining power of payers.
The total median of the scores given by all three groups of experts was consistently 7, 
although the scores given by the industry experts are relatively lower than those given 
by the other groups of panel members (Figure 4.6).
Figure 4.6 Median of the scores given by experts to each section of the WTO-PI Impact 
Rating Scale in the second evaluation (second step)
■  Academia
■ Regulatory authorities 
H Industry
Structure Content Context
The median values were similar when aggregated from all three groups. This finding 
proves that the important parameters were identified and measured because all of the 
medians were between 6 and 7 (Figure 4.6). Furthermore, it may be deduced that in 
general, the content parameters (section B of the items in the study instrument) 
received slightly higher figures from all the panel members.
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general, the content parameters (section B of the items in the study instrument) 
received slightly higher figures from all the panel members.
Internal consistency reliability of the scores
The 29 items of the questionnaire were tested for reliability by measuring Cronbach’s 
alpha in order to explore the internal consistency of the results. The result of the first 
evaluation was 68%, which is within the range of ‘substantial agreement’ according to 
the interpretation in Table 2.3 (chapter 2). Although the reliability result was within the 
acceptable range, the second round of the Delphi technique produced even better 
consistency among the scores. Cronbach’s alpha for the second instrument was 0.73 
which is higher than that for the previous step and still within the range of substantial 
agreement. This improvement in Cronbach’s alpha is a sign of enhanced consensus 
between the experts and emphasises the reproducibility of the data generated by the 
rating scale.
Friedman ranking of the relative importance of the items
Friedman’s test was carried out to prioritise the identified items. This ranking is helpful in 
exploring the most vulnerable aspects of the pharmaceutical industry in the post-WTO 
situation. As the following tables illustrate, the item with the highest median need not 
necessarily have the highest Friedman ranking. This is because some people tend to 
select high scores, while others tend to support low scores. Friedman ranking removes 
this bias from the study results and justifies the following interpretations. The results of 
Friedman ranking along with the median of the responses to the structure, content and 
context statements are presented in Table 4.3.
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Table 4.3 Friedman ranking of the parameters influencing sustainability of the
pharmaceutical industry
Friedman
Rank Statements Median
1 C1 Importation Tariff 8
2 B1 Management Knowledge & Skills 8
3 B5 Training for Employees 7.5
4 A3 Skills of R&D Staff 8
5 B8 Customer Satisfaction 8
6
A11 Patent Review Departments 8
7 B7 Marketing Expenditure 8
8 A5 Good Manufacturing Practices (GMP) 8
9 B6 Licence and Technology Transfer 7
10 C4 Pricing Policy 7.5
11 B9 Mergers and Strategic Alliances 7.5
12 C8 Policies of Paying the Subsidies 7.5
13 A8 Product Packaging 5.5
13 B4 Need for Higher Qualifications for Jobs 7
15 C7 Per Capita Expenditure on Medicines 7
16 C2 Patent Protection law 7
17 A6 Adoption of Modern Manufacturing Techniques 7
18 C6 Regulatory System for Medicinal Products 7
19 B2 Organisational Culture which Supports Productivity 7
20 A2 R&D Expenditure 7
21 B10 Privatisation of Pharmaceutical Companies 6.5
22 A7 Improvement of Operational Management 6.5
23 B3 Innovation and Creativity of Employees 6
24 A10 Reduction of Production Costs 6
25 A4 Development of New Technologies 5
26 C3 Bargaining Power of Payers 6
________
27 A9 Efficiency of Distribution System 6
28 A1 Innovation (new molecules or new processes) 6
29 C5 Bargaining Power of Nongovernmental Organisations 5.5
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As presented in the above table, ‘importation tariff was ranked first among all 29 items, 
followed by ‘management knowledge and skills’ and ‘training for employees’. The 
lowest-ranked items were related to the distribution system, innovation of new 
molecules and the bargaining power of NGOs.
Friedman ranking of all the items grouped according to structure, content and context 
are presented in figure 4.7.
Figure 4.7 Friedman ranking of the three groups of
items
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In relation to structure parameters ‘skills of R&D staff, ‘patent review departments’ and 
‘GMP expenditure’ were seen to be the most important ones. In contrast, ‘development 
of new technologies’, ‘efficiency of distribution system’ and ‘innovation’ were seen to 
receive the lower ranks. All three items were already identified as important items based
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on the analysis of their medians. It is interesting to note that the orders indicated by the 
median analysis and the Friedman ranking are the same, with the exception of the last 
two structure items.
The highest-ranked content statement was ‘management knowledge and skills’. This 
item was followed by ‘training for employees’, ‘customer satisfaction’ and ‘marketing 
expenditure’. The items associated with the privatisation of the industry and innovation 
of the employees did not receive a high position within this group of items. The 
Friedman and median ranking orders are mostly similar for content statements as well.
The ‘importation tariff and ‘pricing policy’ have the highest position among the context 
items, while the lowest positions were occupied by the items related to the bargaining 
power of payers and NGOs. These results are quite similar to those obtained with 
regard to the median of the responses in the earlier parts of this chapter, the median 
and Friedman ranking orders are exactly similar. The data from Table 4.3 are 
summarised in Figure 4.8. Friedman ranking was carried out for all 29 items of the 
questionnaire, and the results are presented in Table 4.3, along with the median of the 
responses.
The participation of the experts in different steps of this study again emphasises the 
importance of conducting such research in the current situation. Many of the 
participants expressed several times that awareness itself is part of the solution, and the 
initiative of conducting this study, through arranging meetings between experts, 
conducting interviews with them and circulating questionnaires among them, elicited a 
significant feedback.
In this part of the study, a final meeting of the experts was arranged to discuss some 
noteworthy points such as the differences in the opinions of the experts from each of the 
three fields. The panel experts’ level of confidence in the questionnaire is reflected by 
the significant Cronbach’s alpha values, which support the process of idea extraction 
and questionnaire design that was presented in the previous chapter. In other words, 
the practicality and applicability of the instrument, designed earlier in this study, was 
tested and approved in this part of the research.
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It should be noted that these relative important factors are identified by a balanced 
group of experts in three areas of the pharmaceutical sector and could not have been 
achieved if one group of experts had been invited to participate in the study.
DISCUSSION
The W TOPI Impact Rating Scale was used to identify the top ten influencing 
parameters which will now be reviewed in order of priority.
1. Importation tariff: The essential purpose of WTO is to help trade flow as freely as 
possible, which can be achieved by lowering trade barriers such as customs duties 
(importation tariffs), import bans or quotas and even issues such as bureaucracy and 
exchange rate policies. According to the WTO’s recommendations, high importation 
tariffs should be abolished and the tariff rates for industrial goods should be gradually 
decreased to less than 4% (WTO, 2005). The importation tariff of 60% for medicines 
which can be locally produced is currently too high to comply with WTO requirements. It 
is assumed that the rigorous consequences of removing this relatively strong 
importation barrier will underline why this item received such a high ranking from the 
expert panel. Even if the differences are negligible, it should be noted that the academic 
experts have given higher scores to the importation tariff, while the industry has given it 
the lowest scores (Table 4.2).
Phasing out the importation tariff is already on the task list of the authorities during the 
accession procedure. However, the reduction in importation tariffs triggers a set of 
consequences resulting from the corresponding reduction in the price of imported 
competitor products. Thus, it is vital to prepare a strategy for empowering the 
susceptible industries because without preparation it will be a threat for the local 
industry without preparation.
2. Management knowledge and skills: According to the study instrument, the 
WTO/TRIPS agreement will increase the need for improved management knowledge 
and skills. Under these circumstances, it is necessary to improve the existing level or 
hire knowledgeable people with sufficient competence to deal with international
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business and trade challenges. This will be a necessary qualification if the industry 
executives want the sector to progress while maintaining its sustainability in the future.
3. Training for employees: The need for better trained employees is complementary to 
the previous item and emphasises companies’ need for more talented and better 
educated human resources, which would enable them to better deal with the situation. It 
has been reported that in most South-East Asian countries, the employment scenario 
worsened in the post-WTO period (The Mahbub ul Haq Human Development, 2004). 
This demonstrates the need for higher qualified people in the post-WTO situation, and 
being prepared for it beforehand can prevent the negative impact on employment 
indicators. An increasing skill premium, accompanied by increasing levels of equality in 
the developing countries, underlines the need for better trained people. It has been 
predicted that countries that are relatively rich in low-skilled labour will specialise in the 
production of unskilled-labour intensive goods (Goldberg, 2006). However a modern 
pharmaceutical industry requires highly skilled human resources.
4. Skills of R&D staff: A tough, competitive environment with strong patent protection 
laws will require the industry to design new products and processes as vital tools for the 
industry’s survival. Skilled R&D employees enable the use of modern R&D tools 
including software, databases, equipment and facilities. In a competitive and rapidly 
changing environment, R&D staff should not only have the ability to identify which 
molecules might produce medicines of real value but also understand the payer’s 
economic perspective during the R&D process (PricewaterhouseCoopers, 2009). R&D 
management and human resources are already considered as a basic need for the 
development of the pharmaceutical industry in India (Joshi, 2003). In order to improve 
R&D efficiency, it is recommended that transnational corporations (TNCs) be 
established for the globalisation of R&D, especially between the developing and 
developed countries (United Nations, 2005).
5. Customer satisfaction: Customer satisfaction is an important element of 
sustainable excellence for achieving a global competitive advantage (Langroudi et al, 
2008). Management models such as the European Foundation for Quality Management
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(EFQM) Excellence Model can measure the customer orientation of a firm in terms of 
‘customer results' (Dahlgaard-Park, 2008). It is important to identify those characteristics 
of the product or process that are critical to the customer’s requirements for quality 
performance and those which contribute to customer satisfaction (Dahlgaard and 
Dahlgaard-Park, 2006). Customer satisfaction and loyalty can also be measured using 
the European Customer Satisfaction Index (Ciavolino and Dahlgaard, 2007). In the 
current situation, government policies protect the industry from its international rivals; 
however, the industry does not have enough motivation to be customer-oriented. For an 
industry to start monitoring its customers’ needs and responding to their demands in a 
timely and cost-efficient manner, it needs to be challenged by the consequences of free- 
market competition. International companies are better adapted to these situations in 
the global market than the Iranian industry and are ready to satisfy the customers’ ever- 
increasing desires.
6. Patent review departments: At present, intellectual property rights, including 
pharmaceutical patents, are not protected by law. This means that companies are not 
obliged to review the patent situation for their current and in-house development 
products. In the post-WTO situation, however, the industry will be compelled to reinforce 
its capabilities in this regard in order to mitigate the harsh consequences of patent 
infringement in the local and international markets. On the other hand, the 
pharmaceutical companies can play an important role in generic substitution by 
suggesting new generic products based on their patent expiration date, as generics 
remain a strong threat to original brands. For example, in April 1998, Abbott paid the 
generics manufacturer Geneva (a subsidiary of Novartis) $4.5 million on a monthly 
basis to prevent it from marketing a generic version of Hytrin (terazosin), and the 
payments continued until the agreement ended in August 1999. This meant that no 
other generic could be launched in the meantime (Seget, 2003).
Patent review departments’ ranked as the first or second-most important item in the 
interviews conducted during the first round of the Delphi technique. However, in the 
second round of the Delphi technique, the experts unexpectedly gave a higher priority to 
parameters such as management knowledge and skills. This change, according to the 
experts, was because parameters such as ‘importation tariff, ‘management knowledge
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and skills’, ‘training for employees’, ‘skills of R&D staff and ‘customer satisfaction’ are 
prerequisites for having a successful patent review.
7. Marketing expenditure: Aggressive marketing strategies are among the most 
important characteristics of the global pharmaceutical industry. Pharmaceutical 
companies commonly spend a considerable amount on advertising, marketing and 
lobbying. According to the Association of the British Pharmaceutical Industry (ABPI), in 
the United Kingdom, around 14% of the industry’s expenditure is on promotion and 
marketing (House of Commons, 2005). In the United States, drug companies spend $19 
billion a year on promotion. There are approximately 100,000 pharmaceutical sales 
representatives in the United States at present, pursuing some 120,000 pharmaceutical 
prescriptions. This number doubled in the four years from 1999 to 2003. In China, for 
example, nearly three-quarters of the information that doctors receive about new 
medicines comes from meetings with sales representatives and conferences 
(PricewaterhouseCoopers, 2009). The pharmaceutical industry in the United States is a 
large and important industry and spends an enormous amount of money on marketing. 
For example, it spends more than any other industry on its sales force ($ 7 billion 
annually) and a very large sum on media advertising ($ 2.8 billion annually. It also 
spends more on marketing than on R&D (e.g., the top nine firms spend 2.5 times the 
amount on marketing than on R&D)) (Manchanda P, 2005). Studies show that 
marketing a product increases the demand for that product, although this effect 
becomes weaker at higher levels of marketing expenditure. On average, pharmaceutical 
marketing significantly reduces doctors’ price elasticity of demand. An increase of 1% in 
the marketing expenditure results in a 0.3% increase in sales. Of this increase, 
approximately 35% results from a decrease in the sales of competing products, while 
the remaining 65% is due to market growth (Laat, 2002). Subsequently, this item has 
direct impact on the local industry’s capacity to retain its markets, considering the 
sophistication of its international rivals. Marketing strategy and technological 
development have been described as two important obstacles in the international 
competition of the pharmaceutical industry in South Korea (Gross, 1999). In India, the 
marketing efforts of local companies have acted as barriers for the entry of multinational 
companies in the local market (Joshi, 2003). Ironically, the marketing activities of
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multinational companies in the third world have evoked considerable criticism (Smith, 
1991).
Joint marketing activities can create synergy between innovative and generic 
companies (Attridge, 2005). In this regard, it is important to note that there is increasing 
resistance to ‘irresponsible’ marketing practices. In May 2007, the member 
governments of the World Health Organisation (WHO) passed a resolution to enact or 
enforce legislation banning the ‘inaccurate, misleading or unethical promotion of 
medicines’ (PricewaterhouseCoopers, 2009). At the heart of this problem may be the 
industry’s current trend to be ever-increasingly driven by its marketing forces, while the 
world needs an industry which is led by the values of its scientists, not those of its 
marketing forces (House of Commons, 2005).
8. Good manufacturing practice (GMP): A world-class market requires a world-class 
manufacturing standard. GMP is a recognised precondition for pharmaceutical 
production, and its main focus is upgrading facilities, equipment, control and monitoring 
systems, and documentation. The Iranian pharmaceutical industry would need to 
establish GMP and compete with foreign companies in the local market, obtain the 
necessary approval from the targeted markets and be accepted as a local partner for 
the multinational companies. It is interesting that the regulatory and academic experts 
gave higher scores to this item (Figure 4.3). This highlights the government’s role in 
stipulating production standards for local and international companies with no 
discrimination, in line with the WTO regulations. Concerns regarding the GMP level of 
pharmaceutical plants and the government’s role in setting regulations and defining 
deadlines for the compliance of the local industry have been underlined as part of a 
significant post-WTO impact on India and China (Yeung, 2002 and Grace, 2004). In 
India, leading companies, such as Ranbaxy, Dr Reddy’s, Sun Pharmaceuticals and 
Lupin have patiently invested in manufacturing facilities that meet the exacting EU and 
US GMP standards and built strategic alliances with US- and EU-based generic 
marketing companies. This has resulted in the current strong position of the Indian 
pharmaceutical manufacturing industry, as compared to those of other nations, in terms 
of the US FDA-approved plants launched and US Drug Master Files held by the
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industry. The industry is now achieving dramatic growth in export sales of active 
ingredients to the US and EU (Attridge, 2005).
9. Licence and technology transfer agreements: The post-WTO situation will create 
an environment wherein Iranian companies are likely to become more involved in 
technical cooperation with multinational companies. This will help the Iranian 
companies’ access new technologies more easily. The international companies in 
cooperation with local companies will then enter the market faster. Licence agreements 
give a well-established generic company the right to produce a patented product, not 
only to supply it to the local market, but also to sell it to other emerging markets, 
including the least developed markets, or even sell it back to the developed countries 
(Attridge, 2005).
10. Pricing policy: Pricing policies will play a crucial role in enabling the Iranian 
pharmaceutical industry to strengthen its infrastructure, especially its technical 
capabilities. Without a rational price structure, the industry cannot prepare itself for the 
post-WTO situation. The experts believe that the current government policy to maintain 
low prices for the local generic products, which favours patients and insurance 
companies, has prevented the local industry from investing in R&D and plant 
renovation. The government’s pricing and reimbursement policies in the post-WTO 
situation should be transparent, with no discrimination between local and imported 
products. In some cases, countries have undermined this law to support local products. 
For example, the unofficial margins for selling local products to hospitals in South Korea 
led to protests from foreign companies (Gross, 1999). Hence, the phasing-out period 
before the accession procedure’s completion provides the government an opportunity to 
empower the local companies. Differential pricing is one policy that resolves the conflict 
between patent protection and the affordability of medicines in developing countries; it 
refers to different prices for different markets based on the ‘Ramsey pricing’ principles, 
price sensitivity and demand elasticity (Danzon, 2001). A report published in 2004 
predicted that the availability and pricing of 90% of the medicines manufactured in India 
and China, including most of the medicines in the WHO model list of essential 
medicines, should not be affected by the introduction of product patents (Grace, 2004).
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This discussion essentially presents a summary of the top ten parameters identified by 
the experts in this study and does not imply that the other parameters are unimportant 
or do not influence the industry in the post-WTO situation. For instance, process 
patenting is an important policy that empowers the pharmaceutical industry during the 
transition phase before strong product patent laws are enforced. During the process 
patent regime, Indian firms developed competence in applied research for developing 
production-process technologies, particularly for synthetic bulk drugs (Chaturvedi, 
2006).
The ten important parameters that were explained in this section of the study can be 
clustered as depicted in Figure 4.8.
The first barrier to fulfilling the WTO/TRIPS requirements is the importation tariff 
policies. In the transition period, which is likely to be provided for the Iranian 
pharmaceutical industry to prepare itself, factors such as management knowledge, 
employees’ training and skills for R&D staff will be the main areas of focus. Thereafter, 
the industry should invest in patent review to select the best patentable products which 
will allow the companies to obtain reasonable prices due to the innovative nature of the 
products in the generic market. At this stage, the industry should commence negotiating 
with brand holders and technology owners in order to sign licence and technology- 
transfer agreements. These achievements should motivate the industry to improve its 
GMP and invest further in marketing activities. The final outcome of this procedure will 
be greater customer satisfaction, which will only make the industry more competitive 
and sustainable in the post-WTO/TRIPS situation.
The overall results of this chapter are in accordance with the findings of other similar 
studies. For instance, Yeung (2002) has mentioned importation tariff, R&D capabilities 
and production capabilities as the major implications of WTO accession for the 
pharmaceutical industry in China. From this study, it would appear (Figure 4.5) that the 
people-related parameters scored higher than the other parameters, which is supported 
by other studies (Dahlgaard-Park and Dahlgaard, 2010).
This chapter successfully presented the WTO-PI, Impact Rating Scale to the expert 
panel and identified the parameters influencing the pharmaceutical industry in the post-
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Figure 4.8 Clustering of the top ten parameters identified as influencing the post-WTO/TRIPS situation
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WTO situation. These results were obtained while a high degree of consensus was 
created among the study participants as an outcome of the methodological fitness 
(Delphi technique) and instrument validity.
SUMMARY
• This part of the study involved a detailed investigation of the parameters 
influencing the post-WTO sustainability of the pharmaceutical companies. For 
this, a second round of the Delphi technique was conducted using WTO-PI 
Impact Rating Scale.
• A group of 17 experts from different fields of activity—including academics, 
regulatory officials and industry experts—answered the questionnaire which had 
been designed and validated earlier in this study.
• The experts responded to the questionnaire (WTO-PI Impact Rating Scale) in 
two steps. In the second step, they could revise their answers to each question 
based on the results of the previous step, from which they were provided the 
median, maximum and minimum scores of the group as well as their own score.
• The results were tested for reliability and showed improved consensus among 
the experts; the two steps of data collection showed Cronbach’s alpha values of
0.68 (first step) and 0.73 (second step).
• The parameters were ranked using Friedman’s test to explore the concerns and 
priorities of the expert panel.
• The importation tariff was identified as the most important influencing parameter. 
This was followed by priorities associated with the qualifications and knowledge 
of the managers, employees and R&D staff. These parameters reflect the 
foremost challenges which the industry is likely to face, as predicted by the 
respondents.
•  The other important parameters include customer satisfaction, patent review 
departments, marketing expenditure, GMP, licence and technology transfer 
agreements, and pricing policy.
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Chapter 5
Development and Psychometric Evaluation of the 
Pharmaceutical Industry Transition Instrument (PITI)
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INTRODUCTION
Chapters 3 and 4 of this thesis focused on exploring the parameters influencing the 
post-WTO situation of the pharmaceutical industry in Iran. This procedure mainly 
involved collating the opinions of a panel of experts and by using the Delphi technique 
resulted in the identification of a total of 29 influencing parameters. In the absence of a 
suitable instrument with which to assess the industry’s position in the transition period, it 
was decided that this study would first develop an instrument specifically for this 
purpose. This chapter, therefore, will focus on describing the development of this 
instrument. According to its conceptualisation, such an instrument should be capable of 
assessing the industry’s readiness to respond to the implementation of the WTO/TRIPS 
agreement by measuring the gap between the industry’s present and future situations. 
Furthermore, it is hoped that the process and outcome of this study will help both the 
industry and policy makers to prepare the right environment for this event.
OBJECTIVES
The objectives of this study were to:
• Select the appropriate parameters from the results obtained in the previous chapter
• Utilise the selected parameters for the development of the Pharmaceutical Industry 
Transition Instrument (PITI)
• Develop the instrument to be suitable for measuring the current situation and future 
importance of each parameter
• Examine the psychometric properties of the PITI (applicability, practicality and 
reliability).
METHODS
A standardised methodology was adopted for the development of the PITI; it is briefly 
described as follows:
Step 1 - Conceptualisation: In line with the research question of the study, it is 
necessary to explore the industry’s situation with respect to the identified parameters,
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such as GMP or R&D capabilities. It should be kept in mind that this is a topical issue 
with sensitive socio-economic implications. Asking people employed in companies 
about their own company’s readiness to survive in a competitive situation may put 
psychological pressure on the respondents and create a false sense of optimism. In 
addition, it is clearly inappropriate to request companies to divulge the real figures of 
their expenditures or revenues due to the confidential nature of this kind information. On 
the basis of these facts, it was necessary to design an instrument that could be used for 
performing a gap analysis by comparing the current situation and future importance of 
each statement.
It was also concluded that the questions pertaining to the scope of the study should be 
presented to management-level employees of pharmaceutical companies, since these 
people are involved in the development, manufacturing and marketing of medicines. 
Ideally, data should be collected from several people in each company in order to obtain 
different views from the company. Collecting data at the plant level is a much easier 
process, but it could result in the collection of less precise data. Managers, however, 
have sufficient information to respond to our questions in a limited period of time; 
therefore, the instrument should be detailed and straightforward. With respect to the 
potential participants, a web-based electronic version of the instrument was designed. 
Development of the electronic version was based on similar experiences in order to 
incorporate maximum advantages of online data collection (UMD, 2010).
In this study, the companies were selected randomly as probability samples. The 
number of companies sampled can be calculated based on the sample volume 
equation, which will be explained in the next chapter.
Step 2 - Item generation: The basic information obtained for the construct of the 
instrument, is described here. The inclusion criteria were mainly the relevance of the 
parameters to the objectives of this study, i.e. evaluation of the industry situation. These 
were mainly categorised as structure and content parameters, and 2-8 items were 
included in each category in order to collect a variety of data about each category.
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Step 3 - Item reduction: It was decided that the items categorised as context 
parameters, which are mainly related to the industry environment, should be excluded 
from the PITI because the instrument is focused on the capabilities and infrastructures 
of the industry.
Step 4 - Development of taxonomy: Considering the familiarity of the participants with
respect to the topic of this study, a proper taxonomy would be based on the names of
departments or management topics in the industry, such as GMP expenditure, product 
0
packaging and so on.
Step 5 - Scale development: This instrument should preferably have a scale to 
measure the current situation and future importance of each item. A scale with a wide 
range of 0 to 10 is useful as it provides the participants with extensive response options.
Step 6 - Psychometric evaluation: In this step, the questionnaire designed according 
to the above requirements would be reviewed by a group of experts for content 
validation. This step of content validation of the questionnaire is based on the method 
formerly discussed and explained in chapters 2 and 3. In this part of the study, a group 
of 18 experts were selected on the basis of their familiarity with the research 
methodology to determine the validity of the instrument. In addition, the internal 
consistency of the scores was measured to determine the reliability of the collected 
data. Psychometric evaluation was also earned out during the pilot study phase by 
asking the respondents whether the statements were clear, easy to understand, easy to 
respond to, relevant and convenient in terms of the time required for completion.
Step 7 - Pilot study: As explained earlier in chapter 2, an initial pilot study test is an 
essential part of questionnaire construction and includes administering the 
questionnaire to a small, typical group of participants, based on their availability and 
readiness. The pilot study may lead to the conclusion that the questionnaire needs to be 
revised in order to make it more user-friendly and comprehensive. If the pilot study 
indicates that the questionnaire contains confusing points, the questionnaire may be 
revised further before being distributed. It may also be necessary to arrange for an
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explanatory session prior to administrating the instrument to the respondents (Flynn B, 
1990). The seven steps of developing the rating scale are illustrated in the Figure 5.1.
Figure 5.1 Development steps of the Pharmaceutical Industry Transition Instrument (PITI)
Stages Issues Considered
1 - Conceptualisation
______
•Considering the general characteristics of the 
instrument as an easy-to-answer rating scale
• Data collection in pharmaceutical companies at 
the individual level
• Calculating the sample volume using the sample 
volume equation
2 - Item Generation
3 - Item Reduction
4 - Development of 
Taxonomy
5 - Scale Development
6 - Psychometric 
Evaluation
7 - Pilot Study
•Using the items already generated and identified 
(see previous chapters) on the basis of the Delphi 
technique
• Excluding the items related to the industry context 
as non-relevant items that resulted in 66 statements 
in 15 categories
•Grouping the selected items pertaining to the 
industry departments and fields of activity
• Designing a scale ranging from 0 to 10 in two 
directions to measure the current situation’ and 
'future importance’ of each item
•Testing the validity of the content of the instrument 
by deploying an expert panel 
•Measuring the Intraclass Correlation Coefficient 
(ICC) to evaluate the reliability of the instrument 
•Assessing the ease of understanding, ease of 
responding, relevance and completion time
•Administering the instrument to a small sample of 
the target population to identify procedural 
difficulties prior to full implementation
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Study Data origin
As was described in chapter 2, the phrasing and format of the questionnaire directly 
influences the practicality and applicability of the study instrument as well as its 
reliability and validity. The PITI was designed using the statements generated in chapter 
4, where a list of parameters identified using a Delphi process were tested for the 
relative importance of their impact on the pharmaceutical industry in the post- 
WTO/TRIPS situation. These statements were re-grouped to form the basis for the 
development of the new instrument, i.e. the PITI (Table 5.1).
Table 5.1 Areas forming the basis for the development of the PITI
1. Patent Review 9. Pricing Policy
2. Licence & Technology Transfer 
Agreements
10. Training for Employees
3. Sales & Marketing 11. Skills of R&D Staff
4. GMP & QA 12. Management Knowledge
5. Research & Development 13. Customer Satisfaction
6. Product Packaging 14. Creativity of the Employees
7. Manufacturing Technology 15. Qualifications for Jobs
8. Mergers & Strategic Alliances
Each of the above-mentioned areas was then populated with a number of statements to 
cover all the relevant topics within the area. The study participants were asked to rate 
their opinions about each statement on a 0-10 scale regarding both the current situation 
and the future importance of each item (Figure 5.2).
Figure 5.2 Structure of statements in the paper version of the PITI
Current Situation 1. Patent Review Future Importance
-4_
absolute compliance no compliance not important at aH very important
■4-------- — w
W e review
10 9 8 7 6 5 4 3 2 1 0
intellectual property 
rights when 
exporting products.
0 1 2 3 4 5 6 7 8 9 10
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Data processing and analysis
Psychometric evaluation data: The data for the psychometric evaluation of the 
questionnaire were obtained in electronic format. The use of electronic instruments not 
only greatly improved the quality of the data but also prevented the errors associated 
with incorrect handwriting interpretation and manual entry of data into the database.
The collected data were subjected to further analysis as follows:
• The medians of the content validation panel members’ responses pertaining to 
the language clarity, completeness, relevance and scoring of the instrument were 
calculated through two content validation exercises in order to explore the 
median of the experts’ opinions for each criterion.
• ICC was used to measure the consensus between the experts and regarded as 
an indicator of the internal consistency of the instrument (Trochim, Research 
Methods , 2002).
Pilot study data: In the pilot study, the responses were collected in both paper and 
electronic format (e-mail attached). Data obtained through electronic sources were 
directly entered from the mailbox into the database. The paper format responses were 
quality controlled for handwriting or other problems. Data entry was double-checked 
prior to data analysis in order to prevent data entry errors. The analysis procedure of the 
pilot study results included the following calculations:
• Mean of the responses to each category and statement
• The gap between the responses pertaining to the current situation and those 
associated with the future importance of each item
• ICC to assess the internal consistency reliability of the responses
The analyses were carried out using SPSS version 17 and Microsoft Excel 2007.
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RESULTS
The results of this chapter are presented in three parts namely Part I to describe 
development of the instrument, Part II to explain how the psychometric properties of the 
instrument were evaluated and Part III to report the pilot study results.
Part I - Instrument development
The instrument contained 66 statements divided into 15 categories under the headings 
presented in Table 5.1. Each of the 15 categories contained a series of statements to 
collect data pertaining to that particular category. It also contained a section with 
general questions covering respondent-related information such as gender, age, 
education and organisational position as well as general company characteristics such 
as company ownership, company name, total sales, number of employees, expenditure 
on R&D and percentage of net profit per sales. In addition, the question regarding 
company characteristics was optional, as indicated. The instrument was prepared in 
electronic and paper formats.
The respondents were asked to rate the level of their agreement with each statement 
with regard to both the current situation in the industry and its future importance. The 
current situation was considered to determine the current efficiency of the industry in 
different areas of the business, while the future importance of each aspect was explored 
in order to understand its importance after the implementation of WTO/TRIPS.
For comprehensive data collection, the respondents were provided with instructions 
covering some necessary information. Thus, the introductory pages of the instrument 
introduced the study and explained its background, study rationale, objectives, 
methodology, study participants, how to complete the questionnaire and the 
confidentiality terms (appendix 5.1).
Paper version: The study participants also received a paper version of the instrument. 
The instructions were given in the cover pages, and the structure of the statements was 
similar to those in the electronic version. Previous experiences indicated that receiving 
both paper and electronic versions of the data collection instruments suit the
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preferences of a greater number of respondents, which may positively influence the 
participation rate. The design of the paper version of the PITI is presented in Figure
5.2.
Electronic version: The electronic data collection mode was considered for this study 
because of its precision. A website was designed for this purpose, and the rating scale 
was uploaded onto the website, which could be accessed by the study participants by 
using the personal username and password provided to them. Instructions similar to 
those provided in the cover pages of the paper version were also provided in the 
electronic version; the statements were provided in both Persian and English. A report 
generator was designed to create real-time online reports. Therefore, during the data 
collection period (35 days), it would be possible to monitor the emerging results. This 
closed Web-based instrument (see chapter 2) and electronic method of data collection 
made the subsequent data processing and analysis easier and very efficient. The 
design of the electronic version of the instrument received positive feedback from the 
study participants (Figure 5.3). The respondents could click on ‘choose an item’, which 
was a drop-down menu, and select their choice from 0 to 10 for both the current 
situation and future importance.
Figure 5.3 A  sam ple  s ta te m e n t o f the e lectronic  vers ion o f the
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Our marketing expenditure is comparable to that of our international rivals.
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Part II - Psychometric evaluation
I Validity: The validity of the instrument was assessed by a panel of content validation
ft
experts. To this end, it was necessary to design a rating form to collect the opinions of 
tie panel members. Although the rating form was designed in both electronic and paper 
versions, all the panel members preferred to receive the electronic format via e-mail. 
The cover pages contained instructions indicating the background to the study and 
explaining how the questions were to be answered. The cover pages provided to the 
• content validation panel members were similar to the Delphi rating scale presented in 
appendix 3.1.
The study participants were asked to express their views on the language clarity, 
completeness, relevance and scoring of each statement. A comment box was also 
provided. The respondents could click on the ‘choose an item’ tab, which was a drop­
down menu, and select their choice from the four options provided, namely, ‘strongly 
agree’, ‘agree’, ‘disagree’ and ‘strongly disagree’. These options were coded as 4, 3, 2 
and 1, respectively, for analysis purposes. With respect to the validity of the instrument, 
17 out of 18 distributed instruments were collected, with the response rate of 94.4%. All 
the responses were e-mailed to the study participants. Figure 5.4 shows how the 
statements appeared in the content validation rating form.
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Figure 5.4 Design of the content validation rating
form
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Table 5.2 presents the results of psychometric evaluation; the scores given by the 
responding experts are indicated as ranging from 1 to 17.
Table 5.2 Median scores given by each content validation panel member
Respondent Language
Clarity Completeness Relevance Scoring
1 ✓  3.81 1 3.17 2 3.10 2 3.21
2 X 2 . 9 5 X  2.97 I  3.14 2 3.11
3 ✓  3.83 ✓  3.97 ✓  3.56 2 3.03
4 ✓  3.82 ✓  3.80 ✓  3.52 ✓ 3 .5 9
5 ✓  3.94 ✓  3.91 ✓  3.82 2 3.12
6 ’ 3.29 I  3.28 2 3.03 2 3.00
7 ✓  3.88 ✓  3.91 ✓  3.97 ✓  3.98
8 X  2.91 2 3.03 X  2.89 2 3.14
9 ✓ 4 .0 0 ✓  4.00 ✓  3.79 ✓ 4 .0 0
10 ✓  3.85 ✓  3.60 ✓  3.72 2 3.02
11 ✓  3.62 I  3.28 2 3.29 X  2 97
12 ✓  3.88 ✓  3.60 ✓  3.53 ✓  3.98
13 I  3.20 I  3.15 • 3.42 2 3.14
14 • 3.26 I  3.14 ? 3.12 2 3.18
15 ✓  3.80 ✓  3.65 ✓  3.82 ✓ 3 .6 3
16 ✓  3.80 ✓  3.82 I  3.48 ✓  3.68
17 i  3.00 X  2.71 ✓  3.58 2 3.09
Median 3.80 3.60 3.52 3.14
+  When the value is greater than 3.5 ! W hen the value is between 3.0 and 3.5 *  When the value is less than 3.0
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The median of the scores given by the experts to each criterion is greater than 3, which 
implies that the results are between ‘agree’ and ‘strongly agree’. As regards the internal 
consistency reliability of the validity results, the ICC was calculated based on the four 
validity scores. The ICC values for language clarity, completeness, relevance and 
scoring are 0.981, 0.988, 0.972 and 0.989, respectively. Chapter two describes the 
interpretation of the ICC results (Table 2.3). The resulted ICC values for all measures 
are greater than 90%, which demonstrates ‘strong agreement’ between experts and 
substantially differentiates these results from those derived by chance. The final version 
of PITI following content validation is presented in Figure 5.5.
It is obvious from Figure 5.5 that the most number of statements (eight statements) are 
under the category of GMP & QA. This topic was one of the two most frequently 
discussed by the expert panel (chapter 3, Table 3.1) and it was necessary that the 
instrument cover all areas related to this category. Research and development was also 
mentioned frequently by the expert panel and subsequently six statements were 
allocated to this topic in the PITI formulation
Part III - Pilot study
Pilot studies are commonly used to confirm that the instrument is practical and 
applicable for measuring the research question (Flynn, 1990). For the purpose of the 
pilot study, the instrument was sent to 30 managers from three companies (10 
managers per company). The questionnaire also contained a psychometric evaluation 
section, titled ‘evaluation of the questionnaire’, which asked the following questions in 
an effort to explore the respondents’ experience of completing the questionnaire:
1. Were the statements clear and easy to understand?
2. Were the statements easy to respond to?
3. Were the statements related to the topic of study?
4. How long did it take to complete the questionnaire?
All 30 questionnaires were collected and the responses were analysed. Two responses 
were excluded because they were incomplete.
145
Figure 5.5 The final version of the PITI
Current Situation
1. Patent Review
Future Importance
^  : W
absolute compliance no compliance ^ not important at all very important
10
9 8 7 6 5 4 3 2 1 0
Our company has dedicated personnel for 
reviewing intellectual property rights to 
prevent patent infringements.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
An intellectual property right is a key issue in 
the selection of a new product.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We review intellectual property rights when 
exporting products.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The financial impact of enforcing patent 
protection on our products has been studied.
0 1 2 3 4 5 6 7 8 9 10
Current Situation
2. Licence & Technology Transfer 
Agreement Future Importance
10 9 8 7 6 5 4 3 2 1 0
Having licensed products is a strategic goal 
for our company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The infrastructure of our company satisfies 
the requirements of reputable licensors.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have licence agreements with innovator 
companies.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have technology transfer agreements 
with technology owners.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Licensed or technology transferred products 
constitute an important part of our total sales.
0 1 2 3 4 5 6 7 8 9 10
Current Situation
3. Sales &Marketing
Future Importance
10 9 8 7 6 5 4 3 2 1 0
Our marketing expenditure is comparable to 
that of our international rivals.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our company regularly increases the ratio of 
marketing expenditure to total sales.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The company measures the effectiveness of 
marketing expenditure.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our marketing activities contribute to 
capturing the market share.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our marketing activities have increased our 
customer loyalty.
0 1 2 3 4 5 6 7 8 9 10
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9
Cont. Figure 5.5 The final version of the PITI
Current Situation 4.GMP&QA Future Importance
absolute compiance no compliance 
< ---------- : - — ■— - .......................—  ► ,
not important at ail verry important
10 9 8 7 6 5 4 3 2 1 0 Our company allocates sufficient budget 
to improve our GMP.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have the GMP approval of 
international inspectors.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have a validation master plan in our 
company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have an appropriate documentation 
system for GMP.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have a change control system for all 
related departments.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our manufacturing areas are updated and 
renovated regularly.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
GMP improvement is a strategic goal for 
our company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The effectiveness of the GMP expenditure 
is measured in our company.
0 1 2 3 4 5 6 7 8 9 10
Current Situation 5. Research and Development Future Importance
10 9 8 7 6 5 4 3 2 1 0
Our company allocates sufficient budget 
for the R&D department.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The effectiveness of R&D expenditure is 
measured in our company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
R&D investment plays a major role in the 
competitiveness of our company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
A major part of our company revenue 
comes from exclusive products.
0 1 2 3 4 5 6 7 8 9 10
•10 9 8 7 6 5 4 3 2 1 0
There are common projects with R&D 
institutions outside our company.
0 1 2 3 4 5 6 7 8 9 10
■10 9 8 7 6 5 4 3 2 1 0
/
We have innovative new formulations. 0 1 2 3 4 5 6 7 8 9 10
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Cont. Figure5.5 The final version of the PITI
Current Situation
6. Products Packaging
Future Importance
absolute compliance no compliance nct important at all verry important
H ------------------------------- :-------........  k•4 ------------- ——------------------- — ---------------:— -►
10 9 8 7 6 5 4 3 2 1 0
The attractiveness of the packaging is a 
strong point of our products.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 6 5 4 3 2 1 0
We invest in improving our product 
packaging.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our packaging lines are similar to those 
of the international rivals of the company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The role of packaging in creating 
customer satisfaction is measured in our
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The quality of packaging is competitive 
with that of the international competitors 
of our company.
0 1 2 3 4 5 6 7 8 9 10
Current Situation 7. Manufacturing Technology Future Importance
10 9 8 7 6 5 4 3 2 1 0
Our company regularly improves the 
production lines.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The automation level in this company is 
similar to that of our international rivals.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our manufacturing technology is in 
compliance with environmental 
standards.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our manufacturing procedures are well 
documented and well executed.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We regularly update the manufacturing 
procedures for our product.
0 1 2 3 4 5 6 7 8 9 10
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O
Cont. Figure 5.5 The final version of the PITI
Current Situation
8. Mergers & Strategic Alliances Future Importance
absolute compliance no compliance ^not important at all verry important
< -------------------- -— - — —------ ;---------------------—► .
10 9 8 7 6 5 4 3 2 1 0
We have strategic alliances with some of 
our partners.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our company is evaluating possible mergers 
and acquisitions.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Being a subsidiary of a holding company 
facilitates strategic alliances.
0 1 2 3 4 5 6 7 8 9 10
Current Situation
9. Pricing Policy Future Importance
10 9 8 7 6 5 4 3 2 1 0 We have competitive pricing in comparison 
with our international rivals.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 We have price flexibility in comparison with 
our rivals.
0 1 2 3 4 5 6 7 8 9 10
Current Situation 10. Training for Employees Future Importance
10 9 8 7 6 5 4 3 2 1 0 Qualifications are considered very important 
when recruiting people in our company.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 We have training programmes for every job. 0 1 2 3 4 5 6 7 8 9 10
10 9 8
7 6 5 4 3 2 1 0 We are increasing the training hours per 
capita for our employees.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 Our company measures the effectiveness of 
the training programmes.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The capabilities of our employees are 
comparable with those of our international 
rivals.
0 1 2 3 4 5 6 7 8 9 10
11.skills of R&D staff
10 9 8 7 6 5 4 3 2 1 0
Our company regularly improves the skills of 
the R&D staff.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 Our R&D team develop innovative products. 0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5‘ 4 3 2 1 0
A considerable part of our company revenue 
is the result of innovation in R&D.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
The skills of our R&D staff have created 
advantages for our company.
0 1 2 3 4 5 6 7 8 9 10
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Cont. Figure 5.5 The final version of the PITI
Current Situation 12. Management Knowledge
• • -4** . ■
Future Importance
absolute compliance no compliance not important at all very important
10
9 8 7 6 5 4 3 2 1 0
We have qualified persons in all managerial 
positions.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We measure the efficiency of the decisions 
taken by our managers.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
There are adequate numbers of 
management graduates in our managerial 
team.
0 1 2 3 4 5 6 7 8 9 10
Current Situation
13. Customer Satisfaction Future Importance
10 9 8 7 6 5 4 3 2 1 0 We have internal programmes to meet the 
customers’ requirements.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have categorised our customers into 
different groups and have communication 
programmes for each group.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 Our company knows the needs of target 
customers.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 We regularly measure the satisfaction levels 
of our customers.
0 1 2 3 4 5 6 7 8 9 10
Current Situation 14. Creativity of the Employees Future Importance
10
9 8 7 6 5 4 3 2 1 0 Our organisation encourages innovation. 0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
We have utilised the innovativeness of our 
employees to create value.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Innovation plays an important role in 
maintaining our competitiveness.
0 1 2 3 4 5 6 7 8 9 10
Current Situation 15. Qualifications for jobs Future Importance
10
9 8 7 6 5 4 3 2 1 0
The minimum qualifications have been 
increased in our organisation in recent 
years. ^
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 Our company has access to people with the 
required qualifications.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0 Our company can afford to employ highly 
qualified people.
0 1 2 3 4 5 6 7 8 9 10
10 9 8 7 6 5 4 3 2 1 0
Our company has offered scholarships to 
obtain employees with the required 
qualifications.
0 1 2 3 4 5 6 7 8 9 10
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Demography o f the respondents: The respondents were requested to specify their 
gender, age, education and organisational position. The distribution of their age was as 
follows: 50% of the respondents were 40-45 years old, and the rest were distributed 
normally within the age ranges of less than 35, 35-40, 45-50 and more than 50 years 
old. From the educational level point of view, 71% of the respondents were pharmacists 
or physicians, 21% had completed their BS and 7% had an MS degree. The 
organisational positions of the respondents were as follows: 15% were managing 
directors and board members, 50% were managers, 25% had other managerial 
designations and the positions of the rest were not mentioned.
Scores given to the PITI statements: The respondents rated their agreement with the 
statements distributed among 15 categories, including Patent Review, Licence & 
Technology Transfer Agreements, Sales & Marketing etc. the category-wise mean of 
their responses to the statements in terms of current situation and future importance are 
shown in the Figure 5.6.
Figure 5.6 The mean of the scores in the pilot study
Current Situation ■ Future Importance
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0
1. Patent Review 
2. License & Technology Transfer Agreement 
3. Marketing Expenditure 
4.GMP&QA 
5. Research & Development 
6. Product Packaging 
7. Manufacturing Technology 
8. Mergers & Strategic Alliances 
9. Pricing Policy 
10. Training for Employees 
11. Skills of R&D Staff 
12. Management Knowledge 
13. Customer Satisfaction 
14. Creativity of the Employees 
15. Qualifications for Jobs
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The figure indicates that the scores for the current situation are relatively lower than 
those for future importance. Conversely, all the scores pertaining to future importance 
are higher than 8, thus representing the importance and relevance of the selected 
items. The lowest figure, which also represents the biggest difference from among the 
other categories, is related to patent review departments. This reflects the significance 
of reviewing the patent situation of the products and the lack of adequate capabilities at 
present. All the categories are ranked according to the extent of the gap, with the 
biggest gap receiving the highest priority (Table 5.3).
Table 5.3 The priority based on the category-wise mean scores in the pilot study
Instrument Categories
Current
Situation
Future
Importance
Gap Priority
Patent Review Department 2.04 8.25 6.21 1
GMP & QA 4.75 9.00 4.25 2
Marketing Expenditure 4.21 8.36 4.15 3
Skills of R&D Staff 4.50 8.51 4.01 4
Product Packaging 4.36 8.25 3.89 5
Manufacturing Technology 4.85 8.71 3.86 6
Mergers & Strategic Alliances 4.85 8.71 3.86 6
Research & Development 4.78 8.45 3.68 8
Licence & Technology Transfer Agreements 5.11 8.73 3.62 9
Customer Satisfaction 5.08 8.61 3.53 10
Management Knowledge 4.81 8.32 3.51 11
Creativity of the Employees 5.10 8.57 3.46 12
Training for Employees 5.32 8.59 3.27 13
Qualifications for Jobs 5.00 8.13 3.13 14
Pricing Policy 6.67 8.34 1.67 15
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Based on these data (gap analysis), the patent review department was given the 
highest priority, followed by GMP and marketing expenditure. It is interesting to note 
that the pricing policy received the lowest rank, which may indicate that the industry has 
fewer concerns pertaining to price competition. The results for all the statements will be 
presented and discussed in the next chapter, after describing the main data collection. 
The distribution of different categories between the axis of future importance and 
current situation is visualised in Figure 5.7.
Figure 5.7 The relationship between the current situation and future importance of the
PITI categories
6.50
5.50
4.50
3.50
2.50
1.50
9.00 9.208.60 8.808.00 8.20 8.40
♦ 1. Patent Review
■ 2. Licence & Technology Transfer Agreement 
a 3. Marketing Expenditure
x 4. GMP & QA 
x 5. Research & Development
♦  6. Product Packaging
+ 7. ManufacturingTechnology 
- 8. Mergers & Strategic Alliances 
- 9 .  Pricing Policy
♦ 10. Training for Employees
■ 11. Skills of R&D Staff
a  12. ManagementKnowledge
13. Customer Satisfaction
14. Creativity of tire Employees 
1 S. Qualifications for Jobs
Future Importance
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The above diagram shows the category of Patent Review as positioned at some 
distance from the other items, which re-emphasises the significant importance of 
working on this area. At the same time, Pricing Policy also occupies a unique position in 
the opposite direction in the diagram. The other items have similar positions in terms of 
the current situation and are differentiated similarly as regards their future importance. 
The scores given to each statement and their ranking according to the size of the gap 
are provided in the Table 5.4. The statements are ordered based on the PITI structure, 
the first figure in the left column shows the PITI category and the second figure presents 
the position of the statement in the category. The median of the ‘Current Situation’ and 
‘Future Importance’ scores are presented for all statements and the size of the gap 
determines the priority of each statement. The larger gap will result in a higher priority.
Table 5.4 The mean scores of the PITI for the pilot study
PITI Statements
Current
Situation
Future
Im
portance
Gap
Priority
1-1
Our company has dedicated personnel for reviewing 
intellectual property rights to prevent patent infringements.
1.14 8.48 7.34 1
1-2
An intellectual property right is a key issue in the selection of 
a new product.
2.71 8.09 5.37 5
1-3
We review intellectual property rights when exporting 
products.
2.95 8.55 5.60 4
1-4
The financial impact of enforcing patent protection law on 
our products is identified.
1.60 7.76 6.16 2
2-1
Producing under-licence products is one of the strategic goals 
of our company.
6.95 9.22 2.26 65
2-2
The infrastructure of this company satisfies the requirements 
of reputable licensors.
4.77 8.82 4.05 25
2-3 We have licence agreements with innovator companies. 5.19 8.91 3.72 42
2-4
We have technology transfer agreements with technology 
owners.
4.95 8.52 3.57 48
2-5
Licensed or technology transferred products constitute an 
important part of our total sales.
4.52 8.52 4.00 28
3-1 Our marketing expenditure is comparable to that of our 2.42 8.04 5.63 3
154
PITI Statements
Current
Situation
Future
Im
portance
G
ap
Priority
international rivals.
3-2
Our company regularly increases the ratio of marketing 
expenditure to total sales.
3.68 8.27 4.59 11
3-3 We measure the effectiveness of our marketing expenditure. 4.17 8.04 3.88 35
3-4
Our marketing activities have contributed to capturing the 
market share.
5.50 8.88 3.38 51
3-5 Our marketing activities have increased our customer loyalty. 5.04 8.87 3.83 37
4-1
This company allocates sufficient funds to improve the GMP 
level.
4.78 9.13 4.35 19
4-2 We have the GMP approval of international inspectors. 3.74 9.09 5.35 6
4-3 We have a validation master plan for GMP. 4.32 9.22 4.90 10
4-4 We have an appropriate documentation system for GMP. 6.22 9.30 3.09 55
4-5 We have a change control system for all related departments. 3.82 8.91 5.09 9
4-6
The manufacturing areas of this company are regularly 
updated and renovated.
4.13 8.48 4.35 19
4-7 GMP improvement is a strategic goal for our company. 6.71 9.43 2.73 59
4-8
The effectiveness of GMP expenditures is evaluated in our 
company.
4.30 8.78 4.48 15
5-1
Our company allocates sufficient funds for the R&D 
department.
4.57 8.70 4.13 23
5-2
The effectiveness of R&D expenditures is measured in our 
company.
3.39 8.61 5.22 7
5-3 R&D investment plays a major role in our competitiveness. 4.63 9.08 4.46 16
5-4
A major part of this company revenue comes from exclusive 
products.
5.42 8.13 2.71 60
5-5
We have joint R&D projects with institutions outside our 
company.
5.64 8.09 2.45 63
5-6 We have innovative new formulations. 4.75 8.38 3.63 45
6-1
The attractiveness of the packaging is a strong point of our 
products.
4.62 8.73 4.12 24
6-2 We invest in improving our product packaging. 5.08 8.42 3.35 52
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PITI Statements
Current
Situation
Future
Im
portance
G
ap
Priority
6-3
Our packaging lines are comparable with those of our 
international rivals.
4.12 8.13 4.01 27
6-4
The role of packaging in creating customer satisfaction is 
measured in our company.
3.81 7.96 4.15 21
6-5
The quality of the packaging is comparable with that of our 
international competitors.
4.35 8.38 4.04 26
7-1 Our company regularly improves the production lines. 4.21 8.75 4.54 13
7-2
The automation level in this plant is comparable with that of 
our international rivals.
3.33 8.54 5.21 8
7-3
The manufacturing technology in this company is in 
compliance with environmental standards.
4.65 8.48 3.83 38
7-4
The manufacturing procedures in this company are well 
documented and well executed.
6.43 9.09 2.65 61
7-5
We regularly update the manufacturing procedures for our 
products.
5.09 9.00 3.91 33
8-1
Our company has strategic alliances with some of our 
partners.
4.40 8.35 3.95 29
8-2 Our company is evaluating possible mergers and acquisitions. 4.22 8.00 3.78 39
8-3
Being a subsidiary of a holding company facilitates strategic 
alliances.
4.50 7.94 3.44 50
9-1
Our company has competitive pricing in comparison with our 
international rivals.
5.96 8.42 2.46 62
9-2
Our company has price flexibility in comparison with our 
rivals.
6.38 8.46 2.08 66
10-1
Qualifications are considered very important while recruiting 
people in this company.
5.22 8.69 3.47 49
10-2 We have training programmes for every job. 5.54 8.81 3.27 54
10-3 We are increasing our training hours per capita. 5.77 8.62 2.85 57
10-4
Our company measures the effectiveness of our training 
programmes.
4.62 8.50 3.88 34
10-5 The capabilities of our employees are comparable with our 5.00 8.32 | 3.32 53
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PITI Statements
Current
Situation
Future
Im
portance
Gap
Priority
international rivals.
11-1 Our company regularly improves the skills of the R&D staff. 4.43 8.57 4.14 22
11-2 Our R&D team can develop innovative products. 4.27 8.64 4.36 17
11-3
A considerable part of the revenue of our company results 
from innovation in R&D. 3.86 8.23 4.36 18
11-4
The skills of our R&D staff have created competitive 
advantages for our company.
4.05 8.59 4.55 12
12-1 We have qualified persons in all managerial positions. 5.60 8.64 3.04 56
12-2
Our company measures the efficiency of the decisions taken 
by the managers.
4.36 8.28 3.92 31
12-3
There are adequate numbers of management graduates in 
our managerial team.
4.48 8.16 3.68 43
13-1
We have internal programmes to meet the customers' 
requirements.
4.88 8.79 3.92 32
13-2
We have categorised our customers into different groups and 
have communication programmes for each group.
4.63 8.50 3.88 36
13-3 Our company knows the needs of its target customers. 4.96 8.54 3.58 47
13-4
We regularly measure the satisfaction levels of our 
customers.
5.38 9.04 3.67 44
14-1 Our organisation encourages innovation. 5.00 8.60 3.60 46
14-2
Our company has utilised the innovativeness of its employees 
to create value.
4.72 8.44 3.72 41
14-3
Innovation plays an important role in maintaining our 
competitiveness.
4.79 8.72 3.93 30
15-1
The minimum qualifications have been increased in our 
organisation in recent years.
5.75 8.58 2.83 58
15-2
Our company has access to people with the necessary 
qualifications.
6.04 8.42 2.38 64
15-3 Our company can afford to employ highly qualified people. 4.42 8.17 3.75 40
15-4
Our company has offered scholarships to obtain employees 
with the required qualifications.
3.08 7.58 4.50 14
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The largest gap belonged to the ‘Patent Review’ and was related to dedicating 
personnel to review the patent situation of their products. This is absolutely 
understandable especially when considering that the companies participating in the pilot 
study were three large companies. The second gap was realised in evaluating the 
financial impact of enforcing TRIPS regulations regarding patent protection. The third 
priority showed the industry concerns about “marketing expenditure of their international 
rivals’. Again, the fourth and fifth priority were reviewing the patent situation while 
developing new products or exporting the products to other countries. The next 
important priority reflects the gap in obtaining GMP approval from international 
inspectors that may indicate the lack of sufficient investment in this area. At the same 
time, the industry is not measuring the effectiveness of its marketing expenditures (the 
seventh priority). Automation level from the category of ‘Manufacturing Technology’ is 
the eighth priority and it is not surprising that a change control system and validation 
master plan (ninth and tenth priorities) are again related to the GMP and QA. Therefore, 
patent review, GMP & QA, marketing expenditure as well as the manufacturing 
technology are the ten major sources of concerns in the pilot companies.
Comparing the results o f the pilot study and the Delphi technique: The results of
the pilot study using PITI, with the final ranking of the parameters resulted from the
Delphi technique applying WTO-PI Impact Rating Scale, are presented in the Table 5.5.
Friedman ranking of the statements listed in the WTO-PI Impact Rating Scale are
compared to the future importance of the PITI statements to realise the perceptions of
the two group of respondents regarding the post-WTO situation. It should be
remembered that the respondents to the PITI were all managers from the industry, while
the respondents to the Delphi questionnaire were a balanced group of experts from
different fields of regulatory authority, academia and industry. In other words, the results
given in this chapter are more indicative of the opinions of the industry mindset, and
comparing these two results may reveal the differences between the two groups of
participants in the study. The greatest increase in the rankings given by the PITI
respondents occurred in the category of Creativity of the Employees (+16 points),
followed by the categories of Manufacturing Technology (+14 points) and Research &
Development (+11 points). This means that the pilot study respondents were more
concerned about incorporating innovation into their R&D and using new technologies
158
and this is why people from industry have put these categories much higher than the 
expert panel. They also upgraded the categories of GMP & QA, Mergers & Strategic 
Alliances and Licence & Technology Transfer Agreements (+7 points).
Table 5.5 Comparison of the results of the pilot study and the Delphi technique
Delphi Technique Pilot Study Rank
Changes
Friedman
Ranking
WTO-PI Impact Rating Scale 
statements
Future
Importance
Scores
PITI Categories
1 Importation Tariff* 9.00 GMP & QA +7
2 Management Knowledge & Skills 8.73 Licence & Technology Transfer Agreements +7
3 Training for Employees 8.71 Manufacturing Technology +14
4 Skills of R&D Staff 8.71 Mergers & Strategic Alliances +7
5 Customer Satisfaction 8.61 Customer Satisfaction 0
6 Patent Review Departments 8.59 Training for Employees -3
7 Marketing Expenditure 8.57 Creativity of the Employees +16
8 GMP 8.51 Skills of R&D Staff -4
9 Licence & Technology Transfer Agreements 8.45 Research & Development +11
10 Pricing Policy 8.36 Marketing Expenditure -3
11 Mergers & Strategic Alliances 8.34 Pricing Policy -1
12 Policies of Paying the Subsidies* 8.32 Management Knowledge -10
13 Product Packaging 8.25 Patent Review Department -7
14 Higher Qualifications for Jobs 8. 25 Product Packaging -1
15 Per Capita Expenditure on Medicines* 8.13 Qualifications for Jobs -1
17 Modern Manufacturing Techniques
20 R&D Expenditure
23 Innovation & Creativity of the employees
*No correspondent PITI category
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Unexpectedly, they dramatically reduced the importance of the Management 
Knowledge (-10 points) in the post-WTO situation. This implies that the pilot study 
respondents were less concerned about their knowledge levels and gave greater priority 
to other issues. They also downgraded Patent Review (-7), Skills of R&D Staff (-4 
points) and Training for Employees (-3 points). The other categories underwent little or 
no change in their importance. These results will be compared with the final scores in 
subsequent chapters in order to determine which results are common for the entire 
group of respondents.
Applicability and Practicality of the PITI: In this part of the pilot study, the 
respondents were asked to rate their agreement with the statements relating to their 
ease of understanding and completing the instrument. The scale ranged from 1 to 9, 
with 1 representing ‘totally disagree’ and 9 representing ‘totally agree’.
Were the statements clear and easy to understand? In general, the industry 
participants found the statements of the PITI as “easy to understand’ (Figure 5.8).
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Figure 5.8 Responses to the question ‘Were the statements clear and easy to
understand?’
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Were the statements easy to respond to? Even more of the respondents labelled 
these statements as ‘easy to respond to’. While 68% of the respondents accorded 
scores of 7 or more to this question, only two respondents gave it scores of equal to or 
less than 3. The mean of the scores for this question is 6.9 (Figure 5.9).
Figure 5.9 Responses to the question ‘Were the statements easy to respond to’?
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Were the statements related to the topic of study? Overall, the participants in the 
pilot study agreed the statements’ relevance to the topic of study (Figure 5.10).
Figure 5.10 Responses to the question ‘Were the statements related to the topic of
study?’
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With 64% of the respondents giving this question a score exceeding 7. Only two 
respondents selected scores equal to or less than 3, and the mean of the responses 
was 7.0.
How long did it take to complete the instrument? The final question in this section 
was regarding the time needed to answer the questions (Table 5.6).
Mean = 7.0
(=7] (=4 & =6) (=3) Blank
Mean of the Scores
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Table 5.6 Responses to the question ‘How long did it take to complete the
questionnaire?’
Time Frequency Percentage
20-30 min 17 61%
30-40 min 6 21%
40-50 min 2 7%
More than 60 min 0 0%
Total 25 100%
More than 61% of the respondents selected 20-30 minutes as the time required to fill 
the questionnaire, which was exactly what had been estimated by the research team 
and mentioned in the cover pages of the instrument.
Internal consistency and reliability of the pilot study results: to investigate the 
repeatability of the resulted data, Cronbach’s alpha was calculated to have a value of 
0.99 which according to Table 2.3, indicates ‘almost perfect agreement’ between the 
study participants and differentiates the data from being obtained by chance.
DISCUSSION
It was a significant challenge to develop a study instrument that would fit the 
requirements of this research, mainly due to the absence of such an instrument in the 
literature. In fact, defining the inclusion and exclusion factors was the first barrier to the 
design and development of a robust research instrument. The current study overcame 
this problem by using the methodology of the Delphi technique (chapter 4), whereby an 
expert panel generated the items that would subsequently be used as the framework of 
the study instrument. This methodology resulted in the development of the PITI 
containing 15 categories (by excluding certain statements that were related to 
contextual issues), which were then populated with a number of statements with the 
help of the research team. Developing the electronic version of the rating scales 
especially the Web-based PITI, contributed to facilitating the data collection procedures 
with respect to the time horizon of the study. The willingness of the study participants
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played a major role in the success of the electronic data collection and in process 
communication. The study participants and other research groups gave a positive 
feedback to the procedures used for the content validation of the study instrument. The 
psychometric evaluation of the PITI yielded acceptable results in the first stage, while 
this process had previously required two stages for completion, as described in chapter 
3. The results of the psychometric evaluation in the pilot study also supported the 
conceptualisation procedure for developing the instrument. The pilot study with the 
industry participants did not require that the PITI should be changed or refined thus 
establishing the validity and reliability of the instrument.
The pilot study revealed a significant difference between the scores given to the current 
situation and those given to the future importance of the statements, which clearly 
indicates the strength of the developed study instrument when it comes to identifying 
the parameters influencing the sustainability of the industry in the post-WTO situation.
With regard to the current situation (CS) and future importance (FI) of each statement, 
there were four possibilities:
• Group A: Areas that the industry neither complies with in the current situation 
(low CS score) nor are likely to be important in the future (low FI score)
• Group B: Areas that are satisfactorily developed at present (high CS score) but 
are not important in the post-WTO/TRIPS situation (low FI scores)
• Group C: Areas that are not only considered important at present (high CS score) 
but also have significant importance in the post-WTO/TRIPS environment (high 
FI scores)
• Group D: Areas that are not complied with in the current situation (low CS score) 
but will have significant importance in the post-WTO/TRIPS environment (high FI 
scores)
These possibilities are illustrated in Figure 5.11.
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Figure 5.11 The distribution matrix of the statements against CS and FI
Group B 
No statements
Group D 
66 statements
Group A 
Low No statements
Low FI High
This matrix indicates that all the statements of the developed instrument are distributed 
within group D, with low scores in terms of the current situation but high scores as 
regards future importance. This group represents the important, insufficiently developed 
areas that are likely to have severe consequences for the industry if no action plan is 
defined to address them in time. This matrix also demonstrates the identification of the 
categories, which confirms the value of the Delphi technique and the precise elaboration 
of the statements in this study.
The fact that the pilot study was carried out in pharmaceutical companies differentiates 
the results from the outcomes of the expert panel with participants from academia, the 
regulatory authority and industry. It should be also noted that the pilot companies were 
three major firms with considerable market share. These companies have been 
inspected by foreign teams both for exportation of their products or licence agreements. 
Therefore, the complications of receiving GMP approval from international bodies are 
clear for them and this is why they have put GMP and QA at the top of the list of their 
future concerns in a position much higher than the expert panel did before. They have 
also underlined the importance of licence and technology transfer agreement by putting 
this category in the second position to bridge the technology gap and produce 
innovative products. The industry, at the same time, believes that manufacturing 
technology will have a remarkable role in the competitive situation post-WTO.
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Comparing these results with the expert panel opinions revealed the fact that the 
industry is more focused on hard structural parameters while the expert panel 
highlighted softer aspects of the industry such as knowledge of the management and 
the skill level of the employees. Conversely, industry has considered the creativity of 
employees much more important than the expert panel.
It was not expected that the industry, in contrast to the expert panel, would put 
management knowledge at the bottom of their future concerns, but this may be 
interpreted by the general trend of highlighting structural aspects by this group of 
respondents.
In general, the obvious difference in the industry’s way of evaluating the consequences 
of joining WTO with the expert panel opinions is a result of their dissimilar backgrounds 
and experiences while at the same time underlines the necessity of a more intra-field 
discussion for creating a consensus among various players in the pharmaceutical 
environment. It will be important to see the results of carrying out the study throughout 
the industry before a final conclusion is reached. It should be also mentioned that the 
respondents were those that had and had not been inspected by GMP auditors. 
Therefore they have had different levels of experience in this regard.
SUMMARY
This chapter described the development of the Pharmaceutical Industry Transition 
Instrument (PITI) as identified by the steps delineated in Figure 5.1.
• The items used for designing the PITI were identified using the Delphi technique,
as explained in the previous chapters.
• In order to study the industry situation, the items categorised under ‘content’ and 
‘structure’ were selected, while the ‘context’ parameters, which basically focused 
on the industry environment, were excluded.
• The items were later grouped into different categories pertaining to various
industry departments and activities, such as the ‘patent review department’,
‘GMP expenditure’ etc. And these categories were thereafter populated with 
several statements, which resulted in a total of 66 statements in the final 
instrument.
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• This instrument was also evaluated for psychometric criteria such as validity, 
reliability and completion time with acceptable results.
• Finally, the instrument was pilot tested on a group of 30 participants from three 
different pharmaceutical companies with 28 acceptable responses (response rate 
of 93%). The results of the content validation were also supported by the 
responses to the applicability and practicality questions in the pilot study.
• The ranking of items resulting from the industry participants (pilot study) was 
compared with that obtained by using an expert panel in the Delphi exercise 
(Table 5.6), thus highlighting the differences between the priorities given to the 
items by the two groups of respondents.
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Chapter 6
Evaluation of the Current Environment and Future 
Aspirations of the Pharmaceutical Industry in Iran
168
INTRODUCTION
The main focus of chapters 3 and 4 was to identify the parameters that are likely to 
influence the pharmaceutical industry in the post-WTO situation. These parameters 
were utilised in chapter 5 to design an instrument to determine the current situation and 
the future importance of these parameters within the industry. The instrument was titled 
the ‘Pharmaceutical Industry Transition Instrument’ (PITI) and this instrument was then 
evaluated for validity and reliability and a pilot study conducted to ensure its applicability 
and practicality. In this chapter, the PITI will be used to evaluate the current situation 
and future aspirations of the pharmaceutical industry and this evaluation will be based 
on the data collected from managers of several pharmaceutical companies.
This chapter will play a crucial role in answering the research question on the ‘post- 
WTO/TRIPS sustainability of the pharmaceutical industry in Iran’. The data generated at 
this stage of the study will provide the information necessary to explore the extent to 
which the industry is aware of the upcoming challenges and the way in which it 
understands the current situation. The scores regarding the future importance of the 
parameters will reveal whether the industry is ready to meet the future challenges. The 
pattern of scoring for the current situation will indicate the extent to which the industry is 
prepared for WTO/TRIPS implementation. Comparing the current situation and future 
importance of the parameters will identify the existing gap, which can help managers 
and policy makers decide how to prioritise and verify critical issues and thereby develop 
strategies to allocate national or organisational resources to meet these challenges.
OBJECTIVES
The data collected in this part of the study, using the PITI as the data collection 
instrument, will be used to evaluate the situation of the pharmaceutical companies by 
assessing the gap between the industry’s readiness to meet future challenges. The 
objectives of this study were to:
• Study the current situation of the industry by identifying its strengths and 
weaknesses
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• Identify the future importance of the various parameters that reflect the industry’s
aspirations to meet the challenges
• Rank and prioritise the actions that need to be taken by the industry
• Explore the statistical significance of the study findings
•  Propose scenarios for developing appropriate strategies to ensure the sustainability
of the pharmaceutical industry
METHODS
In this study, the PITI was used to assess the current environment and future
aspirations of the pharmaceutical industry in Iran. The practical steps that were carried
out in this part of the study are as follows (Figure 6.1):
• The participants were selected according to their eligibility and contacted to 
ensure their willingness to participate in the study
• A website was designed and registered to upload the study instrument to 
facilitate the web-based data collection procedure
• The study instrument (PITI) was distributed among the study participants in both 
paper and electronic formats
• The resulting data were quality controlled and transferred into the data base
• Friedman’s test was carried out to rank the categories of the parameters
• The Binomial test was used to evaluate the current situation and future 
importance of the PITI categories and statements
• Three development scenarios are proposed on the basis of study results in order 
to improve the industry weaknesses, focus on industry strengths and concentrate 
on the future importance of the identified categories of parameters.
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Figure 6.1 The study methodology flowchart
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Study Participants
There are approximately 70 operating pharmaceutical companies in Iran, altogether 
employing some 13,900 personnel (UN, 2005); of these, around 3% occupy managerial 
positions (417 persons). We took 25% of the managers that is beyond the expectation 
in such a study.
Data Collection Procedure
The PITI consists of 15 categories, namely, Patent Review, Licence & Technology 
Transfer Agreements, Sales & Marketing, GMP & QA, Research & Development, 
Product Packaging, Manufacturing Technology, Mergers & Strategic Alliances, Pricing 
Policy, Training for Employees, Skills of R&D Staff, Management Knowledge, Customer 
Satisfaction, Creativity of the Employees and Qualifications for Jobs. Each of these 
categories consists of a number of statements to cover all important aspects within the 
category (see Figure 5.5, chapter 5).
The respondents were requested to rate their agreement with each statement on a 
scale ranging from 0 to 10 for both the current situation of each parameter and its future 
importance. For the current situation, the responses for their satisfaction of the 
compliance of the industry ranged from the statement of ‘strongly disagree’ to ‘strongly 
agree’, while in the case of future importance, the scale ranged from ‘not important at 
all’ to ‘very important’. Data collection was carried out within 35 days during June and 
July 2009. The instrument was distributed to 150 personnel from 22 companies. Each 
company was contacted prior to sending out the instrument in order to ascertain the 
contact person, who would be responsible for receiving the instrument and then 
distributing it among personnel with sufficient knowledge to respond to the PITI. The 
electronic version was also made available on the website, and all the potential 
respondents received a username and password in a sealed envelope; thus, everyone 
had the opportunity to choose whether to respond to the electronic or paper version of 
the PITI. The recipients of the instrument were subsequently contacted by phone and/or 
e-mail to determine the likelihood of their participation in the study and to understand 
the distribution of the instrument throughout the company. An electronic reminder of the 
data collection deadline was sent one week before the end of data collection. The
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companies that did not return the questionnaires by the deadline were subsequently 
contacted either to discuss the possibility of late data provision or to confirm that the 
company or some of its respondents would not participate.
Response Rate
A total of 150 questionnaires were distributed among 22 companies, out of which 90 
were returned from the same number of companies; thus, the response rate was 60%. 
In view of the response rate of 93% in the pilot study (28 respondents from a total of 
30), the overall response rate was 66%. Of out the 90, from this, 9 responses were 
excluded due to the high number of missing items. According to the follow up of the 
non-respondent cases, the main reason they decided not to participate in the study was 
lack of sufficient knowledge, which prevented the person from completing the 
questionnaire. In other words, the real number of people with sufficient information 
regarding the issues investigated in this study was less than our initial expectation. 
There were other reasons for the non-respondents, namely, the data were not readily 
available in the company or could not be made available within the given time frame or 
the concerned person was unwilling to provide information due to reasons of 
confidentiality. As a result of the pilot and main study we had 109 evaluable responses 
and because no amendment was required, the results of the pilot and the main study 
are combined.
Data Processing and Analysis
Once the questionnaires were returned, the data were reviewed to determine data 
quality. Any returned instrument with several unanswered questions was excluded from 
the study.
The respondents were encouraged to provide data using the electronic version, which 
had been designed as a Web-based questionnaire using the Microsoft ASP.NET 3.5 
technology and SQL server 2008 database. The respondents were requested to enter 
their specific username and password to open the instrument pages on the Web page 
www.pharmeconomics.com. which was specifically designed for this study using Visual 
Web Developer 2008. This software can be used for creating online reports for both
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demographic and study questions. The use of an electronic instrument considerably 
improved the quality of the data, thus eliminating the need for additional data handling 
steps and the complications resulting from manually entering data into the database.
The data were processed using Microsoft Access 2007. Both Microsoft Access 2007 
and Microsoft Excel 2007 were used to obtain descriptive statistics of the data, while 
SPSS version 17 for Windows XP was used to run statistical analyses on the data. 
These analyses included the following calculations:
• The mean of the responses to all statements regarding the current situation and 
future importance was calculated, and the gap between the current situation and 
the future importance was determined.
• The internal consistency of the data was tested by calculating Cronbach’s alpha 
to determine the repeatability of the results.
•  The Friedman test was carried out to assess whether the ranking of the 
categories and parameters is significant.
•  Binomial tests were carried out to investigate the significance of categorising the 
parameters as ‘desirable’ with regard to the current situation and ‘important’ in 
terms of the future importance. (The tests were carried out for categories as well 
as statements.)
This chapter explains the above process and its practical steps, which are presented in 
Figure 6.1.
RESULTS 
Demographics of the Respondents
In terms of gender, 69% of the respondents were males, while 37% were females. Their 
educational profile was as follows: 20% had completed their BS; 13%, MS; 58%, 
Pharm. D or MD; and 7%, PhD. The educational qualifications of 2 respondents (2%) 
were not provided. The organisational positions of the respondents were as follows: 
10% were board members and managing directors, 69% were managers, 17% were 
employed in other managerial positions and the designations of 4% were not specified.
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In addition, 90% of the participants were from companies that manufactured finished 
products (Figure 6.2).
Figure 6.2 Demographics of the respondents
Education Gender
■  Pharm D /M  D
■  Others
■  Fem ale
Organisational position
4% 10%
■  M anaging  D irectors/Board M em b e r
■  M anagers
■  others
■  N o t Specified
Reviewing the results showed there were not significant differences between the 
responses of different groups of participants apart from the fact that there were more 
missing items in the non-pharmacist responses.
The Perceptions of the Respondents in View of the PITI Categories
The findings of this chapter revealed the fact that the Iranian pharmaceutical industry is 
ill prepared to face the challenges from joining WTO and implement TRIPS regulations. 
The situation of the industry was evaluated and the important areas were identified by
using the Pharmaceutical Industry Transition Instrument (PITI) developed in the
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previous chapter. This instrument asks the respondents to express their opinions about 
the current situation and future importance of each statement by selecting a figure 
within the anchor of the points from 0 to 10. Selecting 0 for the current situation means 
that the respondent is not satisfied with the compliance of the company with the 
requirements of that statement, while selecting 10 indicates that the respondent 
believes the industry has performed satisfactorily to comply with the requirements. 
Giving 0 to the future importance of a statement is an indication of labelling that 
statement as ‘not important at all’ in the post-WTO situation while, selecting 10 shows 
that the respondent believes that the subject of the statement will be very important in 
the future.
The scores given by the respondents to the current situation of each category and its 
future importance are presented in Table 6.1 and Figure 6.3. It is worth highlighting that 
the lowest score is given to the patent review category in the current situation. This was 
expected because of the absence of a patent protection law in the current legal 
environment. This also re-emphasises the local industry’s lack of competency to deal 
with the situation of enforcing intellectual property rights for their current and future 
products. The highest scores were given to the manufacturing technology and training 
for employees. It is unlikely to believe that the industry’s performance in these two 
groups of parameters would be at an acceptable level especially when considering that 
these scores are less than 6.0. It can be concluded that in general, the scores for the 
current situation were lower or slightly more than 5.0 and this suggests the level of 
satisfaction with the industry performance is low or barely moderate.
Conversely, the scores given to the future importance of the statements are fairly high 
and clearly more than those for the current situation. GMP & QA has received the 
highest score of 9.05, indicating the importance of this item in the coming situation. It is 
interesting to note that the future importance of both Management Knowledge and 
Training for Employees were rated equally by the respondents (both received a score of 
8.61).
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Table 6.1 The mean scores for the current situation and future importance
Categories of Parameters
Current
Situation
Future
Importance
Patent Review 2.93 8.01
GMP & QA 5.29 9.05
Skills of R&D Staff 4.26 8.46
Customer Satisfaction 4.99 8.70
Creativity of the Employees 5.04 8.73
Management Knowledge 4.91 8.61
Marketing Expenditure 4.15 8.23
Research & Development 4.68 8.42
Product Packaging 4.58 8.30
Licence & Technology 
Transfer Agreements
5.15 8.53
Manufacturing Technology 5.60 8.71
Qualifications for Jobs 5.20 8.50
Training for Employees 5.61 8.61
Mergers & Strategic 
Alliances
4.80 7.82
Pricing Policy 5.38 8.08
Even though patent review received low satisfaction in the current situation (mean score 
of 2.93), the industry gave a relatively high future importance score to recognise this 
area as a considerable consequence of joining WTO and implementing TRIPS 
regulations. The mean scores given to each of the statements are presented in 
Appendix 7.1.
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Figure 6.3 The mean scores of the PITI categories
■  C urrent S ituation  H  Future Im portance
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Internal Consistency Reliability
To assess the reliability of the data generated by the PITI, Cronbach’s alpha was 
measured for all 66 statements; it resulted in a value of 0.94 for the current situation and 
0.98 for future importance. According to the interpretation presented in chapter 2 (Table 
2.3), both results are acceptable and indicate almost perfect agreement among the 
respondents.
Prioritising the PITI Categories Using the Friedman Test
All 15 categories of the identified parameters were ranked using the Friedman test 
(Table 6.2). The column of mean rank shows the calculated mean of the ranks based on 
the given responses to the related statements. Since the instrument consists of 15
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categories, the maximum possible mean rank for a particular category would be 15 if all 
the respondents ranked that category first.
According to this table, the category of Manufacturing Technology ranks highest among 
the categories and can therefore be considered the strongest point of the industry in the 
current situation. This item is followed by Training for Employees and Licence & 
Technology Transfer Agreements. The results show the ranking based on the mean 
scores and Friedman ranking are slightly different. For instance the mean score of 5.61 
places training for the employees at the top of the list for current situation which is 
followed by manufacturing technology with the mean score of 5.60 (Table 6.1). This 
order reversed while Friedman ranking was calculated this order for the current situation 
was reversed when the Friedman ranking was calculated (figure 6.2).
Furthermore as expected the Patent Review category was ranked lowest and can 
therefore be regarded as the industry’s greatest weakness in the current situation. It is 
surprising that Patent Review is also the lowest-ranking category for its future 
importance that may indicate a lack of awareness when reviewing this item. However 
this issue needs further investigation for a proper explanation.
As indicated by this table, GMP expenditure is likely to be the most important category 
in the future. The fact that this category ranked fifth in the current situation implies that 
the current GMP levels do not match the future importance of this category that 
suggests more improvements in this area. The other potential area for improvement is 
creativity of the employees with a low Friedman rank of 10 in the current situation and a 
high importance ranking of 4.
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Table 6.2 Prioritisation of the PITI categories using Friedman test
PITI Categories
Current Situation Future Importance
Ranking
Change
Friedman
Ranking
Mean
Rank
Friedman
Ranking
Mean
Rank
Manufacturing Technology 1 10.02 2 9.04 -1
Training for Employees 2 9.66 5 8.42 -3
Licence &  Technology Transfer 
Agreements
3 9.38 8 8.16 -5
Qualifications for Jobs 4 9.19 9 8.02 -5
GMP &  QA 5 9.11 1 10.77 +4
Pricing Policy 6 8.85 12 7.06 -6
Customer Satisfaction 7 8.80 3 8.89 +4
Mergers &  Strategic Alliances 8 8.28 13 6.49 -5
Management Knowledge 9 8.20 6 8.37 +3
Creativity of the Employees 10 8.10 4 8.87 +6
Research &  Development 11 7.96 10 7.60 +1
Product Packaging 12 7.07 11 7.34 +1
Skills of R&D Staff 13 6.13 7 8.17 +6
Marketing Expenditure 14 5.39 14 6.47 0
Patent Review 15 3.88 15 6.34 0
The changes in the rankings of parameter categories also presented in Table 6.2. The 
largest changes occur in the category of “Creativity of the Employees” and Skills of R&D 
staff which each shows a 6-point increase in rank. This means that these two categories 
have relatively low ranks in the current situation as compared to their future importance. 
These are followed by GMP & QA and Customer Satisfaction, which show a 4-point 
increase in rank; hence, they represent the second group of unmet categories, followed 
by Management Knowledge (3-point increase in rank). Meanwhile, Marketing
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Expenditure and Patent Review do not show any change in ranking, which is surprising 
considering the importance of these two categories in the post-WTO/TRIPS situation.
Statistical significance of the Friedman ranking was determined to support its 
application in designing improvement plans for identified areas. Using SPSS version 17 
confirmed the significance of the above ranking for both current situation and future 
importance of the categories (P<0.05).
Performance of the Industry with Respect to the Study Parameters
To assess the performance of the industry a hypothesis was generated for each PITI 
statement as follows:
■ Study Hypothesis: The performance of the industry with respect to this 
statement is satisfactory (mean > 5).
By applying the binomial test, it is possible to evaluate each statement in order to 
determine whether it is significant (P value<0.05) and the hypothesis is accepted 
(observed probability more than 0.5) or rejected (observed probability less than 0.5).
Future Importance of the Study Parameters
The importance of the statements in the post-WTO/TRIPS situation was also evaluated 
by testing the following hypothesis:
■ Study Hypothesis: This statement will be important in the post-WTO/TRIPS 
situation (mean > 5).
An accepted research hypothesis implies that more than 50% of the respondents give a 
score higher than 5 to the concerned statement and that the parameter is either 
satisfactory (in the current situation) or important (for the future), while a rejected 
research hypothesis implies that the parameter is neither satisfactory nor important. It 
should be noted that a P value of more than 0.05 indicates an inordinately large 
variation between the responses, which means that the test result is not significant 
(Table 6.3).
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Table 6.3 Performance of the industry and the future importance of the PITI statements
C urren t S ituation Future Im p ortan ce
No. Category/Statement
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt*
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt* *
1. Patent Review
1-1
O ur com pan y has 
d ed ica ted  personnel fo r  
rev iew ing  in te llectu a l 
p ro p erty  rights to  p re v e n t  
p ate n t in frin gem ents .
0 .15 0 .0 01 re jected 0 .8 6 0 .0 0 1 accepted
1-2
An in te llec tu a l p ro p e rty  
right is a key issue in th e  
selection  o f a n ew  p roduct.
0 .33 0 .0 0 2 re jected 0 .8 6 0 .0 0 1 accepted
1-3
W e  re v ie w  in te llec tu a l 
p ro p e rty  rights w hen  
exporting  products.
0 .2 6 0 .0 01 re jected 0 .8 3 0 .0 0 1 accepted
1-4
The financia l im p act o f  
enfo rc ing  p a te n t p ro tec tio n  
on o ur products has been  
studied .
0 .1 1 0 .0 0 1 re jected 0 .85 0 .0 0 1 accepted
2. Licence & Technology 
Transfer Agreements
2-1
Producing u nd er-licen ce  
products is o ne  o f th e  
strateg ic  goals o f o ur  
com pany.
0 .5 8 0 .1 5 5
not
significant
0 .91 0 .0 01 accepted
2-2
The in fras tru c tu re  o f o ur  
com pany satisfies th e  
req u irem en ts  o f re p u ta b le  
licensors.
0 .5 2 0 .7 6 0
not
significant
0 .9 7 0 .0 01 accepted
2-3 W e  have licence 0 .45 0 .3 5 8 not 0 .93 0 .0 01 accepted
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C u rren t S ituation Future  Im p ortan ce
No. Category/Statement
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt*
significant
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt* *
agreem ents  w ith  in n o v a to r  
com panies.
2-4
W e  have tech no log y  
tra n s fe r ag reem en ts  w ith  
techno logy o w n ers .
0.51 0.001
not
significant
0.96 0.001 accepted
2-5
Licensed o r tech no log y  
trans fe rre d  products  
co n s titu te  an im p o rta n t  
p art o f our to ta l sales.
0.35 0.006 re jected 0.87 0.001 accepted
3. Sales & Marketing
3-1
O ur m arke tin g  e x p e n d itu re  
is co m p arab le  w ith  th a t  o f  
our in te rn a tio n a l rivals.
0.09 0.001 re jected 0.85 0.001 accepted
3-2
O ur com pany  regularly  
increases th e  p ercen tag e  o f 
m arke tin g  e x p e n d itu re  to  
to ta l sales.
0.23 0.001 re jec ted 0.93 0.001 accepted
3-3
W e  m easure  th e  
effectiveness o f our 
m ark e tin g  e x p e n d itu re .
0.32 0.001 re jected 0.94 0.001 accepted
3-4
O ur m ark e tin g  activ ities  
have c o n trib u te d  to  
cap tu ring  th e  m a rk e t 
share.
0.4 0.067
not
significant
0.96 0.001 accepted
3-5
O ur m arke tin g  activ ities  
have increased o ur 
custom er loyalty .
0.4 0.052
not
significant
0.94 0.001 accepted
4. GMP & QA
4-1
O ur com pany a llocates  
suffic ien t funds to  im p ro v e  
th e  G M P  level.
0.54 0.543
not
significant
0.97 0.001 accepted
4-2 W e  have th e  G M P  app ro va l 0.24 0.001 re jec ted 0.97 0.001 accepted
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No. Category/Statement
o f in te rn a tio n a l inspectors.
O bserved
p ro b a b ility *
P
va lue§
Hypothesis
re s u lt*
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt* *
4 -3
W e  have a va lid a tio n  
m aste r p lan  fo r  G M P .
0 .4 4 0 .3 0 1
n o t
significant
0 .9 7 0 .0 0 1 accepted
4 -4
W e  have an a p p ro p r ia te  
d o c u m e n ta tio n  system  fo r  
G M P .
0 .6 6 0 .0 0 2 accep ted 0 .9 8 0 .0 0 1 accep ted
4 -5
W e  have a change con tro l 
system  fo r all re la te d  
d ep a rtm e n ts .
0 .4 0 .0 7 9
n o t
significant
0 .9 7 0 .0 0 1 accep ted
4 -6
The m an u fa c tu rin g  areas o f 
o u r com pan y  a re  reg u larly  
u p d ated  and ren o v a te d .
0 .4 7 0 .6 1 4
not
significant
0 .9 6 0 .0 0 1 accep ted
4 -7
G M P  im p ro v e m e n t is a 
stra teg ic  goal fo r o ur 
com pany.
0 .7 4 0 .0 0 1 accep ted 1 0 .0 0 1 accep ted
4 -8
The effec tiveness  o f G M P  
expen d itu res  is e v a lu a te d  
in o u r com pan y.
0 .3 6 0 .0 0 7 re jec ted 1 0 .0 0 1 accepted
5. Research & 
Development
5-1
O ur com pan y  a llocates  
su ffic ien t fun ds  fo r  th e  
R&D d e p a rtm e n t.
0 .4 1 0 .1 0 4
not
significant
0 .9 8 0 .0 0 1 accepted
5-2
T he  e ffec tiven ess  o f R & D  
expen d itu res  is m easu red  
in o u r com pan y .
0 .1 6 0 .0 0 1 re jec ted 0 .9 2 0 .0 0 1 accepted
5-3
R&D in v e s tm e n t plays a 
m a jo r ro le  in increasing  o u r  
co m p etitiven ess .
0 .4 5 0 .3 6 3
not
significant
0 .9 6 0 .0 0 1 accep ted
5-4
A m a jo r p art o f  o u r  
com pany's  re v e n u e  com es  
fro m  exclusive p roducts .
0 .5 1 0 .9 2 0
not
significant
0 .93 0 .0 01 accep ted
5-5 W e  have jo in t R&D pro jec ts 0 .3 3 0 .0 0 1 re jec ted 0 .8 7 0 .0 01 accepted
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No. Category/Statement
O bserved
p ro b a b ility *
P
v a lu e §
H ypothesis
re s u lt*
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt* *
w ith  ins titu tio ns  o u ts ide  
o u r com pany.
5-6
W e  have in n o va tive  n ew  
fo rm u la tio n s .
0.27 0.001 re je c ted 0.89 0.001 accepted
6. Product Packaging
6-1
T he  attrac tiveness  o f th e  
packaging is a strong  p o in t  
o f o ur products.
0.39 0.035 re jec ted 0.93 0.001 accepted
6-2
W e  invest in im p ro v in g  o u r 
p ro du ct packaging.
0.49 0.920
n ot
s ign ificant
0.92 0.001 accepted
6-3
O u r packaging lines are  
c om parab le  w ith  th o s e  o f  
o u r in te rn a tio n a l rivals.
0.34 0.002 re jec ted 0.92 0.001 accepted
6-4
T he  ro le  o f packaging in 
creating  cus tom er 
satis faction  is m e a s u re d  in 
o u r com pany .
0.25 0.001 re jec ted 0.9 0.001 accepted
6-5
T h e  q u a lity  o f th e  
packaging is c o m p a ra b le  
w ith  th a t  o f o u r  
in te rn a tio n a l c o m p e tito rs .
0.24 0.001 re jec ted 0.92 0.001 accepted
7. Manufacturing 
Technology
7-1
O ur com pan y  reg u larly  
im proves th e  p ro d u ctio n  
lines.
0.46 0.480
n ot
s ignificant
0.97 0.001 accepted
7-2
T he  a u to m a tio n  level in 
this p lan t is c o m p a ra b le  
w ith  th a t  o f o u r  
in te rn a tio n a l rivals.
0.28 0.001 re jec ted 0.9 0.001 accepted
7-3
T h e  m a n u fac tu rin g  
tech no log y  in o u r co m p a n y  
is in com plian ce  w ith
0.56 0.305
not
s ignificant
0.94 0.001 accepted
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No. Category/Statement
O bserved
p ro b a b ility *
P
va lue§
H ypothesis
re s u lt!
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt ! !
en v iro n m e n ta l s tandards.
7-4
The  m an u fac tu rin g  
procedures in th is  com pan y  
are  w e ll d o cu m en ted  and  
w ell execu ted .
0 .6 5 0 .0 0 6 accep ted 1 0 .0 0 1 accepted
7-5
W e  regularly  u p d a te  th e  
m an ufactu rin g  p rocedures  
fo r  our products.
0 .5 8 0 .1 2 9
not
significant
0 .9 6 0 .0 0 1 accepted
8. Mergers & Strategic 
Alliances
8 -1
O ur com pan y  has stra teg ic  
alliances w ith  som e o f o ur  
partners .
0 .3 8 0 .0 2 6 re jec ted 0 .9 1 0 .0 0 1 accepted
8 -2
O ur com pan y  is e v a lu a tin g  
possible m ergers  and  
acquisitions.
0 .3 8 0 .0 2 9 re jec ted 0 .8 3 0 .0 0 1 accepted
8 -3
Being a subsidiary o f a 
hold ing  com pan y  fac ilita tes  
stra teg ic  alliances.
0 .4 4 0 .2 8 9
not
significant
0 .8 2 0 .0 0 1 accepted
9. Pricing Policy
9-1
O ur com pan y has 
c o m p e titiv e  pricing in 
com parison  w ith  o ur 
in te rn a tio n a l rivals.
0 .5 1 0 .9 1 7
not
significant
0 .8 9 0 .0 01 accepted
9-2
O u r com pany  has price  
flex ib ility  in com parison  
w ith  our rivals.
0 .4 5 0 .4 0 7
not
significant
0 .8 9 0 .0 01 accepted
1 0 . Training for Employees
10-1
Q ualifications are  
considered very  im p o rta n t  
w h ile  recru iting  p eo p le  in 
o u r com pany.
0 .5 8 0 .1 3 7
not
significant
0 .9 6 0 .0 01 accepted
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No.
10-2
Category/Statement
O bserved
p ro b a b ility *
0 .5 1
P
value§
0 .8 4 2
H ypothesis
re s u lt*
n ot
significant
O bserved
p ro b ab ility *
0 .9 4
P
value§
0 .0 01
Hypothesis
re s u lt* *
accepted
W e  have tra in in g  
pro gram m es fo r every  jo b .
10 -3
W e  are  increasing our 
tra in in g  hours p er capita .
0 .5 6 0 .2 71
not
significant
0 .9 1 0 .0 01 accepted
10-4
O ur com pan y  m easures th e  
effectiveness o f o ur 
tra in in g  p rogram m es.
0 .4 3 0 .2 28
not
significant
0 .9 4 0 .0 01 accepted
10-5
T he  capab ilities  o f our 
em p loyees  are  co m p a ra b le  
w ith  those o f o ur 
in te rn a tio n a l rivals.
0 .4 9 0 .9 2 0
not
significant
0 .9 3 0 .0 01 accepted
11. Skills of R&D Staff
11-1
O ur com pan y  regularly  
im proves th e  skills o f th e  
R &D staff.
0 .4 1 0 .0 82
not
significant
0 .9 2 0 .0 0 1 accepted
1 1-2
O u r R&D te a m  develops  
in n o va tive  products. 0 .3 1 0 .0 01 re jec ted 0 .9 2 0 .0 01 accepted
11-3
A con s iderab le  p art o f our 
com pan y reven u e  is th e  
resu lt o f in n o va tio n  in R&D.
0 .2 4 0 .0 01 re jec ted 0 .8 9 0 .0 01 accepted
11-4
The skills o f th e  R&D s ta ff 
have c re a te d  advantages  
fo r o u r com pany.
0 .3 1 0 .0 01 re jec ted 0 .9 3 0 .0 01 accepted
12. Management 
Knowledge
12-1
W e  have q ua lified  persons  
in all m an ageria l positions.
0 .5 2 0 .8 3 9
not
significant
0 .9 9 0 .0 0 1 accepted
12-2
O ur com pan y m easures th e  
effic iency o f th e  decisions  
taken  by th e  m anagers.
0 .3 3 0 .0 0 1 re jec ted 0 .9 6 0 .0 01 accepted
12-3 T h ere  a re  a d e q u a te 0 .3 6 0 .0 1 0 re jec ted 0 .9 4 0 .0 0 1 accepted
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No. Category/Statement
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt*
O bserved
p ro b a b ility *
P
value§
Hypothesis
re s u lt* *
n um bers  o f m a n a g e m en t  
graduates  in o u r  
m anageria l te a m .
13. Customer Satisfaction
13 .1
W e  have in tern a l 
p rogram m es to  m e e t th e  
custom ers' req u ire m e n ts .
0 .4 0 .0 54
not
significant
0 .9 8 0 .0 0 1 accepted
13.2
W e  have categorised  o ur 
custom ers in to  d iffe re n t  
groups and have  
com m u nication  
program m es fo r  each  
group .
0 .4 3 0 .1 89
not
significant
0 .93 0 .0 0 1 accepted
13 .3
O ur com pan y  know s th e  
needs o f its ta rg e t  
custom ers.
0 .4 2 0 .1 55
not
significant
not
significant
0 .9 6 0 .0 0 1 accepted
13 .4
W e  regularly  m easure  th e  
satisfaction  levels o f o u r  
custom ers.
0 .4 7 0 .6 1 4 0 .9 8 0 .0 0 1 accepted
14. Creativity of the 
Employees
14.1
O ur organ isation  
encourages innovation .
0 .3 6 0 .0 07 re jected 0 .98 0 .0 0 1 accepted
14.2
O ur co m pan y utilises th e  
innovativeness o f its 
em p loyees  to  c re a te  va lue .
0 .3 6 0 .0 07 re jected 0 .9 8 0 .0 01 accepted
14.3
In n ovation  plays an 
im p o rta n t ro le  in 
m ain ta in ing  o ur  
com petitiveness.
0 .4 0 .0 7 0
not
significant
0 .9 6 0 .0 0 1 accepted
15. Qualifications for Jobs
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No.
15.1
Category/Statement
O b served
p ro b a b ility *
0.66
P
value§
0.002
H ypothesis
re s u lt*
accep ted
O bserved
p ro b a b ility *
0.97
P
va lue§
0.001
Hypothesis
re s u lt* *
accepted
T he  m in im u m  
qualifica tio ns  have been  
increased  in o u r  
o rgan isation  in recen t  
years.
15.2
O ur com pan y  has access to  
p eo p le  w ith  th e  necessary  
q ualifications.
0.59 0.0851
n o t
s ign ificant
0.97 0.001 accep ted
15.3
O ur c o m p an y  can a ffo rd  to  
e m p lo y  highly q ua lifie d  
p eo p le .
0.41 0.104
n o t
sign ificant
0.95 0.001 accepted
15.4
O u r c o m p an y  has o ffe re d  
scholarships to  o b ta in  
em p loyees  w ith  th e  
req u ired  q ua lifica tio ns .
0.3 0.001 re je c ted 0.85 0.001 accepted
‘ O bserved  probability: rep resen ts  th e  p erc e n ta g e  of respondents w ho g a v e  a rating h igher than 5  to the respective  
statem ent.
§ P  value: is the  observed  error.
*T h e  hypothesis testing m ay g e n e ra te  o n e  o f th e  follow ing results: Accepted (satisfactory): observed  probability >  
0 .5  (= 5 0 % ), P va lue  <  0 .0 5 , Rejected (unsatisfactory): observed  probability < 0 .5  (= 5 0 % ), P  va lue  < 0 .0 5 , Not 
significant: P  va lue  > 0 .0 5 .
*  tT h e  hypothesis testing m ay  g en e ra te  o n e  of th e  follow ing results: A ccepted  (im portant): observed  probability > 0 .5  
(= 5 0 % ), P va lue  < 0 .0 5 , R e jec ted  (not im portant): observed  probability < 0 .5  (= 5 0 % ), P va lue  < 0 .0 5 , Not significant:
P value > 0 .0 5 .
Table 6.3 reveals that the test results for the current situation are ‘not significant’ for 34 
statements, representing 52% of the total statements. The research hypothesis is 
accepted for only 4 statements namely: 4.4 (GMP documentation), 4.7 (GMP 
improvement), 7.4 (compliance with environmental standards) and 15.1 (increase in the 
required level of qualification). This suggests that the current situation for only a limited 
number of the statements is recognised as satisfactory, and rejected for 28 statements, 
which constitute 6% and 42% of the total statements, respectively.
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1. Patent Review
With regard to the Patent Review category, respondents from different companies 
admitted that they did not review patents when selecting or exporting products, either 
because they did not have the personnel to do so or because they were unaware of the 
financial implications of enforcing patent protection laws. The observed probabilities for 
the statements are merely 15%, 33%, 26% and 11%, respectively.
2. Licence and Technology Transfer
In the case of Licence & Technology Transfer Agreements, there was a consensus for 
rejecting the importance of licensed and technology transferred products in the 
companies’ total sales. With respect to the results of the former category, it is not 
surprising because of the dependence of licence agreements on their patents protection 
in the host country. As regards the other statements, including the importance of a 
strategic approach to this parameter, creating better infrastructure and forging new 
agreements, the respondents’ opinions are very varied, which may be due to the 
existence of different situations in different companies.
3. Marketing Expenditure
The respondents concurred to say that their company’s marketing expenditure was not 
comparable with that of the company’s rivals. Also, it did not increase as a part of the 
company’s total sales and the company did not measure its effectiveness (the study 
hypotheses were rejected, with the observed probability of 9%, 23% and 32%, 
respectively). The role of the marketing activities in capturing the market share and 
increasing customer loyalty show considerable variations, which means that some 
companies may have captured the market share and increased customer loyalty 
through their marketing expenditures, while others have not.
4. GMP & QA
The respondents expectedly regarded a strategic approach to GMP improvement and 
having appropriate GMP documentation, with the observed probability of 74% and 66%, 
respectively, as satisfactory in the current situation, while they looked upon obtaining 
international GMP certificates and increasing the effectiveness of GMP expenditures as 
unsatisfactory (the study hypotheses were rejected, with the observed probability of 
24% and 36%, respectively). The lack of international GMP certificates is the most
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important finding and this is not surprising because they do not have required funds and 
resources. In addition, there are considerable variations in the responses pertaining to 
the adequacy of GMP budgeting, having validation master plans, change control 
systems, and plant renovation (the results are not significant). This means that the 
importance of dedicating enough research in this area is not realised or there is not 
enough resources to dedicate to this vital issue.
5. R&D Expenditure
The respondents labelled the effectiveness of R&D expenditure, joint R&D projects and 
innovative formulations as ‘unsatisfactory’ in the current situation (with the observed 
probability of 16%, 33% and 27%, respectively), while they had varied views on the 
adequacy of R&D expenditure, R&D-induced competitiveness and the accrual of 
revenue from exclusive products (the results are not significant).
6. Product Packaging
The binomial test results reveal that according to the study participants, the 
attractiveness of packaging, use of world-class packaging lines, measuring the role of 
packaging in customer satisfaction and world-class product packaging are 
unsatisfactory in the current situation,. The results for the statement ‘We invest in 
improving our product packaging’ are not significant, implying that the companies have 
different policies when it comes to investing in upgrading the quality of their packaging.
7. Manufacturing Technology
Documentation of the production procedures is the only parameter labelled as 
‘satisfactory’ in the Manufacturing Technology category, with the observed probability of 
65%, while automation level has been categorised as ‘unsatisfactory’, with the observed 
probability of 28%. The results for the regular improvement of the production line, 
compliance with environmental standards and regular updating of the manufacturing 
procedures indicate high variations between the responses and are categorised as ‘not 
significant’.
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8. Mergers and Strategic Alliances
Having strategic alliances and considering mergers and acquisitions are regarded as 
unsatisfactory, with both statements showing an equal observed probability of 38%, 
while the role played by holding companies in facilitating strategic alliances remains 
somewhat controversial probability because a majority of the companies are state 
owned.
9. Pricing policy
Pricing policy however plays a great role in the survival of the pharmaceutical industry in 
the post-WTO situation. The fact that competitive pricing has been labelled as ‘not 
significant’, indicates that while some of the companies are revising their pricing 
policies, others are not maybe because they are comfortable with the current situation. 
Maybe after WTO/TRIPS, these companies will be out of their comfort zone. Price 
flexibility has also received scores with high variations.
10. Training for Employees
The results for all statements in the Training for Employees category have emerged as 
‘not significant’, which indicates that companies are following different policies in this 
regard. This high variation is surprising because it was expected that at least the basic 
elements of employees training such as having training programmes would be similar 
within the companies.
11. Skills of R&D Staff
The development of innovative products by R&D staff, role of R&D innovations in 
company revenue and creating competitive advantages through R&D skills have been 
classified as ‘unsatisfactory’ in the current situation, therefore the study hypothesis was 
rejected (with the observed probability of 31%, 24% and 31%, respectively). However, 
‘improving the skills of the R&D staff was classed as not significant.
12. Marketing Knowledge
While the experts agreed on the importance of employing qualified persons in 
managerial positions, they also admitted that ‘the efficiency of the managers’ decisions 
are not measured’ and that ‘the company does not employ sufficient numbers of
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management graduates’ (the study hypotheses were rejected, with an observed 
probability of 33% and 36%, respectively).
13. Customer Satisfaction
The divergence of opinions pertaining to customer satisfaction resulted in ‘not 
significant’ labels for all the statements in this category, including ‘having programmes 
to meet customer requirement’, ‘customers categorisation’, ‘knowing the needs of the 
target customers’ and ‘regular measurement of customer satisfaction levels’. That 
means some of the companies still have not realised the important role of the customer 
related issues.
14. Creativity of the Employees
The respondents rejected the importance of encouraging innovation and utilising 
employees’ innovativeness for value creation in the current situation, both statements 
having observed probability of 36%; however, the scores for the role of innovation in 
maintaining the competitiveness of the company show considerable variations. This 
means that some companies have not recognised the importance of innovation but they 
will have to place it as a high priority in the future if the industry wants to be sustainable.
15. Qualifications for Jobs
The respondents agreed on classifying the need to increase minimum qualifications in 
recent years as ‘satisfactory’, revealing the fact that companies are now more conscious 
about the importance of their employees’ capabilities. Access to people with the 
necessary qualifications and being able to compensate the services of highly qualified 
persons show some variations in the results, but at the same time, the companies do 
not appear to support scholarship programmes for obtaining employees with the 
necessary qualifications. This may be due to the fact that the current managers do not 
welcome the challenges that could result from working with qualified persons.
The test results indicate that the study hypotheses accepted for all statements in terms 
of their future importance. This means that the respondents categorised all the 
parameters covered by the statements as ‘important’ in the future. The observed
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probability was higher than 90% for 52 statements and 80-90% for 14 statements. This 
is clearly higher than 50%—the cut-off point for the binomial test. This relatively high 
observed probability, (p value <0.001), not only makes the study hypothesis perfectly 
acceptable but also clarifies the fact that there was strong agreement among the 
participants regarding the future importance of the study parameters. The overall results 
of the binomial tests for the statements are presented in Figure 6.4.
Figure 6.4 Results of the binomial tests for the study parameters 
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Performance of the Industry in Terms of the PITI Categories
In order to determine the industry performance in terms of the categories, it is 
necessary to evaluate the following hypothesis for each category of parameters (15 
hypotheses):
■ Study Hypothesis: The current situation of this category is ‘satisfactory’ 
(mean > 5).
In order to confirm these hypotheses, a binomial test was carried out for each of the 
categories. A binomial test is used when each item in the sample is classified in one of 
two groups; the test reveals whether the distribution of the items in each group has 
been produced by chance or is the result of some pre-specified probabilities (Brenson M 
L, 2009). In this study, since there are two groups of classification, ‘satisfactory’ (mean > 
5) and ‘unsatisfactory’ (mean < 5), on a rating scale ranging from zero to ten, binomial 
tests were conducted to determine the statistical significance of labelling these groups
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as ‘satisfactory’ and ‘unsatisfactory’. The data analysis results are presented in Table 
6.4. A P value that is greater than the standard error of 0.05 indicates a large variation 
between the means, which makes the conclusion statistically impossible and this 
condition is represented as ‘not significant’. Observed probability is the percent of the 
respondents that rated the category with a score more than 5. Therefore, if the P value 
is less than 0.05, an observed probability of more than 0.5 (50%) will group the category 
as ‘satisfactory’ and less than 0.5 indicates that the category is unsatisfactory.
Table 6.4 Comparison between the current situation and future importance of the PITI
categories
Category/Statement
Current Situation Future Importance
O bserved
p ro bab ility *
P§
value
H ypothesis
tes t
result:}
O bserved
p ro b ab ility
P§
value
Hypothesis  
test 
Result}: }
1. Patent Review 0 .2 0 0.001 re jec ted 0 .8 7 0.001 accepted
2. Licence & Technology Transfer 
Agreements 0 .5 6
0 .2 7
not
significant
0 .9 6 0.001 accepted
3. Sales & Marketing 0 .3 4 0.001 re jec ted 0 .9 2 0.001 accepted
4. GMP & QA 0 .5 6 0 .3 2
not
significant
0 .9 5 0.001 accepted
5. Research & Development 0 .4 4 0 .2 7
not
significant
0 .9 3 0.001 accepted
6. Product Packaging 0 .4 4 0 .2 7
not
significant
0 .9 2 0.001 accepted
7. Manufacturing Technology 0 .5 7 0 .1 9
not
significant
0 .9 5 0.001 accepted
8. Mergers & Strategic Alliances 0 .4 1 0 .1 2
n ot
significant
0 .8 9 0.001 accepted
9. Pricing Policy 0 .5 1 0 .9 2
not
significant
0 .9 0 0.001 accepted
10. Training for Employees 0 .6 2 0 .0 2
not
significant
0 .9 1 0.001 accepted
11. Skills of R&D Staff 0 .3 5 0 .001 re jec ted 0 .8 9 0.001 accepted
12. Management Knowledge 0 .4 7 0 .6 8
not
significant
0 .9 3 0.001 accepted
13. Customer Satisfaction 0 .4 6 0 .5 5
not
significant
0 .9 3 0.001 accepted
14. Creativity of the Employees 0 .4 2 0 .1 3
not
significant
0 .9 4 0.001 accepted
15. Qualifications for Jobs 0 .5 2 0 .7 6
not
significant
0 .95 0.001 accepted
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‘ O bserved  probability: rep resents  the  p ercentage of respondents w ho g av e  a rating higher than 5 to the respective  
statem ent.
§ P  value: is the  observed  error.
$ T h e  hypothesis testing m ay g en e ra te  o ne  of the following results: Accepted (satisfactory): observed probability > 
0 .5  (= 5 0 % ), P va lue  < 0 .0 5 , Rejected (unsatisfactory): observed  probability < 0 .5  (= 5 0 % ), P va lue  < 0 .0 5 , Not 
significant: P value > 0 .0 5 .
t  £ T h e  hypothesis testing m ay g en e ra te  one of the  follow ing results: A ccepted  (im portant): observed  probability > 0 .5  
(= 5 0 % ), P  va lue  < 0 .0 5 , R ejected  (not im portant): observed  probability < 0 .5  (= 5 0 % ), P  va lue  < 0 .0 5 , Not significant: 
P va lue  > 0 .0 5 .
Developing 15 categories allowed the calculation of summarised scores which 
established better communication with senior executives in comparison with discussing 
66 statements. Out of the15 categories, three were rejected namely patent review, sales 
and marketing and research and development. This means that for these categories, 
the current situation is definitely unsatisfactory. The above results are statistically 
significant and would need to be addressed as a priority in developing strategies and 
action plans. Only one hypothesis was accepted namely the training for the employees 
and this is also statistically significant (P<0.05) indicating that the training for the Iranian 
pharmaceutical industry is satisfactory. The outcome for 11 categories of “not 
significant” means they are neither satisfactory nor unsatisfactory and this can result 
from intercompany variation or is related to the way in which the individuals evaluate the 
parameters. In order to have a better understanding, it is necessary to look at the 
results of single companies.
DISCUSSION
This chapter focused on evaluating the post-WTO sustainability of the pharmaceutical 
industry in Iran by assessing the performance of the industry with regard to the selected 
parameters. Simultaneously, the future importance of the parameters was determined 
using the PITI as the data collection instrument. The study was unique from the view of 
the conceptualisation and the empirical data collection with a systematic approach to 
identify the study parameters. Experts from different fields of activities in the 
pharmaceutical environment, which would be potentially affected by the outcomes of 
joining WTO, were involved in the study. This process made the results relevant and
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understandable for many participants. The instrument was formulated by developing 
several statements for each topic to cover the whole area. For example the picture that 
is now available for the situation of GMP & QA from the view of the funds, international 
approvals, validation master plans, documentation, change control system, renovation 
of the plants, GMP strategic importance and effectiveness of the GMP expenditure 
could not be obtained without incorporating a sufficient number of statements under this 
heading. In general, there were 3 - 4  statements in each category; however in some 
areas more statements were required to effectively cover all aspects. It should be also 
noted that having an electronic version of the instrument helped to collect this 
information as the study was successful in considering the ideas and evaluations of 109 
managers in 25 companies. The performance of the industry can be presented as 
follows:
The PITI was formulated (chapter 5) on the basis of parameters identified as likely to 
have a considerable impact on the sustainability of the industry in the post-WTO/TRIPS 
situation; these parameters were selected based on the following characteristics:
■ The parameters were expected to reflect the priorities and concerns of the 
regulatory officials, academics and industry experts who participated in the 
Delphi panel as well as the industry managers who responded to the PITI.
■ It was hypothetically accepted that the study’s objective is to identify the unmet 
requirements of the industry for post-WTO/TRIPS sustainability.
■ It was also expected that the parameters would be of significant value in the 
post-WTO/TRIPS scenario. This characteristic was expressed in this study in 
terms of the future importance of the parameters.
The results in this chapter confirm the first and second points based on the low scores
given by the respondents to the current situation of the parameters (Figure 6.3). The
figure also displays the high scores given to the future importance of the parameters. In
fact, the research team had not expected such a substantial difference in the ratings
given to the current situation (satisfactory performance of the industry) and future
importance (significance in the post-WTO/TRIPS situation) of the same parameters.
This occurrence underlines the suitability of the research methodology and the
sensitivity of the PITI as the study instrument. The binomial tests conducted confirmed
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the above scoring pattern, as shown by the observed probability results presented in 
Table 6.3 for all the PITI statements and Table 6.4 for parameter categories.
In order to fully understand the industry situation, it is also important to categorise the 
parameters as ‘satisfactory’ or ‘unsatisfactory’ in terms of the current situation and 
‘important’ or ‘not important’ in terms of the future. Such a classification was carried out 
on the basis of the binomial test results, which indicated that the current performance of 
the industry in only 6% of the parameters are satisfactory, while all of them are 
considered to be important in the post-WTO/TRIPS situation (Figure 6.3). From among 
the 66 PITI statements, the current situation for only 4 statements was classified as 
satisfactory:
■ We have an appropriate documentation system for GMP.
■ GMP improvement is a strategic goal for this company.
■ The manufacturing procedures in this company are well documented and well 
executed.
■ The minimum qualifications have been increased in our organisation in recent 
years.
The fact that the industry managers classified only these four statements as satisfactory 
indicates that the industry needs significant preparation before it can handle the 
challenges of joining the WTO and implementing the TRIPS regulations.
It was also interesting to note the substantial levels of agreement among the industry 
managers participating in the study in terms of classifying some of the statements as 
‘important’ in the post-WTO situation, based on the binomial test which was used to 
confirm the study hypotheses (Table 6.3). However, the study hypotheses for the 
current situation of parameters was rejected for the Patent Review, Marketing 
Expenditure and Skills of R&D Staff categories, which supports the low Friedman 
ranking of these items with regard to the current situation. The table also indicates that 
the study hypotheses were accepted only for statements pertaining to the Training for 
Employees category, which implies that the current situation of this category is 
satisfactory and thus explains the position of these items in the Friedman ranking table. 
The conclusion that 11 categories are ‘not significant’ indicates that the current situation
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needs to be separately evaluated in each company. Nevertheless, this study 
successfully used binomial tests to confirm the statistical significance regarding all the 
PITI categories as ‘important’ with regard to the future.
The statistical confirmation of the unsatisfactory performance of the present situation 
and the importance of future challenges make it necessary to prioritise parameters in 
order to develop improvement strategies for the industry. The Friedman ranking of the 
parameter categories, as presented in Table 6.2, shows that the order of categories in 
the current situation represents the industry’s current degree of compliance with the 
requirements of each category, which in turn indicates that the industry is in a stronger 
position with regard to the higher-ranking categories in the table. As the rank decreases, 
however, the level of compliance decreases accordingly, and the weaknesses of the 
industry are exposed. For instance, the category of Manufacturing Technology received 
the mean score of 5.6 with regard to the current situation, which is the highest score 
among all 15 categories (Table 6.1); this category is therefore located at the top of the 
Friedman ranking list (Table 6.2). These results indicate that the industry is well 
prepared in this regard, and manufacturing technology can be regarded as a strong 
point of the industry. Conversely, Patent Review received the lowest mean score of 2.93 
and was consequently placed at the bottom of the Friedman ranking table. Therefore, 
this category can be regarded as a weakness of the industry as it attempts to tackle the 
post-WTO challenges.
Based on this argument, the industry can define different scenarios for improvement, 
while focusing on its strengths and weaknesses. Another approach would involve 
adopting development strategies on the basis of the importance of the categories 
presented in Table 6.2. These three different proposed scenarios are illustrated in 
Figure 6.5.
The first proposed scenario involves focusing on the current weaknesses of the 
industry; this implies giving a higher priority to the least developed aspects of the 
industry by allocating the necessary funds and defining improvement plans for the 
industry. This strategy would result in an inverted approach to the ranking of the 
categories in Table 6.2 in terms of the current situation, because it would involve 
addressing the least developed item first, which is Patent Review. This would be
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followed by improving marketing expenditure, with skills of the R&D staff taking third 
place.
The second proposed scenario suggests starting from the strengths of the industry, 
which is manufacturing technology. The logic behind this scenario is that the industry is 
already in a better situation in terms of higher expertise in and familiarity with the 
parameters that are its strong points. One of the pitfalls of this scenario, however, is the 
relatively low priority given to customer satisfaction. Despite a low degree of expertise in 
and familiarity with this aspect, the industry should pay greater attention to this category 
as a major future challenge.
The third proposed scenario suggests attributing a higher priority to the most 
important item for the future. This approach underlines the fact that the main impetus for 
investing in the improvement of items is their importance in the post-WTO situation, not 
their present condition. Accordingly, the first item that needs to be addressed is that 
which is likely to be the most important one in the future, which is GMP and QA, 
according to Table 6.2. Following this, the industry should focus on improving 
manufacturing technology and customer satisfaction.
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Figure 6.5 Three proposed scenarios for the improvement of the pharmaceutical industry
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There are three ways in which action plans can be prepared and critically evaluated:
■ On the basis of the most improved areas: The category that is ranked highest 
in Table 6.2, has the highest average scores for its statements and indicates the 
most improved areas. In this approach, improvement plans can be prioritised by 
starting from these most developed areas, which can be turned into competitive 
advantages in the future. One drawback of this method is that the industry may 
end up investing in certain areas which will not be of most importance in the 
future, while it may correspondingly fail to develop alternative areas of greater 
importance in the future.
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■ With regard to the current weaknesses: The lowest-ranking category in Table
6.2 also has the least score and consequently can be regarded as the weakest 
areas. This approach seeks to identify under-developed areas and improve them 
so as to bring them up to the level of other areas. One drawback of this method 
is the possibility of investing in weaknesses which will be unimportant in the 
future situation and may involve expenditure on improvement plans in these 
areas even though they may not create any strategic advantage for the 
companies in the post-WTO situation.
■ By focusing on the future importance of the parameters: In this approach, 
improvement plans will give higher priority to items of future importance, 
regardless of the present condition of those items. However, overlooking the 
present situation may result in investing on important items even when 
companies lack the basic requirements for those items, for example, R&D and 
GMP are both important items in the post-WTO situation, but a company may 
need to first improve its GMP levels to obtain official approval even if this item is 
ranked lower than R&D.
This study will suggest appropriate solutions in the next chapters to overcome the 
above pitfall in developing action plans.
SUMMARY
• This chapter described the deployment of the PITI for studying the situation of 
the pharmaceutical industry in Iran. This, study collected and analysed the 
responses of 118 individuals working at managerial levels in 25 pharmaceutical 
companies; the overall response rate was 65.6%. The main results presented in 
this chapter can be summarised as follows:
• The mean of the scores for all statements and categories were calculated and 
presented in diagrams and tables. The scores for the current situation were less 
than or close to 5, which on an 11-point scale can be interpreted as a low 
industry compliance with the requirements of the post-WTO situation except for 
four areas namely GMP documentation, GMP improvement, compliance with 
environmental standards and increase in the required level of qualification.
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• The future importance of the statements received substantially higher scores, 
revealing the fact that the instrument does, in fact, measure relevant items.
• Binomial tests were used to analyse the respective scores at two levels; 
categories and statements. These tests indicated that the responses for the 
current situation had substantial variations with 52% of the statements classified 
as ‘not significant’. This finding emphasises the need for studying the situation of 
single companies separately. The Friedman test was also carried out to rank the 
parameter categories.
• The rankings of the categories were thereafter used to define three different 
improvement scenarios based on the weaknesses and strengths of the industry 
and future importance of the parameter categories.
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Chapter 7
Gap Analysis and Assessment of Improvement Opportunities 
for the Current and Future Situations
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INTRODUCTION
The previous chapters have elucidated the development and application of the 
pharmaceutical industry transition instrument (PITI), which was used in this study to 
collect data from the industry regarding the current situation and future importance of 
certain industry-related parameters. The Friedman test was used to rank the categories 
and statements of the instrument, while the binomial test was carried out to identify the 
areas that can be labelled as ‘satisfactory’ for the performance of the industry or 
‘important’ in the post-WTO situation. As expected, these findings confirmed the 
substantial importance of the identified parameters in the post-WTO situation by 
relatively high scores given by the participating industry managers. However, the 
considerably low scores given to the performance of the industry to label all of them as 
unsatisfactory and confirming that the industry do not do well was surprising.
The low ranking for the “Patent Review” category in this study was contrary to the 
impression given following discussion with individual participants. This was further 
explained by the results of the pilot study, which measured the gap between the scores 
pertaining to the current situation and future importance of the study parameters. In fact, 
this finding emphasised the crucial importance of studying the gaps between the current 
situation and future importance of the parameters. It is also important to realise the 
extent of the gap between the present and desirable conditions in order to allocate the 
necessary funds and prioritise action plans to close this gap. The concepts of 
measuring the normal gap and opportunity score are used in this study to demonstrate 
the distance between the present and the desirable situation in order to help the 
industry and its decision makers to develop the appropriate improvement plans.
OBJECTIVES
The main objectives of this study were to:
• Measure the gap between the present and future situations and rank the
study categories accordingly
• Explore the improvement opportunities with respect to the future
importance in terms of the ‘opportunity score’
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• Introduce an index for measuring the industry’s readiness for the post- 
WTO situation
• Compare the results of the different models for ranking the study
parameters based on their future importance, gap and opportunity score 
in facing the challenges of the post-WTO situation.
METHODS
This chapter will explain the gap analysis between the current situation and future 
importance of the study parameters, the determination of their opportunity scores and 
the formulation of the PIR index. The methodologies and techniques used in this study 
have been fully described in chapter 2.
The discussion presented in chapter 6 underlines the limitations of ranking the items on 
the basis of their strengths, weaknesses and future importance. Alternatively, 
calculating the gap between current situation and future importance can provide a better 
understanding and logical approach for prioritising the items (see chapter 2). When 
forecasting or developing plans for the future, it is crucial to consider the future condition 
and more desirable to formulate methods which give appropriate weight to aspects that 
will be important in the future. In 2002, Anthony Ulwick introduced such a method, 
called the ‘opportunity algorithm’, which could measure the opportunity score by adding 
the score of the future importance to the gap (Ulwick A. W., 2002). This chapter, 
therefore, will focus on measuring the gap and opportunity scores in order to 
demonstrate the differences in the resultant rankings and discuss the advantages of 
each method. In addition, this chapter will also explain the development of an index for 
measuring the pharmaceutical industry readiness (PIR) index. This index will generate a 
readiness percentage that makes it possible to quantify and compare the companies 
and their trends (see chapter 2).
The gap between the industry’s current situation and future importance, opportunity 
score and the PIR index were measured using standard techniques. The findings 
presented in this chapter will potentially play a crucial role in helping the industry and its 
policy makers to prepare the industry for accession to the WTO and implementation the
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of TRIPS regulations. It should be remembered that these measurements are based on 
the assumption of giving equal weight to all statements and categories (see chapter 2).
Processing and Analysis of the Data
The data were processed using both Microsoft Access and Microsoft Excel to obtain 
descriptive statistics pertaining to the data, while SPSS for Windows was used to carry 
out statistical analyses.
RESULTS
Gap analysis for the parameter categories
As mentioned above, the gap between the current situation and future importance 
scores was measured and the parameter categories were ranked according to the size 
of the gap (Table 7.1 and Figure 7.1).
Table 7.1 Gap analysis and ranking of the PITI categories
Category
Current
Situation
(CS)
Future
Importance
(FI) Gap Ranking
Patent Review 2.93 8.01 5.08 1
Skills of R&D Staff 4.26 8.46 4.20 2
Marketing Expenditure 4.15 8.23 4.08 3
GMP & QA 5.29 9.05 3.76 4
R&D Expenditure 4.68 8.42 3.74 5
Product Packaging 4.58 8.30 3.72 6
Customer Satisfaction 4.99 8.70 3.71 7
Management Knowledge 4.91 8.61 3.70 8
Creativity of the Employees 5.04 8.73 3.68 9
Licence & Technology Transfer 
Agreements
5.15 8.53 3.38 10
Qualifications for Jobs 5.20 8.50 3.31 11
Manufacturing Technology 5.60 8.71 3.11 12
Mergers & Strategic Alliances 4.80 7.82 3.02 13
Training for Employees 5.61 8.61 3.00 14
Pricing Policy 5.38 8.08 2.70 15
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Figure 7.1 The gap between the current situation and future importance for the PITI
categories
In terms of gap, the highest-ranking category is Patent Review, followed by Skills of 
R&D Staff, Marketing Expenditure, GMP & QA and R&D Expenditure. The large gap for 
Patent Review, which is substantially larger than the gaps for the other categories, 
underlines the extent of the effort required to close the gap. In fact, prior to WTO 
accession, it is absolutely necessary to assess the patent situation of currently 
manufactured products as well as those under development. Furthermore, the results 
indicate that the companies should improve the capabilities of their R&D staff in order to 
modify the life cycle of their current products or develop new ones. This should be 
followed by developing a better understanding of the market needs and demands, while 
at the same time adopting the necessary measures for GMP improvement. The quality 
of product packaging is the next category in the ranking of gaps (Table 7.1) and can be 
regarded as a quick-fix—something that would require relatively little resources and 
effort. Following this, the companies should focus on increasing the knowledge of their
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managers in order to foster innovation in their organisations. These findings 
demonstrate that gap analysis can be easily used to plan improvement strategies, while 
the magnitude of the scores indicates the size and complexities of the effort required to 
close the gap between the present and the desired situation of the under-developed 
areas. Furthermore, areas with an enabling influence on the industry have been ranked 
higher than areas which are more results driven. For example, if a company improves 
its GMP, then it will have more possibilities of being involved in licence agreements.
Measures of the opportunity scores for the PITI categories
The opportunity algorithm was used to measure the opportunity score, which adds more 
weight to the future importance in order to identify the improvement opportunities. The 
results for the PITI categories are presented below in Table 7.2.
Table 7.2 The opportunity scores for the PITI categories
Category
Current
Situation
Future
Importance
Opportunity
Score
Opportunity
Rank
Patent Review 2.93 8.01 13.09 1
GMP & QA 5.29 9.05 12.81 2
Skills of R&D Staff 4.26 8.46 12.66 3
Customer Satisfaction 4.99 8.70 12.42 4
Creativity of the Employees 5.04 8.73 12.41 5
Management Knowledge 4.91 8.61 12.31 6
Marketing Expenditure 4.15 8.23 12.30 7
R&D Expenditure 4.68 8.42 12.15 8
Product Packaging 4.58 8.30 12.02 9
Licence & Technology Transfer 
Agreements
5.15 8.53 11.91 10
Manufacturing Technology 5.60 8.71 11.82 11
Qualifications for Jobs 5.20 8.50 11.81 12
Training for Employees 5.61 8.61 11.60 13
Mergers & Strategic Alliances 4.80 7.82 10.84 14
Pricing Policy 5.38 8.08 10.78 15
These results are illustrated in Figure 7.2:
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Figure 7.2 Opportunity scores for the PITI categories
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As shown in the above table and figure, the category with the highest opportunity score 
is Patent Review, followed by GMP & QA, Skills of R&D Staff and Customer 
Satisfaction. The next two important categories are Creativity of the Employees and 
Management Knowledge. An overview of these results indicates that based on the 
existing opportunities, the industry can draft a roadmap for investing in reviewing the 
patent situation of currently manufactured and new products, followed by improving its 
GMP and QA systems and the skills of the R&D staff. This will provide internal 
advantages to the company, enabling it to study the customer requirements. The results 
also reveal that the Creativity of the Employees and Management Knowledge 
categories need attention prior to Marketing and R&D Expenditure. In this way, the 
company can become eligible for participating in licence and technology transfer 
agreements and acquiring modern manufacturing technologies, which necessitate the
presence of higher qualified and better trained employees. Finally, the company will be
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able to participate in possible mergers and can determine its pricing policies for 
optimum revenues.
Comparing the results of the gap analysis and opportunity scores
The differences between the sectional rankings, based on the gap and opportunity 
scores, explain the respondents’ different viewpoint regarding the importance of the 
future opportunities and will be discussed further subsequently in this chapter. Figure
7.3 compares the gap and opportunity score results for each category:
This figure presents the opportunity score in decreasing order and demonstrates that 
the gaps do not follow the same order. For example, the Skills of R&D Staff category 
has a larger gap than GMP & QA, but its opportunity score is lower and this is shown in 
ranking in Table 7.2. This argument is also applicable to the Marketing Expenditure and 
Management Knowledge categories. In contrast, Patent Review occupies the first 
position in both the scenarios.
Figure 7.3 The gap and opportunity score for each PITI categories
12.00 |
io .oo 4
□ Gap
>  c J ' &  0 < " J? .<& < $ V ' < £ \ v o *  J? A
<■? *  ^
□ Opportunity Score
211
The results of measuring the Pharmaceutical Industry Readiness (PIR) index for 
the PITI categories
The PIR index for each category was measured by dividing the average scores for the 
statements in the current situation by the average score of the statements in future 
importance. It was also possible to measure the index for all statements and then 
calculate the average of the resulting indices. Finally, the average of the PIR index for 
all categories was calculated to obtain the total value of the index for the industry. This 
index represents the pharmaceutical industry’s overall readiness to cope with the post- 
WTO situation.
Table 7.3 Pharmaceutical Industry Readiness (PIR) indices for the PITI categories
PITI Categories
Current
Situation
Future
Importance
PIR Index
Patent Review 2.93 8.01 37%
Skills of R&D Staff 4.26 8.46 50%
Marketing Expenditure 4.15 8.23 50%
Product Packaging 4.58 8.30 55%
R&D Expenditure 4.68 8.42 56%
Management Knowledge 4.91 8.61 57%
Customer Satisfaction 4.99 8.70 57%
Creativity of the Employees 5.04 8.73 58%
GMP & QA 5.29 9.05 58%
Licence & Technology Transfer Agreements 5.15 8.53 60%
Qualifications for Jobs 5.20 8.50 61%
Mergers & Strategic Alliances 4.80 7.82 61%
Manufacturing Technology 5.60 8.71 64%
Training for Employees 5.61 8.61 65%
Pricing Policy 5.38 8.08 67%
Overall industry readiness: 57%
The PIR Index results show that if the cut off point of 2/3 is selected as the minimum 
required readiness, there is only one category, pricing policy, where the industry is 
ready for the post-WTO situation. This means the industry is least ready with regard to
the Patent Review category, with a PIR index of 0.37. The Skills of R&D Staff and
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Marketing Expenditure categories both have the same index value of 0.5. The degree of 
readiness gradually increases as one moves from Product Packaging to R&D 
Expenditure, which has the indices of 0.55 and 0.56, respectively. The PIR index for 
both Management Knowledge and Customer Satisfaction is 0.57, while that for 
Creativity of the Employees and GMP & QA is 0.58. The index also progressively 
increases from Licence & Technology Transfer Agreements to Qualifications for Jobs, 
Mergers & Strategic Alliances, Manufacturing Technology and Training for Employees, 
with the index values of 0.60, 0.61, 0.61, 0.64 and 0.65, respectively. The highest index 
is 0.67—for the Pricing Policy category—which indicates that this item will face the least 
problem in terms of industry readiness. It should be mentioned that this pricing policy 
only pertains to the decisions made by the industry itself and does not reflect the 
industry’s current problems with the governmental pricing policies that were mentioned 
by the experts as described in chapters 3 and 4. Nevertheless, this highest index is still 
too far short of the maximum possible value of 1.0 and indicates the intensity of 
challenges that the industry must face to reach an acceptable readiness index. The 
overall industry readiness index is 0.57, which is almost half of the maximum possible 
value of this index and reflects the poor performance of the industry and its low levels of 
readiness to deal with the post-WTO situation.
The gap analysis, opportunity score and Pharmaceutical Industry Readiness
It was explained earlier on in this chapter that the categories would be evaluated using 
the average scores of the results of their statements, based on the assumption that 
each statement would have equal weight. However, for a more precise analysis, and 
especially for identifying future strategy roadmaps and using this methodology at the 
company level, it is necessary to know the results for all the PITI statements. These 
results are presented in Table 7.4.
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Table 7.4 The gap, opportunity scores and PIR Index for the PITI statements
Category/
Statem
ent
PITI Statements
Current Situation
Future 
Im
portance
Cift)■o
Gap 
Rank
Opportunity 
Score
Opportunity 
Rank
Ranking 
Change
PIR 
Index
1. Patent Review
1 - 1
Our company has dedicated 
personnel for reviewing 
intellectual property rights to 
prevent patent 
infringements.
2.16 7.99 5.82 2 13.81 3 - l 27%
1 -2
An intellectual property right 
is a key issue in the 
selection of a new product.
3.95 8.23 4.29 10 12.52 19 -9 48%
1-3
We review intellectual 
property rights when 
exporting products.
3.68 7.90 4.22 15 12.11 38 -23 47%
1-4
The financial impact of 
enforcing patent protection 
on our products has been 
studied.
1.93 7.93 6.00 1 13.92 2 - l 24%
2. Licence & Technology 
Transfer Agreements
2 - 1
Producing under-licence 
products is one of the 
strategic goals of our 
company.
6.23 8.57 2.34 65 10.91 62 3 73%
2 - 2
The infrastructure of our 
company satisfies the 
requirements of reputable 
licensors.
5.42 8.92 3.51 39 12.43 24 15 61%
2-3»
We have licence 
agreements with innovator 
companies.
4.78 8.48 3.70 30 12.19 34 -4 56%
2-4
We have technology transfer 
agreements with technology
4.94 8.75 3.81 23 12.56 17 6 56%
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Category/
Statem
ent
PITI Statements
Current Situation
Future 
Im
portance
6101"O
Gap 
Rank
Opportunity 
Score
Opportunity 
Rank
Ranking 
Change
PIR 
Index
owners.
2-5
Licensed or technology 
transferred products 
constitute an important part 
of our total sales.
4.38 7.91 3.54 38 11.45 54 -16 55%
3 . Sales & Marketing
3-1
Our marketing expenditure 
is comparable to that of our 
international rivals.
2.42 7.84 5.42 4 13.27 6 -2 31%
3-2
We regularly increase the 
percentage of marketing 
expenditure to total sales.
3.74 7.86 4.12 16 11.97 42 -26 48%
3-3
We measure the 
effectiveness of our 
marketing expenditure.
4.03 8.45 4.42 7 12.88 9 -2 48%
3-4
Our marketing activities 
contribute to capturing the 
market share.
5.37 8.67 3.30 45 11.98 41 4 62%
3-5
Our marketing activities 
have increased our 
customer loyalty.
5.19 8.30 3.12 50 11.42 55 -5 62%
4. GMP & QA
4-1
We allocate sufficient funds 
to improve our GMP
5.81 9.13 3.32 43 12.45 22 21 64%
4-2
We have the GMP approval 
of international inspectors.
3.44 8.92 5.48 3 14.40 1 2 39%
4-3
We have a well-planned 
validation master plan for 
GMP.
4.85 9.12 4.27 11 13.40 4 7 53%
4-4 ’
We have an appropriate 
documentation system for 
GMP.
6.08 9.21 3.13 49 12.34 27 22 66%
4-5 We have a change control 4.82 8.88 4.06 21 12.93 8 13 54%
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Category/
Statem
ent
PITI Statements
Current Situation
Future 
Im
portance
a0)■o
Gap 
Rank
Opportunity 
Score
Opportunity 
Rank
Ranking 
Change
PIR 
Index
system for all related 
departments.
4-6
Our manufacturing areas 
are updated regularly.
5.50 8.82 3.32 44 12.13 37 7 62%
4-7
GMP improvement is a 
strategic goal for our 
company.
7.12 9.35 2.23 66 11.57 51 15 76%
4-8
We measure the 
effectiveness of our GMP 
expenditure.
4.65 8.97 4.31 9 13.28 5 4 52%
5. Research & Development
5-1
We allocate sufficient funds 
for our R&D department.
5.26 8.84 3.58 36 12.41 25 11 60%
5-2
We measure the 
effectiveness of our R&D 
expenditure.
3.63 8.37 4.74 5 13.11 7 -2 43%
5-3
R&D investment plays a 
major role in our 
competitiveness.
5.36 8.97 3.61 35 12.58 16 19 60%
5-4
A major part of our revenue 
comes from exclusive 
products.
5.69 8.32 2.63 58 10.95 61 -3 68%
5-5
We have close relations with 
R&D institutions outside our 
company.
4.08 7.82 3.74 28 11.57 52 -24 52%
5-6
We have innovative new 
formulations
4.07 8.19 4.12 17 12.31 29 -12 50%
6. Product Packaging
6-1
The attractiveness of the 
packaging is a strong point 
of our products.
4.95 8.42 3.47 40 11.90 44 -4 59%
6-2
We invest in improving our 
product packaging.
5.33 8.34 3.01 53 11.34 57 -4 64%
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Statem
ent
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6-3
Our packaging lines are 
comparable with those of 
our international rivals.
4.53 8.19 3.66 33 11.85 45 -12 55%
6-4
We measure the role of our 
packaging in creating 
customer satisfaction.
3.80 8.18 4.38 8 12.55 18 -10 46%
6-5
The quality of our packaging 
is comparable with that of 
our international 
competitors.
4.31 8.37 4.06 20 12.43 23 -3 52%
7. Manufacturing Technology
7-1
We regularly improve our 
production lines.
5.40 8.59 3.19 48 11.78 47 l 63%
7-2
The automation level in our 
plant is comparable with that 
of our international rivals.
4.07 8.19 4.12 18 12.30 30 -12 50%
7-3
Our manufacturing 
technology is in compliance 
with environmental 
standards.
5.91 8.65 2.75 56 11.40 56 0 68%
7-4
Our manufacturing 
procedures are well 
documented and well 
executed.
6.52 9.10 2.58 63 11.68 49 14 72%
7-5
We regularly update the 
manufacturing procedures 
for our products.
6.10 9.01 2.91 54 11.92 43 11 68%
8. Mergers 8i Strategic 
Alliances
8-1
We have strategic alliances 
with some of our partners.
4.72 8.15 3.43 42 11.58 50 -8 58%
8-2
We are evaluating possible 
mergers and acquisitions.
4.61 7.63 3.02 52 10.64 65 -13 60%
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8-3
Being a subsidiary of a 
holding company facilitates 
strategic alliances.
5.07 7.67 2.61 61 10.28 66 -5 66%
9. Pricing Policy
9-1
We have competitive pricing 
in comparison with our 
international rivals.
5.52 8.14 2.62 59 10.76 64 -5 68%
9-2
We have price flexibility in 
comparison with our rivals.
5.24 8.01 2.78 55 10.79 63 -8 65%
10. Training for Employees
10-1
Qualifications are 
considered very important 
while recruiting people in our 
company.
6.07 8.76 2.69 57 11.45 53 4 69%
10-2
We have training 
programmes for every job.
5.64 8.68 3.04 51 11.73 48 3 65%
10-3
We are increasing our 
training hours per capita.
5.85 8.43 2.58 64 11.01 60 4 69%
10-4
We measure the 
effectiveness of our training 
programmes.
5.12 8.58 3.46 41 12.03 40 1 60%
10-5
The capabilities of our 
employees are comparable 
with those of our 
international rivals.
5.37 8.58 3.21 47 11.79 46 1 63%
11. Skills of R&D Staff
11-1
We regularly improve the 
skills of our R&D staff.
4.90 8.60 3.70 31 12.30 31 0 57%
11-2
Our R&D team can develop 
innovative products.
4.38 8.62 4.24 14 12.86 11 3 51%
11-3
A considerable part of our 
revenue is the result of
3.67 8.27 4.60 6 12.87 10 -4 44%
218
C
ategory/
Statem
ent
PITI Statements
Current Situation
Future 
Im
portance
O0)TJ
Gap 
Rank
Opportunity 
Score
Opportunity 
Rank
Ranking 
Change
PIR 
Index
innovation in R&D.
11-4
The skills of our R&D staff 
have created advantages for 
us against our rivals.
4.09 8.35 4.25 12 12.60 13 - l 49%
12. Management Knowledge
12-1
We have qualified persons 
in all managerial positions.
5.62 8.90 3.28 46 12.18 35 l l 63%
12-2
We measure the efficiency 
of the decisions taken by our 
managers.
4.55 8.63 4.07 19 12.70 12 7 53%
12-3
There are adequate 
numbers of management 
graduates in our managerial 
team.
4.55 8.31 3.75 27 12.06 39 -12 55%
13. Customer Satisfaction
13-1
We have internal 
programmes to meet the 
customers’ requirements.
5.05 8.82 3.77 25 12.59 14 11 57%
13-2
We have categorised our 
customers into different 
groups and have 
communication programmes 
for each group.
4.62 8.46 3.83 22 12.29 32 -10 55%
13-3
We know the needs of our 
target customers.
5.12 8.66 3.54 37 12.20 33 4 59%
13-4
We measure the satisfaction 
levels of our customers.
5.15 8.87 3.71 29 12.58 15 14 58%
14. Creativity of the 
Employees
14-1
Our organisation 
encourages innovation.
4.96 8.73 3.77 26 12.49 21 5 57%
14-2
We have utilised the 
innovativeness of our
5.00 8.67 3.67 32 12.34 28 4 58%
219
C
ategory/
Statem
ent
PITI Statements
Current Situation
Future 
Im
portance
O
03
T3
Gap 
R
ank
Opportunity 
Score
Opportunity 
R
ank
Ranking 
C
hange
PIR 
Index
employees to create value.
Innovation plays an
14-3 important role in maintaining 5.16 8.78 3.62 34 12.40 26 8 59%
our competitiveness.
15. Qualifications for Jobs
The minimum qualifications
15-1 have been increased in our 6.12 8.71 2.59 62 11.29 59 3 70%
organisation in recent years.
We have access to people
15-2 with the required 6.07 8.69 2.61 60 11.30 58 2 70%
qualifications.
Our company can afford to
15-3 employ highly qualified 4.94 8.72 3.78 24 12.49 20 4 57%
people.
We have offered
scholarships to obtain
15-4 3.66 7.91 4.25 13 12.16 36 -23 46%
employees with the required
qualifications.
The statement with the highest rank, considering the gap between the current situation
and the future importance, is The financial impact of enforcing patent protection on our
products has been studied’ from the Patent Review category, which is also the category
with the first rank. Since this statement shows the largest gap, it reflects the extent of
attention required by this area and shows the study participants’ concerns regarding the
financial consequences of patent infringements by their companies. The industry also
shows the poorest readiness levels of 24% with regard to evaluating the financial
impacts of patent protection. The subsequent ranks are occupied by the statements 
*
This company has dedicated personnel for reviewing intellectual property rights to 
prevent patent infringements’, ‘Our marketing expenditure is comparable to that of our
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international rivals’ and ‘We have the GMP approval of international inspectors’, with 
PIR indices of 27%, 31% and 39%, respectively.
If a PIR index of 66% is regarded as an acceptable readiness level, 11 statement out of 
66, will pass this condition: updating the manufacturing procedures, competitive pricing, 
compliance with the environmental standards, considerable revenue from exclusive 
products, considering qualifications while hiring people, increasing training hours, 
access to the qualified persons, increased minimum qualifications for job documentation 
of the manufacturing procedures and strategic approach to licensed products and GMP 
improvement. Meanwhile, the item related to obtaining GMP certificates from 
international inspectors lies in the top three ranks, with the largest gap and opportunity 
score and a PIR index as low as 39%. It is interesting to note that the second-highest 
PIR index was 73%, concerning the strategy of having licensed products, while having 
licence agreements with innovator companies, which may be a result of this policy, 
received a PIR index of 56%. These two examples reveal the fact that conducting a 
detailed analysis of the above results for all statements will provide a clearer picture of 
the pharmaceutical industry in this transition state.
Table 7.4 also shows that the highest-ranking statement in terms of the opportunity 
scores is ‘We have the GMP approval of international inspectors’. This also underlines 
the future orientation of the opportunity score, because having international GMP 
certificates will be a crucial point in increasing the competitiveness of the companies in 
the future. Another interesting observation is that the highest-ranking statement does 
not belong to the highest-ranking category—a fact that underlines the necessity of 
conducting analysis at the level of statements. The second rank devolves on the 
statement The financial impact of enforcing patent protection on our products has been 
studied’, followed by This Company has dedicated personnel for reviewing intellectual 
property rights to prevent patent infringements’ and W e have a validation master plan 
for GMP’. These results indicate that statement-level analysis acts as a strong tool for 
determining how the industry should allocate its resources in a more efficient manner.
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The readiness of the pharmaceutical companies
The PIR indices for the pharmaceutical companies were located in the relatively wide 
range of 69.9% to 29.8%. While the indices pertaining to individual companies cannot 
be disclosed due to the confidentiality promised to the study participants, the 
anonymised results are presented in Figure 7.4.
This figure presents the PIR index of each company, while the numbers ranging from 1 
to 25 codify the company name. The figure illustrates the gradual increase in the index 
between the companies; however, the substantial difference between the lower and 
higher levels underlines the vital need for undertaking improvement plans in many of the 
companies. The figure also reveals the fact that none of the companies studied has a 
readiness index of more than 70%—the cut-off point for being considered a ‘ready’ 
company.
Figure 7.4 The Pharmaceutical Industry Readiness (PIR) indices for 25 companies
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Company codes
This study collected detailed data regarding the size and ownership of the companies in 
order to explore the possible roles played by these items in deciding the company’s
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readiness (Table 7.5). On the whole, this indicates that large, small, public and private 
companies do not show any clear relationship between their degree of readiness and 
their size and/or ownership attributes.
Table 7.5 Pharmaceutical Industry readiness (PIR) indices for the companies based on their
ownership and size
Company
Codes
Ownership Size Current 
Situation 
(average score)
Future Importance 
(average score)
PIR
Index
1 D aroupakhsh  H o ld ing* Large 5 .68 8 .13 69 .9%
2 Parsdarou G ro u p ** Large 6.23 8 .9 6 69.5%
3 D aroupakhsh  H olding Large 5.81 8 .5 0 68.4%
4 D aroupakhsh  Holding M e d iu m 6.12 9 .0 2 67 .9%
5 Private  C om pany M ed iu m 5.11 7 .7 0 66 .4%
6 P rivate  C om pany M ed iu m 5.64 8.91 63 .3%
7 D aroupakhsh  H olding M e d iu m 5.6 0 8 .8 6 63 .2%
8 Shafa H o ld in g ** * Large 5 .41 8 .5 7 63.1%
9 Shafa H olding M e d iu m 5.61 9 .1 7 61 .2%
10 TAPIC§ Large 4 .3 3 7 .3 6 58 .8%
11 Shafa H olding M e d iu m 5.52 9 .9 4 55 .5%
12 D aroupakhsh  Holding M e d iu m 4 .5 4 8 .2 9 54 .8%
13 A lborz G roup§§ M ed iu m 3.45 6 .47 53 .3%
14 Parsdarou G roup M e d iu m 4 .61 9 .0 6 50 .9%
15 TAPIC Small 3 .12 6 .7 0 4 6 .6%
16 D aroupakhsh  Holding M e d iu m 3 .40 7 .50 4 5 .4%
17 TAPIC Small 3 .92 9 .02 4 3 .4%
18 TAPIC Large 2 .86 6 .8 9 41 .5%
19 P rivate  C om pany M ed iu m 3.19 8 .31 38 .3%
20 TAPIC Small 3 .20 8 .5 8 37 .2%
21 P rivate  C om pany Large 2 .92 9 .61 30 .4%
22§§§ D aroupakhsh  H olding Large 2 .64 8 .8 4 29 .8%
* consists of 14 pharmaceutical companies involved in manufacturing and distributing human and veterinary products. Its main 
shareholder is Tamin Pharmaceutical Investment Co. (TPICO).
* *  consists of 5 companies involved in manufacturing and distributing medicines. Its main shareholder is TPICO.
* * *  consists of 7 companies operating in the areas of production and distribution of medicines.
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§ includes 7 companies operating in the field of finished products and active pharmaceutical ingredients. Its main shareholder is 
TPICO.
§§ consists of 6 pharmaceutical companies.
§§§three of the companies did not belong to the holding companies
The general characteristics of the size and ownership of the companies can be related 
to their degree of readiness as follows:
• Company size: The three highest indices of 69.9%, 69.5% and 68.4% are 
distributed among the five largest companies in the country. At the same time, 
the lowest index of 29.8% also belongs to one of the largest five. In general, 
large and medium-sized companies tend to occupy the higher ranks, while small­
sized companies tend to occupy the middle or lower positions.
• Company ownership: The main shareholder of the top four companies is a 
social security organisation (three of them belong to Daroupakhsh holding), while 
the fifth and sixth positions are occupied by private firms. Interestingly, the last 
company is also from the Daroupakhsh group. The table also shows that private 
companies tend to be distributed in the middle or bottom of the table, indicating 
their relatively lower readiness indices.
The results of the gap analysis, opportunity score and PIR index of the PITI categories 
are presented below in Table 7.6. The positions of three categories have remained 
unchanged in all three measurements: Patent Review shows the largest gap (5.08), the 
highest opportunity scores (13.09) and the lowest PIR index (36.6%), indicating that the 
industry should focus more on this item by analysing all the relevant statements (Table 
7.6); Skills of R&D Staff occupies the second rank in terms of the gap and PIR index, 
which is 50.4%. With regard to the opportunity score, this category ranks third. 
Marketing Expenditure also ranks third for both gap and PIR index, but seventh in terms 
of opportunity rank. This suggests that the priority accorded to this category is reduced 
if its future importance is considered. The fourth rank for the PIR index belongs to 
product packaging (55.2%), but it ranks sixth and ninth in terms of gap analysis and 
opportunity score, respectively. R&D Expenditure occupies the fifth rank for gap and 
readiness index (55.6%), but its opportunity score is ranked eighth, which may indicate
224
that the respondents have underestimated its future importance, to some extent.
While Management Knowledge has the PIR index of 57% and the sixth rank for both 
readiness and opportunity scores, it occupies the eighth rank in terms of gap priority. 
Customer Satisfaction and Creativity of the Employees, with the readiness indices of 
57.3% and 57.8%, respectively, have the seventh and eighth ranks in terms of PIR 
index priority, with similar gap rankings (i.e. seventh and ninth) but higher opportunity 
ranks—fourth and fifth, respectively—thus indicating their greater future importance.
Table 7.6 The gap analysis, opportunity scores and PIR indices for the PITI categories
PITI Categories
Current Situation
Future 
Im
portance
G
ap
Ranking
Opportunity 
Score
Opportunity 
Rank
Ranking 
Change
PIR 
Index 
(%
)
PIR 
Index 
Rank
Patent Review 1
2.93 8.01 5.08 1 13.1 1 0 36.6
Skills of R&D Staff 2
4.26 8.46 4.20 2 12.66 3 -1 50.4
Marketing Expenditure 3
4.15 8.23 4.08 3 12.30 7 -4 50.4
Product Packaging 4
4.58 8.30 3.72 6 12.02 9 -3 55.2
R&D Expenditure 5
4.68 8.42 3.74 5 12.15 8 -3 55.6
Management Knowledge 6
4.91 8.61 3.70 8 12.31 6 2 57.0
Customer Satisfaction 7
4.99 8.70 3.71 7 12.42 4 3 57.3
Creativity of the Employees 8
5.04 8.73 3.68 9 12.41 5 4 57.8
GMP & QA 9
5.29 9.05 3.76 4 12.81 2 2 58.4
Licence & Technology Transfer Agreements 5.15 8.53 3.38 10 11.91 10 0 60.4 10
Qualifications for Jobs 11
5.20 8.50 3.31 11 11.81 12 -1 61.1
Mergers & Strategic Alliances 12
4.80 7.82 3.02 13 10.84 14 -1 61.4
Manufacturing Technology 13
5.60 8.71 3.11 12 11.82 11 1 64.3
Training for Employees
5.61 8.61 3.00 14 11.60 13 1 65.2
14
Pricing Policy 15
5.38 8.08 2.70 15 10.78 15 0 66.6
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The GMP & QA category receives the second priority for opportunity score and the 
fourth priority for gap, but the industry readiness for this item has been given the ninth 
rank, with the PIR index of 58.4%, which implies that while this area requires some 
improvements, there are poorer areas in terms of readiness. The other areas occupy 
more or less similar positions based on the three measurement methods.
DISCUSSION
Further analysis was conducted on the scores given by the respondents to the PITI 
statements. In the first step, the size of the gap between the average scores of the 
current situation and the future importance was calculated for each category. It was 
explained that the bigger the gap, the higher should be the priority for improvement.
In the next step, the opportunity scores were measured by using the opportunity 
algorithm, which in turn was based on adding the importance score to the gap. This 
analysis resulted in a ranking of categories which was different from the ranking 
produced by measuring the gap. The logic behind calculating the opportunity score, 
after adding the future importance to the size of the gap, generates an opportunity- 
algorithm-based ranking that is more future-oriented; hence, the higher ranked 
categories in this system of ranking are likely to be of greater importance in the future. 
In other words, when items are ranked based on the size of the gap, it is possible to 
accord a high rank to an item that may be of low future importance.
In the final step, the PIR index was introduced as an indicator to measure the industry 
readiness based on the collected data. This index recommends some areas for 
improvement that are different from the priorities suggested by the other two 
measurements—gap and opportunity score—for some of the statements and 
categories. The advantages of this method, in comparison with gap analysis and 
opportunity score, are as follows:
• The PIR index represents the overall readiness of the industry as well as its 
readiness at the level of individual statements and categories.
• Since this index can be measured at the company level, the situation of the 
companies can be compared with each other.
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• The companies can evaluate their performance with regard to the overall index of 
the industry.
• It is possible to study the general trend of industry readiness over time, for 
example, by comparing the PIR indices on an annual basis.
However, all the above-mentioned methods can be applied to explain the current 
situation and future aspirations of the pharmaceutical industry from different points of 
view. For developing the appropriate improvement plans, the decision-makers can apply 
the most appropriate method for studying their case, and the data presented in this 
study can be used as a directive for this selection.
With regard to the gap analysis, opportunity scores and readiness index, it is possible to 
define three different scenarios for planning improvement programmes for the industry. 
Following the three scenarios proposed in the previous chapter, we will label these as 
scenarios 4, 5 and 6, as follows:
Figure 7.5 Three scenarios based on gap, opportunity scores and PIR index
Managem ent Knowledge
Scenario 5: ^
Improve opportunities
Patent ReviewPatent Review Patent Review
Skills of R&D Staff
GMP & QA
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Scenario 4 suggests that the higher priority be given to the biggest gap. Based on this 
scenario, the industry should start with improving the patent review process, skills of the 
R&D staff and marketing expenditure. This should be followed by concentrating on GMP 
& QA, R&D expenditure, product packaging and customer satisfaction.
Scenario 5 is based on ascribing priorities according to the opportunity scores. Again, 
the starting point is patent review, followed by GMP & QA, skills of the R&D staff and 
customer satisfaction. Thereafter, two human-resource-related areas with good 
improvement opportunities should be addressed—creativity of the employees and 
management knowledge—while marketing expenditure should be improved in the next 
step.
Scenario 6 proposes improving areas on the basis of the PIR index, which reflects the 
levels of industry readiness. The first three steps of this scenario are similar to those of 
scenario 3 discussed earlier; however, product packaging now occupies the fourth 
position in the list of readiness priorities. Figure 7.5 presents the list of selected priorities 
in all three of the above-described scenarios.
SUMMARY
This chapter focused on prioritising the improvement areas and proposing improvement 
scenarios based on the study results, which were analysed at two levels— PITI 
categories and statements (categories and parameters).
• The first step involved measuring the gap between the present and desirable 
situations in order to identify the areas with the largest gap and consequently a 
higher priority. All the statements and categories were ranked according to the 
size of the gap, and a scenario was proposed for planning the appropriate 
improvement strategies.
• In the second step, the opportunity algorithm was used to identify the areas of 
improvement by adding the future importance to the size of the gap.
• In the final step, the pharmaceutical industry readiness (PIR) index was 
calculated by dividing the scores for the current situation by those for the future 
importance; this index has the unique characteristic of representing the overall
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industry readiness in one figure. The overall PIR index for the industry was 57%, 
which does not indicate a significant level of readiness.
• The seven most important improvement areas according to scenario 4, which is 
based on the size of the gap, were identified as patent review, skills of the R&D 
staff, marketing expenditure, GMP & QA, R&D expenditure, product packaging 
and customer satisfaction.
• Scenario 5 repeated five of the above areas, albeit with different rankings, but 
replaced R&D expenditure and product packaging with the two human-resource- 
related areas of creativity of the employees and management knowledge.
• The last scenario, scenario 6, repeated six of the above-mentioned areas, while 
replacing GMP & QA with management knowledge.
• At the level of statements, the lowest readiness indices indicated the categories 
that showed the highest priority in terms of this indicator. The PIR index ranged 
from 24% to 76%. It is interesting to note that the statements with higher indices 
are more closely related to future planning, and not to the obtained results. In 
addition, the PIR indices of all the sampled companies were within the range of 
29.8% to 69.9%, with no specific relationship associated with their size and 
ownership.
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Chapter 8
Development of a Strategy Map to Secure the Post-WTO 
Sustainability of the Pharmaceutical Industry in Iran
INTRODUCTION
The study of the post-WTO/TRIPS sustainability of the pharmaceutical industry in Iran 
resulted in proposing six different scenarios on the basis of the strengths, weaknesses, 
future importance, gap analysis, development opportunities and industry readiness. This 
gives the pharmaceutical companies and other stakeholders the opportunity to define 
specific preparation plans with respect to their situation and resources and the fitness 
with one of the proposed scenarios.
This chapter will study the possibility of giving a more holistic solution to cover some 
limitations of the scenarios such as the step by step approach which is inherent in the 
priority-oriented decision-making. This chapter focuses on developing a strategic map 
as a toolbox to uphold the priority concept as well as causal effect, lead and lag 
indicators and balanced improvements. The outcome of this new approach should 
enable the interested individuals and firms to incorporate their own priorities and 
concerns into the plans and simultaneously take into account a long term view and the 
dynamics of the environmental changes.
OBJECTIVES
The objectives of this study were to:
• Develop a working and practical strategy map for the Iranian pharmaceutical 
industry in order to secure its post-WTO sustainability
• Determine the relationships between the parameters by using the standardised 
logical order (concept of lead and lag indicators)
• Translate the identified parameters into a series of balanced scorecards
• Inform the policy makers as to how they should develop their strategy in synergy 
with that of the industry
METHODS
The key methodologies to achieve the objectives of this chapter and facilitate the 
interpretation of the results were to develop balanced score cards and a strategy map. 
For the strategy map, it was necessary to use the concept of lead and lag indicators as
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well as cause and effect relationships between the study parameters. The idea of 
balanced score cards was first introduced by R. Kaplan and D. Norton in 1992 as a tool 
for the development and improvement of organisational performance. They believed 
that balanced scorecards provide the tool for future competitive success (Kaplan and 
Norton, 1996). They defined this concept later in 2000 as a visualised plan to present 
the goals and interrelations between required actions in a strategic plan.
Balanced scorecards can be defined as a conceptual framework which translates the 
corporate strategies into measurable indicators and then creates a balanced distribution 
between the key organisational aspects. In this way, it is a powerful and integrated tool 
for controlling the key areas of the financial, customer, processes and growth & 
learning. A strategy map is used by half of Fortune 1000 companies and by more than 
two thirds of international corporations (Person, 2009). This methodology is also used 
in many pharmaceutical companies such as Novartis, Novo Nordisk and Bristol Myers 
Squibb (Francesco G.G.Zingales, 2003). The step by step procedures for developing 
balanced scorecards and drawing Strategy Maps are explained by Person (2009) and 
Stettinius et al. (2005). According to Person (2009), the advantages of balanced 
scorecards are to:
■ Clarify strategy. The discussions during developing the strategy map create an 
atmosphere of clarity and understanding between the departments in an 
organisation.
■ Translate strategy into action and executing it. A clear road map will be given 
if a strategy map is combined with a tactical action and implementation plan. The 
balanced scorecards will help to monitor execution of the strategies.
■ Aligning business units around the strategy. A strategy map and tactical 
action plans require that the walls between departments come down and the 
whole organisation becomes unified to follow the road map.
■ Communicate the strategy to all levels. The process of cascading the 
balanced scorecards through the executive and operational levels gives the 
opportunity to all of them to contribute to organisational success.
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■ Monitoring and managing strategic execution. Using balanced scorecards 
helps executives to focus on strategic leadership instead of concentrating on 
operational performance.
Balanced scorecards are known as a tool to close the gap between the strategic levels 
of vision, mission, values and strategies with daily action and they fill this gap by 
implementation and focusing on strategies and strategic initiatives. In other words, 
balanced scorecards enable the organisations to remove the barriers for the successful 
implementation of their strategies. In addition, an important aspect of balanced 
scorecards is the cause and effect relationship between different parameters. For 
example financial sustainability needs customer satisfaction which is dependent on the 
efficiency and quality of the internal processes such as GMP and QA that needs to be 
supported by the skills and training of the employees. It takes its name from the fact 
that it uses balanced perspectives of what drives business and strategy including 
financial, customer and marketplace, internal processes and learning and growth. Some 
of the key terms of balanced scorecards and a strategy map are defined as follows 
(Kaplan and Norton, 1996; Person, 2009):
Financial perspective - These are related to profitability by operating income, return on 
capital employed or economic value added as well as sales growth or generation of 
cash flow.
Customer perspective - The core outcome measures include customer satisfaction, 
customer retention, new customer acquisition, customer profitability, short lead time and 
on time delivery as well as a constant stream of innovative products and the ability to 
anticipate customers’ emerging needs.
Internal processes - The parameters that cause overall excellence throughout 
operational and logistical processes are included in this area. These processes enable 
the industry to deliver the value propositions that will attract and retain customers and 
satisfy shareholder expectations of excellent financial returns.
Learning and growth perspective - Organisational procedures examine alignment of 
employee incentives with overall organisational success factors (Kaplan and Norton, 
1996). Norton and Kaplan explained there are three categories of intangible assets in
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this perspective: human capital (skills, talents and knowledge of the employees), 
information capital (databases, information systems, networks and technology 
infrastructures) and organisation capital (culture, knowledge share, people alignment 
with strategies) (Kaplan and Norton, 2004).
Strategy gap - The distance between the operational plan for today’s business and the 
grand vision for what the business needs to become is called the “strategy gap” 
(Coveney et al, 2003).
Strategic theme - This is generally a vertical slice within the strategy map and is a 
subset of the overall strategy consisting of a distinct set of related strategic objectives 
(Kaplan and Jackson, 2007). Strategic themes are defined to concentrate the resources 
at critical points. It is recommended to define three to five strategic themes. There are 
three financial themes that drive the business strategy: revenue growth (new products, 
new applications, new customers and markets, new relationships, new product and 
service mix and new pricing strategies), cost reduction, productivity improvements and 
asset utilisation. Kaplan and Jackson (2007) recommended that the strategy map is 
preferred to have maximum of 24 objectives depending on the size of the company.
Causal effect - A strategy is a set of hypotheses about cause and effect. Causal links 
show the hypotheses of how the success in one objective drives the success in another. 
The entire chain of cause and effect relationships was established as a vertical vector 
through the four balanced scorecards perspectives.
Measures and Metrics - Measure is the unit by which the progress to the objective is 
evaluated. If you cannot measure, you cannot manage your objectives and the 
measurement system changes the behaviour of people. Metrics are a quantifiable 
evaluation of the measures. It is important to pinpoint a “critical few” metrics which 
means being focused and one must not select too many metrics. Metrics can be divided 
into two groups: leading and lagging metrics. In our example, the number of new 
products in the pipeline and the time to market are metrics for the defined measures. 
Leading metrics drive an objective and are the arrowhead of the causal link while 
lagging metrics are the result of an objective. Measures in the financial perspective are 
all lagging while measures in learning and growth perspective are all leading indicators.
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They drive progress in the internal processes and customer perspectives. Internal 
operations and customer perspectives are a mixture of both lead and lag indicators.
Initiatives - These are collections of actions or projects that are scheduled in order to 
achieve the strategic objectives. Identifying the right projects, motivating the people and 
developing operational and executive dashboards are key elements for a successful 
strategy implementation.
The starting point for developing a strategy map will be in the learning and growth 
perspective in order to organise the developments for the internal processes of the 
companies. It is obvious that the learning of the employees and management is a 
prerequisite for investing in processes and technological aspect. For instance, investing 
in new technologies or higher GMP levels without prior training of the employees and 
managers will be simply wasting the financial resources. After improving the internal 
processes, the company can focus on attracting customer satisfaction because only 
improved processes can create value for the customers that should be advertised and 
proved to them. Finally having loyal customers will secure long term profitability for the 
shareholders in the financial perspective. Due to the financial constraints, it is necessary 
that the learning and growth layer be supported by the pricing policy in order to 
generate the required financial resources. It should be noted that the pharmaceutical 
industry is highly influenced by the regulatory environment that puts the pricing policy 
into a regulatory context (Figure 8.6). The key message of this concept is to emphasise 
the importance of preparing the ground for lag indicators such as customer or financial 
results to be achieved by prior investment on lead indicators such as internal processes 
and learning and growth perspectives. These relationships are presented in Figure 8.1.
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Figure 8.1 the lead and lag m etrics in balanced scorecards perspectives
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RESULTS
The results of this chapter are presented in two parts. The first part describes the 
development of the strategy map and the second part explains how the industry can 
operationalise the subsequent strategy.
Part 1 - Development of a Strategy Map
To develop a strategy map for the pharmaceutical industry seven steps were involved:
Step 1: Defining the Vision, Mission and Values - these key terms are defined in this 
study as follows:
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■ Vision -  a vision statement describes what the industry will be like in the future.
Sustainable profitability in the post-WTO situation is the major aspiration of the 
industry and can be considered as the industry vision.
■ Mission -  a mission statement explains the reason for existence. The vision of
the local pharmaceutical industry in Iran can be defined as “to create value for 
stakeholders”.
■ Values — values are what the people believe in and determine how they act and
what their ethics are. Providing quality medicines is a value that the 
pharmaceutical industry cannot afford to miss. However, a company should 
achieve their goals without compromising the quality of their product.
Step 2: Assessing the external and internal environment - The internal and external 
environment may be evaluated by using the following methodologies:
■ PESTEL approach (Political, Economical, Social, technological, Environmental 
and Legal),
■ Porter’s 5 forces (substitute products, entry of new competitors, competitive 
rivalry, consumer bargaining power and suppliers bargaining power),
■ SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis,
■ PITI (Pharmaceutical Industry Transition Instrument)
In this study the external and internal environment were analysed using PITI and the 
study parameters were identified based on this analysis.
Step 3: Development of the balanced scorecards - Norton and Kaplan introduced the 
balanced scorecards in order to monitor the strategy from different points of views. 
Strategic objectives are categorised into four perspectives of the balanced scorecards 
as follows:
■ 1. Financial perspective: Financial measures are valuable in summarising the
measurable economic consequences of actions already taken. In this study, 
sustainable profitability, international sales, local market sales, improving cost 
structure and increasing asset utilisation were considered to be the key financial 
aspirations of the local industry in the post-WTO/TRIPS situation.
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■ 2. Customer perspective: This perspective includes several core or generic 
measures of the successful outcomes from a well formulated and implemented 
strategy. In this study customer satisfaction, quality improvements and innovation 
are included.
■ 3. Internal processes perspective: The areas considered in this context were: 
manufacturing technology, mergers and strategic alliances, qualifications for jobs, 
research and development, licence and technology transfer agreements, GMP and 
QA, product marketing and patent review.
■ 4. Learning and growth perspective: This perspective identified the infrastructure 
that the organisation must build to create long term growth and improvement. The 
three principal sources for organisational learning and growth are: people, systems 
and procedures. Employee-based measures are: employee satisfaction, retention, 
training and skills (including particular skills required for a new competitive 
environment). Information systems capabilities can be measured by real time 
availability of the accurate information critical for customer and internal processes of 
the front line of decision-making and action. Therefore, training for the employees, 
management knowledge, creativity of employees and skills of R&D staff were 
included for the strategy map.
The role of the balanced scorecards to fill the gap between the strategy and operation is 
illustrated in the Figure 8.2.
The main objective of the pharmaceutical industry balanced scorecards is to close the 
gap between the strategic and operational level. In practice, strategies are defined by 
higher managerial levels and are not efficiently communicated with the operational 
levels of company. A balanced scorecard, as will be described further in this chapter, 
provides a robust tool to translate the strategies into operation. It should be noted that 
there is a temptation to rely on financial results to measure the performance of 
organisations while they only show the results of what has happened before and only a 
balanced view will drive the industry towards superior performance (Figure 8.1).
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Figure 8.2 Closing the gap between strategy and operation by balanced scorecards
Source: adapted from (Kaplan & Norton, 2004)
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Step 4: Determining the strategic themes. It is important that the strategic themes 
differentiate the company from its competitors and guarantees its sustainability in the 
future. Therefore, each company should identify the appropriate strategic theme on the 
basis of its unique capabilities. In general, this study selected the strategic themes of 
increasing local and international sales (as revenue growth strategy), increasing asset 
utilisation and the improvement of cost structure (as productivity strategies) for the 
Iranian pharmaceutical industry.
Step 5: Identifying the strategic objectives. Industry objectives are goals that help to 
accomplish the strategic theme and all PITI categories were considered as appropriate 
industry objectives. The following objectives were derived from other categories 
because of their critical role for the industry’s sustainability.
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■ In terms of financial perspective, sustainable profitability was considered as 
the ultimate objective. International sales and local market share were also 
considered under revenue growth strategy while increasing asset utilisation 
and improving cost structure were placed under productivity strategies.
■ In terms of customer perspective two objectives of quality improvement (as a 
result of GMP and QA system) and innovative products (as a result of 
improvements in research and development) were added.
■ Product packaging was not considered as an objective, but was reviewed as 
part of the quality improvement in customer perspectives.
Step 6: Synthesis of the casual links between objectives. The relationship between 
objectives were interpreted in terms of causal effects in the strategy map are described 
later in this chapter. It is important to note the essential role of this concept in an 
effective resource allocation. For instance, investing in modern technology without 
having well trained employees and managers will not only result in better performance, 
but waste the financial resources for other basic needs of the industry. To realise the 
most important causal effects in a company and also at an industry level, it is important 
to communicate the subject with the employees and industry experts in order to take the 
right decisions.
Figure 8.3 illustrates that:
■ Improvement in management knowledge drives success in research and 
development as does hiring qualified managers and employees, entering into 
mergers and strategic alliance agreements as well as improving manufacturing 
technologies. In fact this objective in learning and growth perspective has 
tremendous influence on all other objectives in this area.
■ This objective will indirectly facilitate GMP & QA, licence and technology transfer 
agreements and marketing expenditure.
■ These improvements will drive success in innovative products and quality 
improvements that finally will result in customer satisfaction.
■ Satisfied customers will create sustainable profitability through revenue growth 
and productivity achievements.
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In this figure indirect effects are illustrated by thin arrows as an example. Indirect effects 
are not presented in the next diagrams but can be discussed and assessed for better 
understanding of the objectives causal relationships (Figure 8.3).
Figure 8.3 The causal effects arising from management knowledge
Figure 8.4 The causal effects arising from skills of R&D staff
* ftc r
a St
According to Figure 8.4:
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■ Skills of R&D staff will directly support successful implementation of the research 
and development projects. It will also prepare appropriate resources for the 
industry to review the patent situation of their current and developing products.
■ Innovative products will be developed in light of the availability of the above 
infrastructures.
■ Success in developing such products will enable the industry to achieve more 
local and international market share especially in competition with the 
international rivals in the local market.
■ Producing high value products will improve the cost structure of the industry that 
finally leads to sustainable profitability. Development of the innovative product is 
the key factor in achieving a higher level of customer satisfaction as well as lower 
marketing cost that is imposed on the industry when producing plain generic 
medicines.
Figure 8.5 The causal effects influenced by creativity of the employees.
Figure 8.5 presents:
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■ Creativity of the employees in the learning and growth perspective which enables 
the industry to develop or deploy more advanced manufacturing technology
■ The quality of the products will be improved by using a higher level of the 
manufacturing technologies
■ Higher quality will enable the industry to satisfy their customers needs and meet 
their expectations
■ The cost structure will be improved by better operational performance and less 
waste and reworks which are obtained by modern technology. The resulting 
production continuity will also improve asset utilisation. All of these achievements 
facilitate responding to the customers’ needs
■ The sustainable profitability for the industry will be then achieved in the light of 
these consecutive improvements.
Figure 8.6 The causal effects arising from training for employees
Figure 8.6 shows:
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■ Training for employees will facilitate implementation of GMP and quality 
assurance systems as well as licence and technology transfer agreements and 
improvement of manufacturing technologies
■ As a consequence of the above achievements, the quality of the products will be 
significantly improved
■ Higher quality products will result in improved customer satisfaction
■ More satisfied customer will support the sustainable profitability of the industry in 
a competitive environment in the post-WTO situation.
Examination of the causal effects revealed the relationship between strategic objectives 
which are not limited to the above cases and therefore several direct and indirect effects 
may be realised on the basis of different experiences and backgrounds.
Step 7: Drawing the strategy map. Merging the four figures (8.3, 4, 5 and 6) described 
in step six results in the strategy map for the pharmaceutical industry presented in the 
Figure 8.7.
In this map three parameters of patent law, pricing policy and importation tariff underline 
the important role of the regulatory environment on sustainability of the pharmaceutical 
industry in Iran. A review of the value of the balanced scorecards, the cause and effect 
concept together with the lead and lag indicators, provide the necessary information to 
develop a strategy map of the pharmaceutical industry which was developed with the 
following considerations:
• Learning and growth; A rational pricing policy at the governmental level 
supports the four objectives in the learning and growth perspectives 
namely the skills of R&D staff, creativity of the employees as well as 
the training for the employees and management knowledge.
• Internal processes; Eight strategic objectives in the internal company 
process perspective including patent review, mergers and strategic 
alliances, manufacturing technology, qualification for jobs, product 
marketing, research and development, GMP & QA and licence & 
technology transfer agreements are influenced by the objectives in the 
learning and growth perspective.
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• Customer perspective; All the above mentioned objectives are likely to 
influence customer satisfaction in the context of the customer 
prospective.
• Financial perspective; Finally, attaining profitability in the financial 
perspective will secure post-WTO sustainability of the pharmaceutical 
industry.
Figure 8.7 The strategy map to secure the post-WTO sustainability of the pharmaceutical
industry in Iran
Revenue Growth Strategy Productivity Strategy
Patent Law Importation Tariff
Part II - How to operationalise the strategy map
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Having now the generic strategy map, as a prototype, the following steps should be 
taken to operationalise this map in the companies (Figure 8.8):
Figure 8.8 The steps to operationalise the strategy map as an
example
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Stepl: Defining the measures of the objectives - Success in the strategic objective 
of developing innovative products can be measured not only by the innovative products 
in the pipeline but by the speed of introducing them into the market. It should be noted 
that defining too many measures should be avoided while the important ones should be
selected by the strategic planning teams.
Step2: Specifying metrics - The number of innovative products in this example is 
considered as the metric for the objective of developing innovative products. Time to 
market can be also considered as a suitable metric for this objective.
Step3: Determine the Targets - Target is the desirable quantity of metrics needed to 
achieve the objectives. In our example the target quantity of the innovative products is 
five products in the pipeline and the target for time to market is 2 years.
Step 4: Develop initiative plans - The initiatives are defined by brainstorming and it is 
important to prioritise them with regards to the industry situation. In our example, the
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objective of innovating products will be supported by project management optimisation. 
It should be emphasised that this initiative is mentioned just as an example and the 
strategy planning team may recognise budget allocation or R&D expenditure as the 
critical initiative.
DISCUSSION
In this chapter, study parameters identified by the industry managers resulted in the 
formulation of a strategy map. Approaching the deadlines of WTO and the tough price 
driven competitive market as well as the economic crisis underlines the need for a 
reliable roadmap for the industry such as the strategy map developed in this chapter. 
The regulatory context has a crucial role in the achievements of the industry objectives 
and a strategic alignment is the only way that facilitates making right decisions, taking 
right measures and allocating the resources efficiently in both country and company 
levels.
Three contextual parameters of patent law, importation tariff and pricing policy are the 
drivers for the further progression of all other scorecard perspectives. Without a 
rationale patent law, it is almost impossible to anticipate sensible investments in 
research projects by local companies or the granting of manufacturing licences by the 
multinational companies. Pricing rewards for any degree of product or process 
innovation, quality awareness or GMP improvement stimulates movement in all layers 
of the strategy map. A gradual decrease in the importation tariff in parallel with 
supportive policies will also differentiate the responsive parts of the industry and 
determine its future survival. It should be taken into consideration that the sustainability 
of the local industry has an inevitable contribution to the success of national plans for 
the accessibility of patients to safe and affordable medicines.
The industry associations have a key role to play in this strategy and define the 
measures and initiatives for the whole industry in an agreement with the regulatory 
officials and industry associations. These associations and holding companies can use 
the concept of a corporate scorecard to create additional value throughout the industry 
or a group of companies (Norton, 1999).
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The outcome from this chapter can be used by companies and modified to their specific 
priorities and concerns. This map is the outcome of a country-wide study based on 
established methodology which is hoped will be acceptable at an executive and 
operational level and reduces psychological barriers of bias or irrelevant judgements. It 
should be noted that balanced scorecards fail for a variety of reasons such as; lack of 
senior management commitment, lack of a driving need for change, determining too 
many inappropriate metrics, too long plans and cultural mismatch (dictatorial executives 
and low performance norms) (Person, 2009). Therefore a successful implementation 
requires qualified teams to define and prepare the ground work with respect to the 
requirements of each company. The PITI statements are a good source of initiatives 
and improvement plans that can be used to translate strategies to operational plans.
Finally the findings of this chapter should be communicated to shareholders, patients’ 
associations and physicians in order to obtain their cooperation and support by 
highlighting the threats of industry failure for their future benefit. It is important to note 
that strategy is a hypothesis that makes assumptions about outcomes that can be 
achieved and its proper communication to all stakeholders has an important role in this 
achievement (Norton, 1999).
SUMMARY
This chapter focused on a strategy map using a balanced scorecard concept in the 
following way:
• The study parameters from previous chapters were refined to be considered as 
strategic objectives for the industry.
• The objectives were distributed in four balanced scorecard perspectives namely 
financial, customer, internal processes and learning and growth.
• An additional level was considered as the regulatory environment included the 
three parameters of pricing policy, patent law and importation tariff.
• The causal effect relationship between the strategic objectives were then 
analysed and merged to formulate a strategy map.
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• Examples of defining measures, metrics, targets and initiatives were provided to 
demonstrate how to operationalise this map and translate the strategies into 
operational plans.
• The map can then be cascaded down by using the PITI statements to define 
initiatives and improvement projects
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Chapter 9
General Discussion
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INTRODUCTION
In the practice of Zen Buddhism, the true master is able to discover the few key 
elements that drive all variables and bring them back to their purest form. There are no 
quick fixes, to do the things in the right way, it is important to know that the journey is 
the destination. (Buytendijk, 2008)
The role of all the experts and industry managers that participated in this study was to 
shape the study hypotheses, conclusions and discussions that highlighted the inductive 
approach as a powerful dynamic for creating and sharing the knowledge within a wide 
range of professionals in different organisations. Furthermore, the use of primary data 
as opposed to secondary data highlights the importance of the study. In fact, many 
studies focusing on the WTO impact on the pharmaceutical industry have collected 
financial and quantitative data such as research and development expenditure, number 
of employees working in marketing or R&D departments, the budget allocated for GMP 
improvements and the market value of the revenue resulting from innovative products 
and process developments. Quantitative research philosophy was not followed in this 
study for two reasons: the first was the confidential nature of the required data that 
could substantially affect the data collection procedure and the second was the 
complexity of the data manipulation and comparing the results for making decisive 
conclusions. The advantage of the interpretative philosophy applied in this study is the 
opportunity for self-assessment and self evaluation given to the study participants and 
this prevents the study results from being disputed for their inaccuracy due to the 
ambiguities in financial figures and the ways that different companies categorise their 
expenditures.
An important result of this study was the development of a quantitative measure, the
Pharmaceutical Industry Readiness (PIR) index, to evaluate the readiness of the
industry for joining WTO and the implementation of TRIPS. This evaluation was carried
out for all 66 parameters and the relevant 15 categories. This measure is also
applicable for determining the readiness for a company, a group of companies and for
the whole industry. This study showed that the overall readiness of the pharmaceutical
industry to face the WTO/TRIPS challenges is 57%. The ability of the developed
methodology and relevant instruments to measure this index is considered as a unique
251
feature of this study. This is supported by a recent study (Farzandi and Mostafavi, 2010) 
where twenty companies listed in Tehran stock market were analysed. It was concluded 
that the overall performance of these companies was 62%. With regards to the 
standardised European Foundation for Quality Management (EFQM) model and the 
totally different methodology that was applied in this study, the correlation of 62% 
quality management performance with the 57% readiness, underlines the significance of 
the findings of this study.
The findings from this study are comparable with a number of previously reported 
studies in this area. For example: licence and technology transfer agreements 
(Supakankunti et al, 2001; Grace, 2004; Goyal, 2006 and Chaudhry, 2009), R&D 
investment (Grace, 2004; Dhar and Gopakumar, 2006; Chaudhry, 2009), training of the 
employees and qualifications for jobs (Lim and Wei, 2010), knowledge management 
(Lim and Wei, 2010), customer focus, marketing investment, patent review (Hason and 
Shimotake, 2006), importation tariff (Yeung, 2002) (Semin and Guldal, 2008), price 
changes (Chaudhry, 2009), strategic reorientation of the firms (Dhar and Gopakumar, 
2006) and many other factors that are explored and discussed in this study are refered 
to in other countries’ studies. Therefore, the findings of this study are comparable with 
similar research projects, with some differences, that reflect a different scope and 
objectives. For instance detailed legal aspects of TRIPS implementation or FDI were not 
deeply analysed in this study because contextual factors were not included in the PITI 
and the focus of this study was mainly on direct industrial issues. However, none of the 
reviewed studies collected this amount of data from the pharmaceutical companies nor 
developed the robust study instruments as in the case of this study. Proposing 
alternative scenarios and developing a strategy plan were also not reported in these 
studies. This study may contribute to the current limited knowledge in this area in 
general and provides seminal information and strategic direction for Iran’s situation in 
particular.
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Current Challenges to the Post-WTO Sustainability of the 
Pharmaceutical Industry in Iran
As a result of the findings of this study, the following fifteen challenges were identified:
1. Patent Review - Due to the lack of a strong patent protection law, the industry has 
not dedicated sufficient personnel to review the patent situation of their products. It is 
surprising that this evaluation is not carried out even when the companies intend to 
export their products into other countries. Although the common exporting destinations 
for Iranian pharmaceutical companies are countries such as Afghanistan, Iraq and some 
African countries who do not respect the TRIPS agreement, a considerable risk to the 
industry is imposed in the case of litigation. It would therefore be expected that the 
industry would review the patent situation when selecting products for development to 
protect their investment in the post-WTO/TRIPS situation. It was concluded that a 
separate study should evaluate the financial impact of enforcing the TRIPS agreement. 
Patent review is a top priority to address the industry weaknesses (see scenario 1 in 
chapter 6), but is also the first priority to bridge the gap between the current situation 
and future importance, improve opportunities and increase the post-WTO/TRIPS 
readiness of the Iranian pharmaceutical industry (see scenarios 4, 5 and 6 in chapter 7).
2. Licence and Technology Transfer Agreements - A significant investment in R&D is 
needed to develop innovative pharmaceutical products. For small or medium sized 
companies it is highly recommended to develop licence or technology transfer 
agreements with companies as a way to obtain technical capabilities in manufacturing, 
quality control and marketing of high value products. This study found a significant 
variation between the performances of the companies in this area. Further analysis 
showed that larger companies were in a better situation while small companies did not 
have a strategic approach towards licensed and technology transferred products due to 
their lack of appropriate infrastructures. However licensed and technology transferred 
products do not make a major contribution to the total sales of the respective 
companies. The pharmaceutical industry had a high score of performance in this 
category that subsequently made it a priority for the industry while focusing on the gap 
in one of the suggested scenarios (see chapter 6).
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2. Sales and Marketing - The performance of the industry in this category was 
identified as unsatisfactory mainly due to the limited funds for marketing activities. It 
should be also noted that most of the companies do not have differentiated products 
with the competition being mainly limited to local companies. Reviewing the Iranian 
pharmaceutical market shows that there is considerable price oriented competition 
which underlines the lack of differentiated products. However this situation will be 
changed by the gradual decreasing of importation tariffs. There were variations in the 
performance of different companies in their contribution to marketing expenditures in 
order to gain a higher market share and increasing customer loyalty which would 
endanger the sustainability of the local industry in the competitive environment that is 
anticipated in the post-WTO situation. The industry should learn how to target the right 
customers and how to efficiently allocate its limited marketing funds to ensure obtaining 
acceptable results such as increased market share or customer satisfaction. Sales and 
marketing would be a top priority in the scenarios for improving weaknesses, closing the 
gap and increasing the industry readiness.
4. GMP & QA - This category can be considered as one of the main functions of the 
industry to compete in the post-WTO situation and enabling it to export their products 
and obtain agreements with reputable companies as licensors or co-development 
partners. It was expected that the industry would show a varied performance in this 
area due to their different financial and technological capabilities. However, the whole 
industry unanimously considered this category as one of their strategic goals. The 
industry also identified ‘having a documentation system’ as satisfactory that reflected 
the primary steps in GMP improvement. GMP and QA are major topics for the industry 
to address if the focus on importance or improvement opportunities is to be the selected 
scenario.
5. Research and development -  One of the key advantages of pharmaceutical 
companies in the competitive environment resulting from implementing the WTO/TRIPS 
agreement will be their ability to develop new products which for generic companies 
mainly means new formulations. In general this category was recognised with high 
variations between the companies mainly due to different performances to allocate R&D 
funds and its role in creating competitiveness and developing exclusive products.
However, the results were unsatisfactory in measuring the effectiveness of R&D 
expenditures and developing new formulations. This means the importance of this area 
has not been recognised by the industry and it was expected that they would be more 
willing to invest in new formulations. Research and development can be considered as 
one of the choice strategies for improving weaknesses, bridging the gap and increasing 
the readiness of the industry.
6. Product Packaging - It was a major surprise from the early stages of this study that 
product packaging was a major concern for the industry experts and managers. 
Attractiveness, proper sealing, ease of reading and understanding, child proofing and 
durability of the pharmaceutical packaging are some of the unmet characteristics in this 
area. Improving the packaging of pharmaceutical products requires less technological 
and financial resources in comparison with other product development aspects such as 
developing new molecules from chemical or biological sources. This study showed that 
the industry has failed to design packages as attractive and appropriate as their 
international rivals and this was identified as a result of constraints in modern packaging 
lines. The study showed that some companies are allocating resources to improve their 
packaging but the results have not been realised as yet or the attempts have not been 
successful. Product packaging was identified as an important area for improving the 
weaknesses, closing the gap and increasing the readiness of the industry.
7. Manufacturing technology - Companies differed with regard to this category as 
expected because of their inherent differences in their technological experience. The 
only parameter that was satisfactory in this group was documentation of the 
manufacturing procedures but all respondents considered that their automation level 
was unsatisfactory. These results show that the industry has started to do the paper 
work that is required for modern technology implementation but the automation level 
that presents on important aspects of the GMP complied technologies are not deployed 
yet. The automation level is affected by both financial capabilities and the legal 
environment but the current labour law does not permit the firms to cut jobs in order to 
replace automated systems and manual work is frequently used especially in 
transporting the material in the process of manufacturing and also in packaging the 
finished goods. However the companies need to upgrade their automation level in order
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to comply with rigorous current GMP regulations that are required by both local and 
international regulatory bodies. For instance, closed systems are more and more 
common for transferring in-process material to prevent the susceptibility of the 
employees from the harmful effects of pharmaceutical materials and at the same time to 
protect the product from human sourced contamination. The industry has identified the 
manufacturing technology category as one of its strengths and this would be one of the 
top priorities focusing on strengths and importance scenarios.
8. Mergers and Strategic Alliances - The performance of the Iranian pharmaceutical 
industry in evaluating possible mergers was recognised as unsatisfactory by the 
participants in this study. The largest pharmaceutical companies in Iran have annual 
sales of 100-150 million US dollars but this is considered as small or medium sized 
even on a regional scale. Optimum size is one of the important factors affecting the 
success of the pharmaceutical companies in the international environment. This lack of 
evaluation shows the industry is not taking serious steps towards international 
competition. Merging between companies with complementary product portfolios, 
merging with manufacturers of the key raw materials or with owners of well-established 
R&D facilities are suggestions that have been rehearsed with local and even 
international companies, especially in China and India. Involvement of the Iranian 
pharmaceutical companies in strategic alliances was also recognised as unsatisfactory. 
Strategic alliances can be formed for co-development of innovative products with 
significant marketing efforts or procurement of the key raw materials leading to increase 
sales or the reduction of costs. Unsatisfactory performance in this area is a clear sign of 
the lack of readiness of the industry to face these future challenges.
9. Pricing Policies - The respondents did not show any agreement to indicate that the 
pricing policy of the local industry was either satisfactory or unsatisfactory. However, 
with the current high importation tariff for imported products, it is expected that the 
industry is not sufficiently motivated to reassess its pricing strategies. With the 
challenges that will appear in the post-WTO situation, especially by considering the 
inexpensive generics from India and China, it is crucial for the industry’s sustainability to 
ensure the competitiveness of the local industry particularly in the case of price 
sensitive generic products. It is important that many companies claim even higher prices
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to cover their cost without sufficient attempts to demonstrate the efficiency of their cost 
control policies such as enhancing productivity, strategic alliances or deploying more 
efficient technologies. In general, pricing was recognised as one of the strengths of the 
industry and can be considered as an important strategy in the scenario of focusing on 
strengths.
10. Training for Employees - This was the only category that was identified as 
satisfactory in this study although the results varied for single statements. This result 
was not surprising with regards to the increasing importance of human resources in the 
success of companies especially in a knowledge-based industry such as 
pharmaceuticals. Providing necessary training for employees is also required by the 
Iranian inspectors from the Iranian Ministry of Health. This is why the average 
performance of the industry in this category reached a satisfactory level although better 
results were expected for some of the parameters such as having training programmes 
for employees. This shows a gradual increase in local regulatory standards that would 
allow the industry to cope with the requirements and improve results. It is important that 
future competition will not only deploy new technologies or own differentiated products, 
but that talented and well trained staff will play a crucial role in the sustainability of the 
firms. Development of progressive training programmes for employees will be a 
preferred strategy in the scenarios dedicated to focusing on strengths and importance.
11. Skills of R&D Staff - Not surprisingly, this category was identified as unsatisfactory. 
The results varied for the regular improvement of the skills of the R&D staff, but 
developing innovative products and their contribution to company revenues or 
competitive advantage remained unsatisfactory. This result may indicate the lack of 
either sufficient funds or equipment to allocate to skills improvement in R&D 
departments. It may also be the result of poor protection of intellectual property rights. 
Highly skilled personnel can easily move to competitor companies and share acquired 
expertise. It is obvious that one of the key requirements for developing innovative 
products is having skilled staff in R&D departments. The overall results specified this 
category as important in all proposed scenarios.
12. Management Knowledge - The level of management knowledge was differently 
evaluated by individuals participating in this study. The study also revealed the fact that
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there are not adequate numbers of management graduates in pharmaceutical 
companies and the availability of qualified persons in managerial positions is a 
controversy. In general, pharmacists and accountants or finance graduates are key 
decision-makers in Iranian pharmaceutical companies, while the need for management 
graduates such as MBAs and human resource experts was frequently identified in this 
study. The consequences of management decisions are also not followed according to 
findings from this study. An appropriate way for management can only be realised by 
competent and qualified managers leading the company toward sustainability in a 
competitive environment. This fact is very important and noted by investors and boards 
of companies in appointing the right people in managerial positions. Reviewing the 
proposed scenarios showed that management knowledge was not considered as the 
preferred strategy either if the industry wants to focus on its strengths or to bridge the 
gap, but is a priority in improving weaknesses, focusing on importance, improving 
opportunities and increasing the industry readiness.
13. Customer Satisfaction - Being customer oriented was not a characteristic of this 
study and the results showed a major variation between the companies. The 
constraints of the organisational resources dictate rational resource allocation based on 
customer needs and requirements. Categorising the customers, identifying their needs 
and evaluating the level of their satisfaction are preliminary steps for being a customer- 
oriented company. In the pharmaceutical environment, customers are patients, 
physicians and pharmacists. It is important to categorise the priorities and concerns of 
each of these customer groups. Physicians are more concerned about the onset of 
action, side effects and efficacy of the prescribed medicines. Pharmacists are more 
involved in product stability, interactions, route of administration, accompanying 
information (labels and leaflets) and logistical issues while patients are affected by all 
the above factors. Finally price, insurance coverage and reimbursement are important 
for all of the stakeholders. The companies, in a competitive environment, should have 
the ability to monitor the performance of their products in the marketplace and in 
meeting these important aspects. Even in the current situation there is a degree of 
competition between local companies and it was surprising that the companies have 
such a poor performance even in easier tasks such as categorisation of the different
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groups of customers. Apart from the scenario of improving weaknesses, all other 
proposed scenarios considered customer satisfaction as an important area.
14. Creativity of the Employees - The performance of the companies to encourage 
innovation among its employees and its further utilisation for value creation was not 
satisfactory, despite the fact that this category will have an essential role in driving the 
industry towards sustainability in the post-WTO era. It should also be noted that 
reaching a satisfactory level in this category is not a quick fix as there are many pre 
requisites such as proper cultural dimensions for being successful in these areas. 
Focusing on future importance of the identified parameters would place this category as 
one of the top priorities as well as playing an important part in the noted scenarios of 
improving weaknesses and opportunities.
15. Qualifications for jobs - It was interesting to note that the minimum qualification 
requirement for jobs has been increased and therefore the industry performance in this 
area was satisfactory. This means the industry has realised the importance of having 
qualified staff to face future challenges. Giving scholarship to potential applicants is a 
popular way to ensure access to qualified persons, but here the industry performance 
was unsatisfactory. Having access to qualified staff and the ability to compensate their 
services remained a controversy among the participants of this study. These findings 
show that industry considers this category as one of its strengths.
It is believed that there are some areas that are underestimated by the participants of 
this study. For instance two parameters, related to the role of the payers, were ranked 
low by the expert panel as well as the policies of paying subsidies and bargaining power 
of the payers. It should be noted that in recent years, with increasing importance of 
health technology assessments, economic evaluation of medicines by governments and 
insurance companies has become a major barrier for market access. Nowadays, time to 
reimbursement, and not time to licensing, as was in the past, is the main barrier to 
products being marketed. This argument can also be used to explain the role of the 
patients’ associations. Increased knowledge sharing in society, especially with regards 
to the role of the internet, has made ample information, including benefit-risk 
assessment outcomes, available to many patients and their relatives. This has created 
an unprecedented bargaining power for patients’ associations. For an economically
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superior product, regardless of being more expensive or cheaper, this can be an 
advantage. Therefore, patients may push the regulators to support a more expensive 
imported product as a result of its health technology assessment outcome. The findings 
presented in chapter four demonstrate the lack of sufficient awareness with respect to 
these topics and the importance of these parameters for the pharmaceutical community 
in influencing their sustainability in the competitive environment of post-WTO.
In summary approaching the deadlines of WTO in 2016 highlights the importance of 
such a study and its timely nature. The findings of this study have demonstrated that the 
industry as a whole is ill prepared in many areas and this underlines the need for a 
reliable roadmap such as the strategy map proposed earlier in chapter 8 .The case of 
Singapore, explained earlier in this chapter, highlights the role of government to support 
the industry for a competitive global economy. Conversely, a lack of readiness 
strategies as mentioned in the case of Turkey would result in increased importation, 
decreased exportation leading to a deterioration of the domestic pharmaceutical 
industry. Thus, the proposed strategy map provides a strong base for starting from a 
most efficient and effective position. The causal effects and the lead and lag indicators, 
applied for the development of this strategy map, provides the necessary tool for 
enabling rational and efficient resource allocation.
LIMITATIONS OF THE STUDY
There were a number of limitations to this study and these are as follows:
• Methodology: in an ideal world, the panel experts would have been randomly 
selected from a much larger pool including academics, the pharmaceutical 
industry, physicians, patients and government officials. However this was not 
possible because of the limited availability of appropriate experts who are known 
and available with appropriate knowledge and experience of this particular topic.
• Patients: the main group of stakeholders who will be affected by the introduction 
of the TRIPS agreement are the patients. If time had allowed, an appropriate 
questionnaire would have been developed and piloted in a sample population, 
which would have provided a different perspective from what has been given in 
this study.
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• Physicians: prescribing physicians and the practicing pharmacists are 
significantly affected by the introduction of the WTO/TRIPS agreement. The 
availability of innovative medicines in the post-WTO period will significantly affect 
the armamentarium of the practicing prescriber. Their perspective on this issue 
would have been considered valuable.
• Government: the local industry is responsible for the production of 95% of the 
prescribed medicines in Iran of which the majority are the generics. However, 
innovative medicines are a key to the future of medical practice. Therefore, it is 
the responsibility of the government including payers and regulators to secure 
the patients’ access to appropriate medicines. The government perspective of 
the impact of WTO is considered essential to define the appropriate strategies.
RECOMMENDATIONS
As result of this study there are a number of key recommendations that would contribute 
to the sustainability of the pharmaceutical industry in the post-WTO era.
• Policy makers: It is recommended in preparation for joining WTO that the 
government consider the country’s pharmaceutical industry as a partner in the 
development of appropriate strategies. In addition they should be willing to 
support and motivate the industry in this respect. It is essential that in facing 
these challenges the government should put in place contingency funds that 
would allow pharmaceutical companies that get into difficulties in the new 
situation to be rescued as they could well in turn contribute both to the GDP and 
an improved healthcare environment. It is considered vital for the government 
work with industry to ensure the implementation of a current international 
standard to enable the industry to be a significant player in the competitive 
environment of the post-WTO era including the creation of local patent 
protection. Setting up joint government and industry task forces can facilitate this 
process as there are similar experiences even in developed countries such as 
UK (PICTF, 2001; PICTF, 2005).
• Industry and investors: in view of the importance of the TRIPS agreement for
the pharmaceutical industry, it is recommended every company’s first priority is
to carry out a situational analysis of their own organisation using such tools as:
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SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis, PEST 
(Political, Economic, Social and Technological) analysis and using PITI 
(Pharmaceutical Industry Transition Instrument). This should be followed by an 
awareness programme for employers and employees, which would include a 
comprehensive review of the WTO/TRIPS agreement and its implications for 
their own company. It is recommended that they prepare an appropriate strategy 
map and allocate sufficient resources for its implementation. In addition, the 
industry should align their strategy with government policies to protect public 
health and work closely with patient advocate groups in order to remove their 
concerns and reassure them of the industry’s commitment to patients access to 
medicines.
• Patients’ associations: the patients’ advocate groups should communicate their 
expectations to the industry and seek a clear understanding as to how and to 
what extent their members need to adjust their expectations in preparing for a 
potential short and long term shortage of medicines in the post-WTO situation 
and hope to overcome such difficulties. In this quest the patient groups should 
collaborate with the industry in an attempt to understand their difficulties and 
become involved in the industry’s strategic direction in preparing for the 
competitive environment of the post-WTO era.
•  Medical and pharmacy practitioners: Physicians and pharmacists have a 
central role in delivering effective healthcare to patients. In the post-WTO 
situation, the pharmaceutical industry may have to be innovative in order to 
produce new medicines which will need to be evaluated in Iran for quality, safety 
and efficacy prior to marketing. This will require appropriate systems to be in 
place for the approval of clinical research i.e. clinical research certificates. It is 
recommended that government consider financing appropriate clinical research 
centres in hospital and academia and in addition physicians and pharmacists (in 
government and private practice) would need to be trained in Good Clinical 
Practice. As these new products may initially only be marketed in Iran, an 
effective post marketing surveillance system would also need to be in place and 
this again will require the cooperation and collaboration of all relevant
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stakeholders. It is hoped that these initiatives will evolve to the development of 
Centres of Excellence for clinical research.
FUTURE WORK
This study is the first of its kind to evaluate the sustainability of the pharmaceutical 
industry in Iran in the post-WTO environment. Once it is realised that this research has 
resulted in the development of instruments to measure the impact of the TRIPS 
agreement on the pharmaceutical industry. Further work is now required in the five 
years that remain before this TRIPS agreement is implemented in 2016.
■ Initially, as a follow up study it would be critical to develop appropriate 
questionnaires in order to assess the impact of the WTO/TRIPS agreement on 
other stakeholders such as patients, physicians and payers
■ The strategy map that has been successfully developed from this research for 
the pharmaceutical industry should now be adopted or adapted to individual 
companies’ requirements. This may require a different approach for small, 
medium or large companies. Once a company has a roadmap and relevant 
strategies in place it would be essential to develop a methodology in order to 
monitor its implementation
■ In view of the limited time available, there was no opportunity to look at the 
economic impact of the WTO/TRIPS in Iran. In view of the significant financial 
implications of these initiatives, it is essential that future work should include an 
economic evaluation of the impact of the WTO/TRIPS agreement on individual 
companies, as well as the country at large.
■ Finally it is important that the government should develop a critical evaluation of 
the changes or modifications with respect to the regulations that need to be in 
place in order to comply with the WTO/TRIPS agreement in the field of trade 
agreements in Iran. It would be an advantage if this could be carried out in 
association with a review of what regulatory changes were required in other 
countries that have gone through this accession procedure.
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An overarching framework, that would be apply to all of the above suggestions for future 
work to ensure its long term success and relevance, would be the continuous 
improvement underpinned by development, implementation and evaluation and 
monitoring cycle (Figure 9.1).
Figure 9.1 Continuous improvement cycle
A \
Development
V
gm sV J
MR
■ AK
CONCLUSION
This study, for the first time, provides a detailed insight into the current situation of the 
pharmaceutical industry in Iran covering the whole spectrum of activities from molecule 
to market place and their future importance to WTO accession. The findings can help 
the government and the industry to shape their strategy in fostering a harmonised 
approach, involving all stakeholders, to embrace the paradigm shift of the pre and post- 
WTO/ TRIPS agreement.
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Dear
I would like to take the opportunity to thank you for accepting to take part in this study with the 
purpose of identifying the impact of WTO/TRIPS on pharmaceutical industry in Iran. This 
represents round 2 of the Delphi technique which has been formulated from the responses to 
round 1. As you will see, a divergence of opinions has been expressed by experts who took part 
in round 1, underlining the need for such a study.
Your responses will be treated in the strictest confidence and will be analysed without identifying 
individual respondents. Any responses that are used in the subsequent rounds or in publications 
will be anonymised.
Please read each statement and rate your agreement by selecting a figure from 1 to 9. Selecting 1 
means that you strongly disagree with the meaning of the statement while selecting 9, shows your 
strong agreement. The other figures are in between the two extremes.
It is estimated that the questionnaire will take 15-20 minutes to complete. Your continued input
in this process is highly appreciated. Our deadline to collect all responses is 30th of October
2009.
May I remind you of the ground rules of the Delphi method:
• The questionnaire should be completed independently by the respondent.
• The proceeding of the study should not be discussed with colleagues or co-workers until 
the final round is completed. This is to ensure anonymity and independent generation of 
ideas.
• A list of experts taking part in this study is attached for your information.
Following completion of the project, you will receive a copy of the final report.
Thank you very much for your help and time
Yours Sincerely,
Gholamhossein Farzandi, Pharm. D 
PhD Research Fellow
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Background
Iran has planned to join the World Trade Organisation (WTO). This organisation aims to 
minimize trade barriers between the member states, this means the high importation 
tariffs are mostly hard to maintain, which for instance is now 90% for importation of 
medicines. An essential part of accession procedure to WTO is enforcing trade related 
intellectual property rights (TRIPS). This can be considered as granting protection to 
patents for a period of 20 years from the date of filing the patent. These consequences 
including low importation tariffs and high degree of patent protection have been 
considered as major challenges for the pharmaceutical industry in all the countries that 
have joined the WTO so far. This will be a real challenge for Iran as well.
Objectives
This study aims to identify the impact of WTO/TRIPS on the sustainability of the 
pharmaceutical industry. These impacts can be on internal aspects of the industry as 
well as on the regulatory environment.
Methodology
This study has been designed to identify the most vulnerable aspects of the industry by 
using a Delphi method, which is characterized by interviewing a panel of experts 
independently until they reach a consensus. This method normally consists of three 
rounds.
Round 1: This involves extracting the experts’ opinions by asking them a number of 
open-ended questions (sometimes using some background information on the subject).
Round 2: This involves generating a series of statements based on the results of round
1. All participants will be asked to rate their agreement with each statement.
Round 3: The summarised results of round 2 are fed back and participants have the 
opportunity to change the rating of their agreement. (There may be a need to repeat the 
final round to reach better consensus).
We have categorised the statements under three main headings:
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Structure Parameters: Tangible resources (technology/ procedures, methods, 
information technology system, financial strength, GMP and R&D resources)
Context Parameters: Background variables such as: physicians’ behaviour; consumer 
culture, regulation (patent protection & tariffs), market structure, international situation
Content Parameters: Intangible resources, human resource, culture and behaviour of 
the industry, management, training, etc.
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Introduction
The pharmaceutical industry in the Islamic Republic of Iran has seen tremendous 
growth in recent decades; however, unless it adopts a new strategy in the coming 
years, it could face a bleak future once the country joins the World Trade Organisation 
(WTO). Iran must join the WTO in order to compete in the international market and 
contribute to the decision-making process of the international economy. The WTO aims 
to minimise trade barriers between its member states and this means that high 
importation tariffs are mostly hard to maintain, which, for instance, exceed 60% in the 
case of imported medicines. We are currently faced with various views on the pros and 
cons of joining or not joining the WTO, in both the government and private sectors, but it 
is essential that Iran’s pharmaceutical industry learn to deal with the important issue of 
how to react to and cope with the effects of joining the WTO.
Background
An essential part of the accession procedure to WTO is enforcing trade-related 
intellectual property rights (TRIPS). This can be regarded as granting protection to 
patents for a period of 20 years from the date of filing the patent. The consequences, 
which include low importation tariffs and a high degree of patent protection, have been 
regarded as major challenges for the pharmaceutical industries of all the countries that 
have joined the WTO so far. Coping with this situation is likely to be a real challenge for 
Iran as well.
Study rationale
This study aims to identify the impact of WTO/TRIPS on the sustainability of the 
pharmaceutical industry in Iran. These impacts can be on internal aspects of the 
industry as well as on the regulatory environment. The rationale for this study is based 
on not only the vital role played by this industry in maintaining and improving the
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healthcare standards of society but also the direct impacts of the WTO/TRIPS 
ascension on the economic aspects of the pharmaceutical industry. In other words, a 
sustainable pharmaceutical industry plays an important role in the healthcare and 
economy of the country.
Objectives 
The objectives of this study are to:
• Identify the most vulnerable aspects of the pharmaceutical industry and propose 
relevant strategies to address them
• Identify the current situation of the industry and its desirable situation
• Compare the current and desirable situations and identify the gap between them
• rank and prioritise the actions required to meet this gap
• explore the readiness and fitness of Iran’s pharmaceutical industry to join the WTO 
Methodology
The first step of the study used the Delphi technique to identify the variables. This 
technique was characterised by selecting a group of experts and collecting their 
opinions through an interview and two subsequent questionnaires until a consensus 
was reached. The group was selected from the three major areas of the pharmaceutical 
industry, regulatory authorities and academia to cover a wide range of opinions 
regarding the topic of this study. Based on this step, we obtained a list of ranked 
variables indicating the most important impacts of the WTO/TRIPS on the 
pharmaceutical industry.
At this stage of the study, you are requested to rate your evaluation of each statement 
in terms of both the current situation (the extent of the work which is currently being 
done) and its future importance (the extent of the work that will be done in a competitive 
environment after WTO/TRIPS).
For example, a high score for the current situation implies that the industry is paying 
high attention to the subject of the statement, while a high score for future importance
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indicates that the subject of the statement will have a high priority in the post- 
WTO/TRIPS situation.
If a subject with high future importance receives a low score in the current situation, it 
will indicate a low level of readiness of the industry for WTO/TRIPS implementation. 
This difference can be referred to as a gap analysis.
Study participants
This questionnaire is being sent to people employed at managerial levels in 
pharmaceutical companies. The responses from each company will be collected 
separately, thus giving us the opportunity to analyse the situation of every single 
company. It is emphasised here that the names of the companies will not be disclosed 
in any published material and are only used to map the company situation with respect 
to other companies (the other companies will be denoted by letters of the alphabet in 
the final report that you will receive).
How to complete the questionnaire
Please complete the questionnaire on your own and do not share your ideas with other 
colleagues to maintain the accuracy of the responses. The average time needed for 
reading the instructions and compieting the questionnaire is 30 minutes. You are 
requested to answer all questions, but if any question is outside your area of expertise, 
you may leave it blank. The scoring of the statements is as follows:
For the current situation:
A score of 0 means ‘no compliance’ and indicates that the company has not done 
anything with regard to the subject of the statement.
A score of 10 means ‘absolute compliance’ and indicates that the company has 
completely and satisfactorily dealt with that subject matter; the other figures (i.e. 1-9) 
indicate levels of compliance between 0 and 10.
For the future importance:
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A score of 0 means, this item will be of no importance at all after WTO/TRIPS 
implementation.
A score of 10, means, this item is likely to be extremely important after WTO/TRIPS 
implementation.
Please first provide answers for the ‘current situation’ and then consider the 
‘future importance’ of each statement.
Confidentiality policy:
This is an academic research project, and all names and addresses of the respondents 
will be protected as confidential information and will not be reported in any published 
form of material. If the top management of a company wishes to receive an individual 
report, the diagrams will show ‘y°ur company’, while the other companies will be 
represented by coded figures.
This questionnaire has been tested for reliability and validity before being sent to 
you to ensure that it is clear and easy to answer. Nevertheless, your comments 
are highly welcome and will be used for further analysis.
Contents of the Questionnaire
1. General questions
2. Patent review
3. Licensing and technology transfer agreements
4. Marketing expenditure
5. GMP expenditure
6. R&D expenditure
7. Product packaging
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8. Manufacturing technology
9. Mergers and strategic alliances
10. Pricing policy
11. Training for employees
12. Skills of R&D staff
13. Management knowledge
14. Customer satisfaction
15. Creativity of the employees
16. Qualifications for jobs
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Pharmacoeconomics refers to the application of 
economic evaluations for analyzing the impact of 
pharmacy services, pharmaceutical processes and 
products on health care systems and healthcare 
organizations with the aim of effective resource 
allocation.
Health expenses have grown dramatically during recent 
decades and due to the premise of scarcity of 
resources, considering economic impact (as well as 
health impact) of different health related products 
application and different medical interventions is vital 
and inevitable for each healthcare system. In this 
regard, pharmaceutical companies , specially in 
developing countries, have an essential role in 
controling and minimizing the costs of health provision 
by applying efficient and effective drug development 
and delivery process to improve the affordability and 
accessibility of essential medications.
In Iran, pharmacoeconomics is growing and certainly 
many challenges and opportunities lie ahead as the 
field continues to grow and respond to unforeseeable 
future events. It  is our hope that pharmeconomics.com 
can become a useful reference for students of 
pharmacoeconomics and those are learning in "the real 
world' who will respond to the challenges to discuss the 
problems and share information and experiences with 
each other. We are always students of our own 
discipline and looking forward to receiving your 
comments to improve this resource. We hope that this 
website will be educational for all of us.
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Appendix 4
Friedman Ranking for All Statements of the PITI
293
Current situation: all statements
ID Statements Mean
Rank
F5.7 GMP improvement is a strategic goal for us. 51.71
F8.4 Our manufacturing procedures are well documented and well executed. 47.73
F3.1 Having licensed products is a strategic goal for our company. 47.22
F16.1 The minimum qualifications have been increased in our organisation in recent years. 46.31
F8.5 We regularly update the manufacturing procedures for our products. 45.25
F16.2 We have access to people with the required qualifications. 44.61
F l l . l Qualifications are considered very important while recruiting people in our company. 43.71
F5.4 We have an appropriate documentation system for GMP. 43.61
F I 1.3 We are increasing our training hours per capita. 42.92
F83 Our manufacturing technology is in compliance with environmental standards. 42.19
F6.4 A major part of our revenue comes from exclusive products. 41.57
F13.1 We have qualified persons in all managerial positions. 39.09
F11.2 We have training programmes for every job. 38.76
F5.1 We allocate sufficient funds to improve our GMP. 38.38
F3.2 The infrastructure of our company satisfies the requirements of reputable licensors. 38.20
F14.1 We have internal programmes to meet the customers’ requirements. 37.88
F6.3 R&D investment plays a major role in our competitiveness. 37.55
F14.3 We know the needs of our target customers. 37.51
F I 1.5 The capabilities of our employees are comparable with those of our international rivals. 37.09
F4.4 Our marketing activities contribute to capturing the market share. 36.85
F4.5 Our marketing activities have increased our customer loyalty. 36.70
F14.4 We measure the satisfaction levels of our customers. 36.63
F5.6 Our manufacturing areas are updated regularly. 36.59
F10.1 We have competitive pricing in comparison with our international rivals. 36.56
F I 1.4 We measure the effectiveness of our training programmes. 36.36
F8.1 We regularly improve our production lines. 36.35
F7.2 We invest in improving our product packaging. 36.12
F9.3 Being a subsidiary of a holding company facilitates strategic alliances. 35.72
F6.1 We allocate sufficient funds for our R&D department. 35.53
F7.1 The attractiveness of the packaging is a strong point of our products. 34.45
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ID Statements Mean
Rank
F15.3 Innovation plays an important role in maintaining our competitiveness. 34.28
F15.2 We have utilised the innovativeness of our employees to create value. 34.27
F14.2 We have categorised our customers into different groups and have communication 
programmes for each group.
34.23
F16.3 Our company can afford to employ highly qualified people. 34.10
F5.3 We have a well-planned validation master plan for GMP. 33.90
F13.3 There are adequate numbers of management graduates in our managerial team. 33.85
F9.2 We are evaluating possible mergers and acquisitions. 33.78
F3.4 We have technology transfer agreements with technology owners. 33.72
F10.2 We have price flexibility in comparison with our rivals. 33.71
F3.3 We have license agreements with innovator companies. 33.52
F15.1 Our organisation encourages innovation. 32.97
F12.1 We regularly improve the skills of our R&D staff. 32.78
F13.2 We measure the efficiency of the decisions taken by our managers. 32.02
F9.1 We have strategic alliances with some of our partners. 31.54
F7.5 The quality of our packaging is comparable with that of our international competitors. 31.43
F5.5 We have a change control system for all related departments. 30.72
F3.5 Licensed or technology transferred products constitute an important part of our total sales. 29.45
F7.3 Our packaging lines are comparable with those of our international rivals. 29.28
F12.2 Our R&D team can develop innovative products. 29.09
F5.8 We measure the effectiveness of our GMP expenditure. 28.56
F8.2 The automation level in our plant is comparable with that of our international rivals. 27.78
F6.5 We have close relations with R&D institutions outside our company. 27.57
F I 6.4 We have offered scholarships to obtain employees with the required qualifications. 27.41
F2.2 Intellectual property right is a key issue in the selection of a new product. 26.79
F7.4 We measure the role of our packaging in creating customer satisfaction. 26.50
F6.6 We have innovative new formulations. 25.39
F12.4 The skills of our R&D staff have created advantages for us against our rivals. 25.15
F4.3 We measure the effectiveness of our marketing expenditure. 24.89
F6.2 We measure the effectiveness of our R&D expenditure. 24.20
F4.2 We regularly increase the percentage of marketing expenditure to total sales. 24.06
F12.3 A considerable part of our revenue is the result of innovation in R&D. 22.98
F2.3 We review intellectual property rights when exporting products. 22.60
F5.2 We have the GMP approval of international inspectors. 22.07
F2.1 Our company has dedicated personnel for reviewing intellectual property rights to prevent 13.62
295
ID Statements Mean
Rank
patent infringements.
F4.1 Our marketing expenditure is comparable to that of our international rivals. 13.17
F2.4 We know the financial impact of enforcing patent protection on our company. 10.49
Future Importance: all statements
ID Statements Mean
Rank
F5.4 We have an appropriate documentation system for GMP. 46.26
F5.7 GMP improvement is a strategic goal for us. 45.42
F5.3 We have a well-planned validation master plan for GMP. 43.73
F5.1 We allocate sufficient funds to improve our GMP. 41.89
F8.4 Our manufacturing procedures are well documented and well executed. 41.64
F3.2 The infrastructure of our company satisfies the requirements of reputable licensors. 41.45
F5.2 We have the GMP approval of international inspectors. 40.17
F8.5 We regularly update the manufacturing procedures for our products. 39.94
F6.3 R&D investment plays a major role in our competitiveness. 39.81
F6.1 We allocate sufficient funds for our R&D department. 39.61
F l l . l Qualifications are considered very important while recruiting people in the company. 39.61
F5.5 We have a change control system for all related departments. 38.76
F5.8 We measure the effectiveness of our GMP expenditure. 38.39
F13.1 We have qualified persons in all managerial positions. 38.30
F3.4 We have technology transfer agreements with technology owners. 37.17
F3.1 Having licensed products is a strategic goal for our company. 37.12
F5.6 Our manufacturing areas are updated regularly. 37.05
F14.4 We measure the satisfaction levels of our customers. 36.98
F15.3 Innovation plays an important role in maintaining our competitiveness. 36.95
F14.1 We have internal programmes to meet the customers’ requirements. 36.62
F4.4 Our marketing activities contribute to capturing the market share. 36.34
F15.1 Our organisation encourages innovation. 36.24
F12.2 Our R&D team can develop innovative products. 35.92
F11.2 We have training programmes for every job. 35.89
F8.3 Our manufacturing technology is in compliance with environmental standards. 35.36
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F3.3 We have licence agreements with innovator companies. 35.21
F13.2 We measure the efficiency of the decisions taken by our managers. 34.39
F16.3 Our company can afford to employ highly qualified people. 34.31
F16.1 The minimum qualifications have been increased in our organisation in recent years. 34.14
F16.2 We have access to people with the required qualifications. 33.90
F15.2 We have utilised the innovativeness of our employees to create value. 33.64
F14.3 We know the needs of our target customers. 33.60
F I 1.4 We measure the effectiveness of our training programmes. 33.35
F12.1 We regularly improve the skills of our R&D staff. 33.35
F6.6 We have innovative new formulations. 33.01
F11.5 The capabilities of our employees are comparable with those of our international rivals. 32.92
F4.5 Our marketing activities have increased our customer loyalty. 32.30
F4.3 We measure the effectiveness of our marketing expenditure. 32.20
F8.1 We regularly improve our production lines. 32.14
F6.4 A major part of our revenue comes from exclusive products. 32.13
F2.2 Intellectual property right is a key issue in the selection of a new product. 31.91
F12.3 A considerable part of our revenue is the result of innovation in R&D. 31.77
F I 1.3 We are increasing our training hours per capita. 31.58
F7.3 Our packaging lines are comparable with those of our international rivals. 31.07
F7.1 The attractiveness of the packaging is a strong point of our products. 31.01
F6.2 We measure the effectiveness of our R&D expenditure. 30.73
F14.2 We have categorised our customers into different groups and have communication 
programmes for each group.
30.70
F7.5 The quality of our packaging is comparable with that of our international competitors. 30.62
F13.3 There are adequate numbers of management graduates in our managerial team. 30.40
F9.1 We have strategic alliances with some of our partners. 29.65
F12.4 The skills of our R&D staff have created advantages for us against our rivals. 29.55
F7.2 We invest in improving our product packaging. 29.37
F7.4 We measure the role of our packaging in creating customer satisfaction. 28.91
F10.1 We have competitive pricing in comparison with our international rivals. 27.76
F2.3 We review intellectual property rights when exporting products. 27.74
F8.2 The automation level in our plant is comparable with that of our international rivals. 27.58
F16.4 We have offered scholarships to obtain employees with the required qualifications. 26.95
F2.1 Our company has dedicated personnel for reviewing intellectual property rights to prevent 
patent infringements.
26.90
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F2.4 We know the financial impact of enforcing patent protection on our company. 26.43
F6.5 We have close relations with R&D institutions outside our company. 25.80
F9.3 Being a subsidiary of a holding company facilitates strategic alliances. 25.64
F3.5 Licensed or technology transferred products constitute an important part of our total sales. 25.41
F4.2 We regularly increase the percentage of marketing expenditure to total sales. 24.90
F10.2 We have price flexibility in comparison with our rivals. 24.41
F9.2 We are evaluating possible mergers and acquisitions. 24.27
F4.I Our marketing expenditure is comparable to that of our international rivals. 22.77
